Background  ||| S:24 E:43 ||| NNP
Atherosclerosis  ||| S:43 E:59 ||| NNP
and  ||| S:59 E:63 ||| CC
coronary  ||| S:63 E:72 ||| JJ
heart  ||| S:72 E:78 ||| NN
disease  ||| S:78 E:86 ||| NN
( ||| S:86 E:87 ||| -LRB-
CHD ||| S:87 E:90 ||| NNP
)  ||| S:90 E:92 ||| -RRB-
have  ||| S:92 E:105 ||| VBP
long  ||| S:105 E:110 ||| RB
been  ||| S:110 E:115 ||| VBN
considered  ||| S:115 E:126 ||| VBN
major  ||| S:126 E:132 ||| JJ
contributors  ||| S:132 E:145 ||| NNS
to  ||| S:145 E:148 ||| TO
morbidity  ||| S:148 E:158 ||| VB
and  ||| S:158 E:170 ||| CC
mortality  ||| S:170 E:180 ||| NN
in  ||| S:180 E:183 ||| IN
developed  ||| S:183 E:193 ||| JJ
countries  ||| S:193 E:203 ||| NNS
[  ||| S:203 E:205 ||| -LRB-
1 ||| S:205 E:206 ||| CD
,  ||| S:206 E:208 ||| ,
2 ||| S:208 E:209 ||| CD
,  ||| S:209 E:211 ||| ,
3 ||| S:211 E:212 ||| LS
] ||| S:212 E:213 ||| -RRB-
.  ||| S:213 E:215 ||| .
One  ||| S:215 E:219 ||| PRP
noted  ||| S:219 E:233 ||| VBD
exception  ||| S:233 E:243 ||| NN
is  ||| S:243 E:246 ||| VBZ
the  ||| S:246 E:250 ||| DT
low  ||| S:250 E:254 ||| JJ
mortality  ||| S:254 E:264 ||| NN
of  ||| S:264 E:267 ||| IN
CHD  ||| S:267 E:271 ||| NNP
in  ||| S:271 E:274 ||| IN
France ||| S:274 E:280 ||| NNP
,  ||| S:280 E:290 ||| ,
particularly  ||| S:290 E:303 ||| RB
the  ||| S:303 E:307 ||| DT
southwest  ||| S:307 E:317 ||| JJS
region  ||| S:317 E:324 ||| NN
[  ||| S:324 E:326 ||| -LRB-
4 ||| S:326 E:327 ||| CD
,  ||| S:327 E:329 ||| ,
5 ||| S:329 E:330 ||| CD
,  ||| S:330 E:332 ||| ,
6 ||| S:332 E:333 ||| CD
] ||| S:333 E:334 ||| -RRB-
.  ||| S:334 E:336 ||| .
This  ||| S:336 E:349 ||| DT
phenomenon ||| S:349 E:359 ||| NN
,  ||| S:359 E:361 ||| ,
commonly  ||| S:361 E:370 ||| RB
referred  ||| S:370 E:379 ||| VBN
to  ||| S:379 E:382 ||| TO
as  ||| S:382 E:385 ||| IN
the  ||| S:385 E:389 ||| DT
French  ||| S:389 E:396 ||| JJ
paradox ||| S:396 E:403 ||| NN
,  ||| S:403 E:405 ||| ,
may  ||| S:405 E:417 ||| MD
be  ||| S:417 E:420 ||| VB
associated  ||| S:420 E:431 ||| VBN
with  ||| S:431 E:436 ||| IN
high  ||| S:436 E:441 ||| JJ
consumption  ||| S:441 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
red  ||| S:456 E:460 ||| JJ
wine  ||| S:460 E:465 ||| NN
[  ||| S:465 E:467 ||| -LRB-
7 ||| S:467 E:468 ||| CD
,  ||| S:468 E:470 ||| ,
8 ||| S:470 E:471 ||| CD
] ||| S:471 E:472 ||| -RRB-
.  ||| S:472 E:474 ||| .
A  ||| S:474 E:484 ||| DT
negative  ||| S:484 E:493 ||| JJ
correlation  ||| S:493 E:505 ||| NN
between  ||| S:505 E:513 ||| IN
CHD  ||| S:513 E:517 ||| NNP
and  ||| S:517 E:521 ||| CC
alcohol  ||| S:521 E:529 ||| NN
consumption  ||| S:529 E:549 ||| NN
was  ||| S:549 E:553 ||| VBD
first  ||| S:553 E:559 ||| RB
noted  ||| S:559 E:565 ||| VBD
25  ||| S:565 E:568 ||| CD
years  ||| S:568 E:574 ||| NNS
ago ||| S:574 E:577 ||| RB
,  ||| S:577 E:579 ||| ,
and  ||| S:579 E:583 ||| CC
numerous  ||| S:583 E:592 ||| JJ
studies  ||| S:592 E:600 ||| NNS
since  ||| S:600 E:614 ||| IN
have  ||| S:614 E:619 ||| VBP
confirmed  ||| S:619 E:629 ||| VBN
a  ||| S:629 E:631 ||| DT
statistically  ||| S:631 E:645 ||| JJ
significant  ||| S:645 E:657 ||| JJ
inverse  ||| S:657 E:673 ||| JJ
relationship  ||| S:673 E:686 ||| NN
between  ||| S:686 E:694 ||| IN
these  ||| S:694 E:700 ||| DT
two  ||| S:700 E:704 ||| CD
factors  ||| S:704 E:712 ||| NNS
[  ||| S:712 E:714 ||| -LRB-
9 ||| S:714 E:715 ||| CD
,  ||| S:715 E:717 ||| ,
10 ||| S:717 E:719 ||| CD
,  ||| S:719 E:721 ||| ,
11 ||| S:721 E:723 ||| CD
,  ||| S:723 E:725 ||| ,
12 ||| S:725 E:727 ||| CD
,  ||| S:727 E:729 ||| ,
13 ||| S:729 E:731 ||| CD
,  ||| S:731 E:741 ||| ,
14 ||| S:741 E:743 ||| CD
] ||| S:743 E:744 ||| -RRB-
.  ||| S:744 E:755 ||| .
In  ||| S:755 E:758 ||| IN
vivo  ||| S:758 E:763 ||| JJ
studies  ||| S:763 E:771 ||| NNS
have  ||| S:771 E:776 ||| VBP
shown  ||| S:776 E:782 ||| VBN
that  ||| S:782 E:787 ||| IN
wine  ||| S:787 E:800 ||| NN
consumption ||| S:800 E:811 ||| NN
,  ||| S:811 E:813 ||| ,
particularly  ||| S:813 E:826 ||| RB
red  ||| S:826 E:830 ||| JJ
wine ||| S:830 E:834 ||| NN
,  ||| S:834 E:836 ||| ,
is  ||| S:836 E:839 ||| VBZ
more  ||| S:839 E:844 ||| RBR
effective  ||| S:844 E:854 ||| JJ
in  ||| S:854 E:865 ||| IN
the  ||| S:865 E:869 ||| DT
prevention  ||| S:869 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
CHD  ||| S:883 E:887 ||| NNP
not  ||| S:887 E:891 ||| RB
seen  ||| S:891 E:896 ||| VBN
with  ||| S:896 E:901 ||| IN
other  ||| S:901 E:907 ||| JJ
forms  ||| S:907 E:913 ||| NNS
of  ||| S:913 E:924 ||| IN
alcoholic  ||| S:924 E:934 ||| JJ
beverages  ||| S:934 E:944 ||| NNS
[  ||| S:944 E:946 ||| -LRB-
15 ||| S:946 E:948 ||| CD
,  ||| S:948 E:950 ||| ,
16 ||| S:950 E:952 ||| CD
,  ||| S:952 E:954 ||| ,
17 ||| S:954 E:956 ||| CD
] ||| S:956 E:957 ||| -RRB-
.  ||| S:957 E:959 ||| .
Accordingly ||| S:959 E:970 ||| RB
,  ||| S:970 E:972 ||| ,
it  ||| S:972 E:975 ||| PRP
has  ||| S:975 E:979 ||| VBZ
been  ||| S:979 E:992 ||| VBN
postulated  ||| S:992 E:1003 ||| NNS
that  ||| S:1003 E:1008 ||| WDT
naturally  ||| S:1008 E:1018 ||| RB
occurring  ||| S:1018 E:1028 ||| VBG
components  ||| S:1028 E:1039 ||| NNS
in  ||| S:1039 E:1042 ||| IN
wine  ||| S:1042 E:1055 ||| NN
might  ||| S:1055 E:1061 ||| MD
afford  ||| S:1061 E:1068 ||| VB
or  ||| S:1068 E:1071 ||| CC
contribute  ||| S:1071 E:1082 ||| VB
to  ||| S:1082 E:1085 ||| TO
its  ||| S:1085 E:1089 ||| PRP$
enhanced  ||| S:1089 E:1098 ||| JJ
protection  ||| S:1098 E:1117 ||| NN
against  ||| S:1117 E:1125 ||| IN
CHD  ||| S:1125 E:1129 ||| NNP
by  ||| S:1129 E:1132 ||| IN
targeting  ||| S:1132 E:1142 ||| VBG
sites  ||| S:1142 E:1148 ||| NNS
that  ||| S:1148 E:1153 ||| WDT
participate  ||| S:1153 E:1165 ||| VBP
in  ||| S:1165 E:1168 ||| IN
the  ||| S:1168 E:1180 ||| DT
etiology  ||| S:1180 E:1189 ||| NN
of  ||| S:1189 E:1192 ||| IN
CHD ||| S:1192 E:1195 ||| NNP
,  ||| S:1195 E:1197 ||| ,
including  ||| S:1197 E:1207 ||| VBG
soluble  ||| S:1207 E:1215 ||| JJ
blood  ||| S:1215 E:1221 ||| NN
components  ||| S:1221 E:1232 ||| NNS
( ||| S:1232 E:1233 ||| -LRB-
LDL ||| S:1233 E:1236 ||| NNP
) ||| S:1236 E:1237 ||| -RRB-
,  ||| S:1237 E:1247 ||| ,
cellular  ||| S:1247 E:1256 ||| JJ
blood  ||| S:1256 E:1262 ||| NN
elements  ||| S:1262 E:1271 ||| NNS
( ||| S:1271 E:1272 ||| -LRB-
platelets ||| S:1272 E:1281 ||| LS
) ||| S:1281 E:1282 ||| -RRB-
,  ||| S:1282 E:1284 ||| ,
or  ||| S:1284 E:1287 ||| CC
the  ||| S:1287 E:1291 ||| DT
vasculature  ||| S:1291 E:1311 ||| NN
itself  ||| S:1311 E:1318 ||| PRP
( ||| S:1318 E:1319 ||| -LRB-
endothelium ||| S:1319 E:1330 ||| LS
) ||| S:1330 E:1331 ||| -RRB-
.  ||| S:1331 E:1333 ||| .
Siemann  ||| S:1333 E:1341 ||| NNP
and  ||| S:1341 E:1345 ||| CC
Creasy  ||| S:1345 E:1352 ||| NNP
proposed  ||| S:1352 E:1361 ||| VBD
that  ||| S:1361 E:1374 ||| IN
trans-resveratrol ||| S:1374 E:1391 ||| NNP
,  ||| S:1391 E:1393 ||| ,
a  ||| S:1393 E:1395 ||| DT
tri-hydroxy  ||| S:1395 E:1407 ||| JJ
stilbene ||| S:1407 E:1415 ||| NN
,  ||| S:1415 E:1417 ||| ,
in  ||| S:1417 E:1420 ||| IN
red  ||| S:1420 E:1424 ||| JJ
wine  ||| S:1424 E:1437 ||| NN
exhibits  ||| S:1437 E:1446 ||| VBZ
cardioprotective  ||| S:1446 E:1463 ||| JJ
properties  ||| S:1463 E:1474 ||| NNS
[  ||| S:1474 E:1476 ||| -LRB-
18 ||| S:1476 E:1478 ||| CD
]  ||| S:1478 E:1480 ||| -RRB-
and  ||| S:1480 E:1484 ||| CC
can  ||| S:1484 E:1488 ||| MD
inhibit  ||| S:1488 E:1504 ||| VB
LDL  ||| S:1504 E:1508 ||| JJ
oxidation  ||| S:1508 E:1518 ||| NNS
[  ||| S:1518 E:1520 ||| -LRB-
19 ||| S:1520 E:1522 ||| CD
] ||| S:1522 E:1523 ||| -RRB-
,  ||| S:1523 E:1525 ||| ,
suppress  ||| S:1525 E:1534 ||| JJ
smooth  ||| S:1534 E:1541 ||| JJ
muscle  ||| S:1541 E:1548 ||| NN
proliferation  ||| S:1548 E:1562 ||| NN
[  ||| S:1562 E:1572 ||| -LRB-
20 ||| S:1572 E:1574 ||| CD
] ||| S:1574 E:1575 ||| -RRB-
,  ||| S:1575 E:1577 ||| ,
induce  ||| S:1577 E:1584 ||| FW
nitric  ||| S:1584 E:1591 ||| FW
oxide  ||| S:1591 E:1597 ||| FW
synthase  ||| S:1597 E:1606 ||| FW
expression  ||| S:1606 E:1617 ||| FW
[  ||| S:1617 E:1619 ||| -LRB-
21 ||| S:1619 E:1621 ||| CD
]  ||| S:1621 E:1623 ||| -RRB-
and  ||| S:1623 E:1635 ||| CC
block  ||| S:1635 E:1641 ||| VB
collagen-induced  ||| S:1641 E:1658 ||| JJ
aggregation  ||| S:1658 E:1670 ||| JJ
responses  ||| S:1670 E:1680 ||| NNS
in  ||| S:1680 E:1683 ||| IN
washed  ||| S:1683 E:1698 ||| JJ
platelets  ||| S:1698 E:1708 ||| NNS
[  ||| S:1708 E:1710 ||| -LRB-
22 ||| S:1710 E:1712 ||| CD
,  ||| S:1712 E:1714 ||| ,
23 ||| S:1714 E:1716 ||| CD
,  ||| S:1716 E:1718 ||| ,
24 ||| S:1718 E:1720 ||| CD
] ||| S:1720 E:1721 ||| -RRB-
.  ||| S:1721 E:1723 ||| .
However ||| S:1723 E:1730 ||| RB
,  ||| S:1730 E:1732 ||| ,
relatively  ||| S:1732 E:1743 ||| RB
few  ||| S:1743 E:1747 ||| JJ
studies  ||| S:1747 E:1763 ||| NNS
have  ||| S:1763 E:1768 ||| VBP
been  ||| S:1768 E:1773 ||| VBN
performed  ||| S:1773 E:1783 ||| VBN
on  ||| S:1783 E:1786 ||| IN
the  ||| S:1786 E:1790 ||| DT
effects  ||| S:1790 E:1798 ||| NNS
of  ||| S:1798 E:1801 ||| IN
resveratrol  ||| S:1801 E:1813 ||| NN
on  ||| S:1813 E:1824 ||| IN
vascular  ||| S:1824 E:1833 ||| JJ
components  ||| S:1833 E:1844 ||| NNS
such  ||| S:1844 E:1849 ||| JJ
as  ||| S:1849 E:1852 ||| IN
the  ||| S:1852 E:1856 ||| DT
endothelial  ||| S:1856 E:1868 ||| JJ
cells ||| S:1868 E:1873 ||| NNS
,  ||| S:1873 E:1875 ||| ,
which  ||| S:1875 E:1889 ||| WDT
are  ||| S:1889 E:1893 ||| VBP
known  ||| S:1893 E:1899 ||| VBN
to  ||| S:1899 E:1902 ||| TO
play  ||| S:1902 E:1907 ||| VB
a  ||| S:1907 E:1909 ||| DT
critical  ||| S:1909 E:1918 ||| JJ
role  ||| S:1918 E:1923 ||| NN
in  ||| S:1923 E:1926 ||| IN
maintaining  ||| S:1926 E:1938 ||| VBG
the  ||| S:1938 E:1950 ||| DT
integrity  ||| S:1950 E:1960 ||| NN
and  ||| S:1960 E:1964 ||| CC
functioning  ||| S:1964 E:1976 ||| VBG
of  ||| S:1976 E:1979 ||| IN
the  ||| S:1979 E:1983 ||| DT
vascular  ||| S:1983 E:1992 ||| JJ
endothelium ||| S:1992 E:2003 ||| NN
.  ||| S:2003 E:2013 ||| .
Homeostasis  ||| S:2013 E:2025 ||| NNP
of  ||| S:2025 E:2028 ||| IN
the  ||| S:2028 E:2032 ||| DT
vascular  ||| S:2032 E:2041 ||| JJ
endothelium ||| S:2041 E:2052 ||| NN
,  ||| S:2052 E:2054 ||| ,
both  ||| S:2054 E:2059 ||| DT
with  ||| S:2059 E:2064 ||| IN
respect  ||| S:2064 E:2080 ||| NN
to  ||| S:2080 E:2083 ||| TO
metabolic  ||| S:2083 E:2093 ||| VB
and  ||| S:2093 E:2097 ||| CC
physiologic  ||| S:2097 E:2109 ||| JJ
activities ||| S:2109 E:2119 ||| NNS
,  ||| S:2119 E:2121 ||| ,
can  ||| S:2121 E:2125 ||| MD
be  ||| S:2125 E:2128 ||| VB
affected  ||| S:2128 E:2137 ||| VBN
by  ||| S:2137 E:2148 ||| IN
overall  ||| S:2148 E:2156 ||| JJ
nutritional  ||| S:2156 E:2168 ||| JJ
status  ||| S:2168 E:2175 ||| NN
and  ||| S:2175 E:2179 ||| CC
by  ||| S:2179 E:2182 ||| IN
specific  ||| S:2182 E:2191 ||| JJ
ingredients  ||| S:2191 E:2203 ||| NNS
in  ||| S:2203 E:2214 ||| IN
the  ||| S:2214 E:2218 ||| DT
diet  ||| S:2218 E:2223 ||| NN
[  ||| S:2223 E:2225 ||| -LRB-
25 ||| S:2225 E:2227 ||| CD
,  ||| S:2227 E:2229 ||| ,
26 ||| S:2229 E:2231 ||| CD
,  ||| S:2231 E:2233 ||| ,
27 ||| S:2233 E:2235 ||| CD
] ||| S:2235 E:2236 ||| -RRB-
.  ||| S:2236 E:2246 ||| .
The  ||| S:2246 E:2250 ||| DT
aims  ||| S:2250 E:2255 ||| NNS
of  ||| S:2255 E:2258 ||| IN
the  ||| S:2258 E:2262 ||| DT
present  ||| S:2262 E:2270 ||| JJ
study  ||| S:2270 E:2276 ||| NN
were  ||| S:2276 E:2281 ||| VBD
to  ||| S:2281 E:2284 ||| TO
determine  ||| S:2284 E:2294 ||| VB
changes  ||| S:2294 E:2310 ||| NNS
resulting  ||| S:2310 E:2320 ||| VBG
from  ||| S:2320 E:2325 ||| IN
resveratrol ||| S:2325 E:2336 ||| NNS
: ||| S:2336 E:2337 ||| :
endothelial  ||| S:2337 E:2349 ||| JJ
cell  ||| S:2349 E:2354 ||| NN
interaction ||| S:2354 E:2365 ||| NN
.  ||| S:2365 E:2367 ||| .
We  ||| S:2367 E:2378 ||| PRP
observed  ||| S:2378 E:2387 ||| VBD
that  ||| S:2387 E:2392 ||| DT
resveratrol  ||| S:2392 E:2404 ||| JJ
induced  ||| S:2404 E:2412 ||| JJ
significant  ||| S:2412 E:2424 ||| JJ
cellular  ||| S:2424 E:2433 ||| JJ
and  ||| S:2433 E:2445 ||| CC
biochemical  ||| S:2445 E:2457 ||| JJ
changes  ||| S:2457 E:2465 ||| NNS
in  ||| S:2465 E:2468 ||| IN
endothelial  ||| S:2468 E:2480 ||| JJ
cells ||| S:2480 E:2485 ||| NNS
,  ||| S:2485 E:2487 ||| ,
which  ||| S:2487 E:2493 ||| WDT
were  ||| S:2493 E:2506 ||| VBD
accompanied  ||| S:2506 E:2518 ||| VBN
by  ||| S:2518 E:2521 ||| IN
altered  ||| S:2521 E:2529 ||| JJ
functional  ||| S:2529 E:2540 ||| JJ
responsiveness  ||| S:2540 E:2555 ||| NN
to  ||| S:2555 E:2566 ||| TO
conditions  ||| S:2566 E:2577 ||| NNS
simulating  ||| S:2577 E:2588 ||| VBP
arterial  ||| S:2588 E:2597 ||| JJ
flow ||| S:2597 E:2601 ||| NN
.  ||| S:2601 E:2603 ||| .
Since  ||| S:2603 E:2609 ||| IN
previous  ||| S:2609 E:2618 ||| JJ
studies  ||| S:2618 E:2634 ||| NNS
have  ||| S:2634 E:2639 ||| VBP
shown  ||| S:2639 E:2645 ||| VBN
several  ||| S:2645 E:2653 ||| JJ
signaling  ||| S:2653 E:2663 ||| JJ
molecule  ||| S:2663 E:2672 ||| NN
changes  ||| S:2672 E:2680 ||| NNS
during  ||| S:2680 E:2695 ||| IN
reorganization  ||| S:2695 E:2710 ||| NN
of  ||| S:2710 E:2713 ||| IN
the  ||| S:2713 E:2717 ||| DT
endothelial  ||| S:2717 E:2729 ||| FW
cell  ||| S:2729 E:2734 ||| FW
cytoskeleton  ||| S:2734 E:2755 ||| FW
accompanying  ||| S:2755 E:2768 ||| FW
arterial  ||| S:2768 E:2777 ||| FW
shear  ||| S:2777 E:2783 ||| FW
stress  ||| S:2783 E:2790 ||| FW
[  ||| S:2790 E:2792 ||| -LRB-
28 ||| S:2792 E:2794 ||| CD
,  ||| S:2794 E:2796 ||| ,
29 ||| S:2796 E:2798 ||| CD
,  ||| S:2798 E:2800 ||| ,
30 ||| S:2800 E:2802 ||| CD
,  ||| S:2802 E:2804 ||| ,
31 ||| S:2804 E:2806 ||| CD
] ||| S:2806 E:2807 ||| -RRB-
,  ||| S:2807 E:2809 ||| ,
we  ||| S:2809 E:2820 ||| PRP
evaluated  ||| S:2820 E:2830 ||| VBD
the  ||| S:2830 E:2834 ||| DT
same  ||| S:2834 E:2839 ||| JJ
set  ||| S:2839 E:2843 ||| NN
of  ||| S:2843 E:2846 ||| IN
biochemical  ||| S:2846 E:2858 ||| JJ
parameters  ||| S:2858 E:2869 ||| NNS
in  ||| S:2869 E:2880 ||| IN
resveratrol-treated  ||| S:2880 E:2900 ||| JJ
cells ||| S:2900 E:2905 ||| NNS
.  ||| S:2905 E:2907 ||| .
Use  ||| S:2907 E:2911 ||| NN
of  ||| S:2911 E:2914 ||| IN
selective  ||| S:2914 E:2924 ||| JJ
signaling  ||| S:2924 E:2942 ||| JJ
pathway  ||| S:2942 E:2950 ||| NNS
inhibitors  ||| S:2950 E:2961 ||| VBP
allowed  ||| S:2961 E:2969 ||| VBN
the  ||| S:2969 E:2973 ||| DT
demonstration  ||| S:2973 E:2987 ||| NN
that  ||| S:2987 E:2992 ||| IN
the  ||| S:2992 E:3004 ||| DT
cytoskeletal  ||| S:3004 E:3017 ||| JJ
changes  ||| S:3017 E:3025 ||| NNS
elicited  ||| S:3025 E:3034 ||| VBN
by  ||| S:3034 E:3037 ||| IN
resveratrol  ||| S:3037 E:3049 ||| JJ
depended  ||| S:3049 E:3058 ||| NN
on  ||| S:3058 E:3069 ||| IN
intracellular  ||| S:3069 E:3083 ||| JJ
calcium  ||| S:3083 E:3091 ||| NN
and  ||| S:3091 E:3095 ||| CC
tyrosine  ||| S:3095 E:3104 ||| JJ
kinase  ||| S:3104 E:3111 ||| JJ
activity  ||| S:3111 E:3120 ||| NN
changes ||| S:3120 E:3127 ||| NNS
,  ||| S:3127 E:3137 ||| ,
and  ||| S:3137 E:3141 ||| CC
also  ||| S:3141 E:3146 ||| RB
appeared  ||| S:3146 E:3155 ||| VBD
to  ||| S:3155 E:3158 ||| TO
be  ||| S:3158 E:3161 ||| VB
linked  ||| S:3161 E:3168 ||| VBN
to  ||| S:3168 E:3171 ||| TO
integrity  ||| S:3171 E:3181 ||| NN
of  ||| S:3181 E:3184 ||| IN
actin  ||| S:3184 E:3198 ||| JJ
microfilaments  ||| S:3198 E:3213 ||| NN
and  ||| S:3213 E:3217 ||| CC
microtubule  ||| S:3217 E:3229 ||| JJ
network ||| S:3229 E:3236 ||| NN
.  ||| S:3236 E:3238 ||| .
Resveratrol  ||| S:3238 E:3258 ||| JJ
treatment  ||| S:3258 E:3268 ||| NN
also  ||| S:3268 E:3273 ||| RB
led  ||| S:3273 E:3277 ||| VBN
to  ||| S:3277 E:3280 ||| TO
activation  ||| S:3280 E:3291 ||| VB
of  ||| S:3291 E:3294 ||| IN
ERK1 ||| S:3294 E:3298 ||| CD
/ ||| S:3298 E:3299 ||| CD
2  ||| S:3299 E:3301 ||| CD
MAP  ||| S:3301 E:3305 ||| JJ
kinase ||| S:3305 E:3311 ||| NN
,  ||| S:3311 E:3321 ||| ,
similar  ||| S:3321 E:3329 ||| JJ
to  ||| S:3329 E:3332 ||| TO
changes  ||| S:3332 E:3340 ||| NNS
induced  ||| S:3340 E:3348 ||| VBN
by  ||| S:3348 E:3351 ||| IN
shear  ||| S:3351 E:3357 ||| NNS
[  ||| S:3357 E:3359 ||| -LRB-
30 ||| S:3359 E:3361 ||| CD
,  ||| S:3361 E:3363 ||| ,
31 ||| S:3363 E:3365 ||| CD
] ||| S:3365 E:3366 ||| -RRB-
.  ||| S:3366 E:3368 ||| .
Thus  ||| S:3368 E:3381 ||| RB
resveratrol  ||| S:3381 E:3393 ||| RB
may  ||| S:3393 E:3397 ||| MD
act  ||| S:3397 E:3401 ||| VB
by  ||| S:3401 E:3404 ||| IN
a  ||| S:3404 E:3406 ||| DT
mechanism ||| S:3406 E:3415 ||| NN
( ||| S:3415 E:3416 ||| -LRB-
s ||| S:3416 E:3417 ||| LS
)  ||| S:3417 E:3419 ||| -RRB-
closely  ||| S:3419 E:3427 ||| RB
resembling  ||| S:3427 E:3446 ||| VBG
that  ||| S:3446 E:3451 ||| IN
triggered  ||| S:3451 E:3461 ||| VBN
by  ||| S:3461 E:3464 ||| IN
shear  ||| S:3464 E:3470 ||| JJ
stress ||| S:3470 E:3476 ||| NN
.  ||| S:3476 E:3500 ||| .
Results  ||| S:3500 E:3527 ||| NNP
Resveratrol  ||| S:3527 E:3539 ||| NNP
induces  ||| S:3539 E:3547 ||| VBZ
morphologic  ||| S:3547 E:3559 ||| JJ
change  ||| S:3559 E:3566 ||| NN
in  ||| S:3566 E:3579 ||| IN
endothelial  ||| S:3579 E:3591 ||| JJ
cells  ||| S:3591 E:3607 ||| NNS
Sterilized  ||| S:3607 E:3618 ||| JJ
plastic  ||| S:3618 E:3626 ||| NN
18  ||| S:3626 E:3629 ||| CD
mm  ||| S:3629 E:3632 ||| CD
×  ||| S:3632 E:3634 ||| CD
21  ||| S:3634 E:3637 ||| CD
mm  ||| S:3637 E:3640 ||| CD
coverslips  ||| S:3640 E:3651 ||| NNS
were  ||| S:3651 E:3666 ||| VBD
seeded  ||| S:3666 E:3673 ||| VBN
with  ||| S:3673 E:3678 ||| IN
BPAEC  ||| S:3678 E:3684 ||| NNP
and  ||| S:3684 E:3688 ||| CC
treated  ||| S:3688 E:3696 ||| VBD
24  ||| S:3696 E:3699 ||| CD
h  ||| S:3699 E:3701 ||| NNS
later  ||| S:3701 E:3707 ||| RB
with  ||| S:3707 E:3712 ||| IN
various  ||| S:3712 E:3730 ||| JJ
concentrations  ||| S:3730 E:3745 ||| NNS
of  ||| S:3745 E:3748 ||| IN
resveratrol ||| S:3748 E:3759 ||| NN
.  ||| S:3759 E:3761 ||| .
Following  ||| S:3761 E:3771 ||| VBG
an  ||| S:3771 E:3774 ||| DT
additional  ||| S:3774 E:3785 ||| JJ
2  ||| S:3785 E:3797 ||| CD
day  ||| S:3797 E:3801 ||| NN
of  ||| S:3801 E:3804 ||| IN
culture ||| S:3804 E:3811 ||| NN
,  ||| S:3811 E:3813 ||| ,
the  ||| S:3813 E:3817 ||| DT
coverslips  ||| S:3817 E:3828 ||| NN
containing  ||| S:3828 E:3839 ||| VBG
the  ||| S:3839 E:3843 ||| DT
attached  ||| S:3843 E:3862 ||| JJ
BPAECs  ||| S:3862 E:3869 ||| NN
were  ||| S:3869 E:3874 ||| VBD
fixed ||| S:3874 E:3879 ||| VBN
,  ||| S:3879 E:3881 ||| ,
stained  ||| S:3881 E:3889 ||| VBG
with  ||| S:3889 E:3894 ||| IN
rhodamine-phalloidin ||| S:3894 E:3914 ||| NNP
,  ||| S:3914 E:3916 ||| ,
and  ||| S:3916 E:3930 ||| CC
mounted  ||| S:3930 E:3938 ||| VBN
onto  ||| S:3938 E:3943 ||| IN
slides  ||| S:3943 E:3950 ||| NNS
for  ||| S:3950 E:3954 ||| IN
analysis  ||| S:3954 E:3963 ||| NN
by  ||| S:3963 E:3966 ||| IN
confocal  ||| S:3966 E:3975 ||| JJ
microscopy ||| S:3975 E:3985 ||| NN
.  ||| S:3985 E:3997 ||| .
The  ||| S:3997 E:4001 ||| DT
polyphenol  ||| S:4001 E:4012 ||| NN
( ||| S:4012 E:4013 ||| -LRB-
100  ||| S:4013 E:4017 ||| CD
μM ||| S:4017 E:4019 ||| NN
)  ||| S:4019 E:4021 ||| -RRB-
had  ||| S:4021 E:4025 ||| VBD
a  ||| S:4025 E:4027 ||| DT
distinct  ||| S:4027 E:4036 ||| JJ
morphologic  ||| S:4036 E:4058 ||| JJ
effect ||| S:4058 E:4064 ||| NN
,  ||| S:4064 E:4066 ||| ,
changing  ||| S:4066 E:4075 ||| VBG
the  ||| S:4075 E:4079 ||| DT
cells  ||| S:4079 E:4085 ||| NNS
from  ||| S:4085 E:4090 ||| IN
a  ||| S:4090 E:4092 ||| DT
boxy ||| S:4092 E:4096 ||| JJ
,  ||| S:4096 E:4098 ||| ,
cobblestone-like  ||| S:4098 E:4125 ||| JJ
appearance  ||| S:4125 E:4136 ||| NN
( ||| S:4136 E:4137 ||| -LRB-
panel  ||| S:4137 E:4143 ||| NN
A ||| S:4143 E:4144 ||| NN
,  ||| S:4144 E:4146 ||| ,
Fig.  ||| S:4146 E:4151 ||| CD
1 ||| S:4151 E:4152 ||| CD
)  ||| S:4152 E:4154 ||| -RRB-
to  ||| S:4154 E:4157 ||| TO
an  ||| S:4157 E:4160 ||| DT
elongated ||| S:4160 E:4169 ||| NN
,  ||| S:4169 E:4171 ||| ,
ellipsoidal  ||| S:4171 E:4193 ||| JJ
shape  ||| S:4193 E:4199 ||| NN
with  ||| S:4199 E:4204 ||| IN
long ||| S:4204 E:4208 ||| JJ
,  ||| S:4208 E:4210 ||| ,
tortuous  ||| S:4210 E:4219 ||| JJ
processes  ||| S:4219 E:4229 ||| NNS
( ||| S:4229 E:4230 ||| -LRB-
panel  ||| S:4230 E:4236 ||| NN
B ||| S:4236 E:4237 ||| NNP
) ||| S:4237 E:4238 ||| -RRB-
.  ||| S:4238 E:4240 ||| .
As  ||| S:4240 E:4243 ||| IN
little  ||| S:4243 E:4260 ||| JJ
as  ||| S:4260 E:4263 ||| IN
25  ||| S:4263 E:4266 ||| CD
μM  ||| S:4266 E:4269 ||| JJ
resveratrol  ||| S:4269 E:4281 ||| NN
sufficed  ||| S:4281 E:4290 ||| VBD
to  ||| S:4290 E:4293 ||| TO
induce  ||| S:4293 E:4300 ||| VB
these  ||| S:4300 E:4306 ||| DT
cellular  ||| S:4306 E:4325 ||| JJ
changes ||| S:4325 E:4332 ||| NNS
,  ||| S:4332 E:4334 ||| ,
in  ||| S:4334 E:4337 ||| IN
passage  ||| S:4337 E:4345 ||| NN
4-7  ||| S:4345 E:4349 ||| CD
cells  ||| S:4349 E:4355 ||| NNS
( ||| S:4355 E:4356 ||| -LRB-
compare  ||| S:4356 E:4364 ||| VB
panel  ||| S:4364 E:4370 ||| NN
C  ||| S:4370 E:4372 ||| NNP
with  ||| S:4372 E:4377 ||| IN
panel  ||| S:4377 E:4393 ||| NN
A ||| S:4393 E:4394 ||| NN
,  ||| S:4394 E:4396 ||| ,
Fig.  ||| S:4396 E:4401 ||| CD
2 ||| S:4401 E:4402 ||| CD
) ||| S:4402 E:4403 ||| -RRB-
.  ||| S:4403 E:4405 ||| .
To  ||| S:4405 E:4408 ||| TO
quantify  ||| S:4408 E:4417 ||| VB
the  ||| S:4417 E:4421 ||| DT
percentages  ||| S:4421 E:4433 ||| NNS
of  ||| S:4433 E:4436 ||| IN
cells  ||| S:4436 E:4442 ||| NNS
with  ||| S:4442 E:4447 ||| IN
the  ||| S:4447 E:4461 ||| DT
elongated  ||| S:4461 E:4471 ||| JJ
morphology ||| S:4471 E:4481 ||| NN
,  ||| S:4481 E:4483 ||| ,
a  ||| S:4483 E:4485 ||| DT
minimum  ||| S:4485 E:4493 ||| NN
of  ||| S:4493 E:4496 ||| IN
300  ||| S:4496 E:4500 ||| CD
cells  ||| S:4500 E:4506 ||| NNS
in  ||| S:4506 E:4519 ||| IN
representative  ||| S:4519 E:4534 ||| JJ
microscopic  ||| S:4534 E:4546 ||| JJ
field  ||| S:4546 E:4552 ||| NN
were  ||| S:4552 E:4557 ||| VBD
counted  ||| S:4557 E:4565 ||| VBN
and  ||| S:4565 E:4569 ||| CC
the  ||| S:4569 E:4583 ||| DT
results  ||| S:4583 E:4591 ||| NNS
presented  ||| S:4591 E:4601 ||| VBN
in  ||| S:4601 E:4604 ||| IN
Fig.  ||| S:4604 E:4609 ||| CD
3 ||| S:4609 E:4610 ||| CD
.  ||| S:4610 E:4612 ||| .
The  ||| S:4612 E:4616 ||| DT
percentage  ||| S:4616 E:4627 ||| NN
of  ||| S:4627 E:4630 ||| IN
cells  ||| S:4630 E:4646 ||| NNS
showing  ||| S:4646 E:4654 ||| VBG
the  ||| S:4654 E:4658 ||| DT
elongated  ||| S:4658 E:4668 ||| JJ
phenotype  ||| S:4668 E:4678 ||| NN
is  ||| S:4678 E:4681 ||| VBZ
proportional  ||| S:4681 E:4694 ||| VBN
to  ||| S:4694 E:4697 ||| TO
the  ||| S:4697 E:4711 ||| DT
concentration  ||| S:4711 E:4725 ||| NN
of  ||| S:4725 E:4728 ||| IN
resveratrol  ||| S:4728 E:4740 ||| NN
added  ||| S:4740 E:4746 ||| VBD
to  ||| S:4746 E:4749 ||| TO
the  ||| S:4749 E:4753 ||| DT
culture ||| S:4753 E:4760 ||| NN
.  ||| S:4760 E:4772 ||| .
Treatment  ||| S:4772 E:4782 ||| NN
with  ||| S:4782 E:4787 ||| IN
resveratrol  ||| S:4787 E:4799 ||| VBG
also  ||| S:4799 E:4804 ||| RB
suppressed  ||| S:4804 E:4815 ||| JJ
growth  ||| S:4815 E:4822 ||| NN
of  ||| S:4822 E:4835 ||| IN
BPAEC  ||| S:4835 E:4841 ||| NNP
( ||| S:4841 E:4842 ||| -LRB-
data  ||| S:4842 E:4847 ||| NNS
not  ||| S:4847 E:4851 ||| RB
shown ||| S:4851 E:4856 ||| VBN
) ||| S:4856 E:4857 ||| -RRB-
,  ||| S:4857 E:4859 ||| ,
as  ||| S:4859 E:4862 ||| IN
we  ||| S:4862 E:4865 ||| PRP
previously  ||| S:4865 E:4876 ||| RB
reported  ||| S:4876 E:4885 ||| VBD
[  ||| S:4885 E:4897 ||| -LRB-
21 ||| S:4897 E:4899 ||| CD
] ||| S:4899 E:4900 ||| -RRB-
.  ||| S:4900 E:4930 ||| .
Resveratrol  ||| S:4930 E:4942 ||| JJ
treatment  ||| S:4942 E:4952 ||| NN
leads  ||| S:4952 E:4958 ||| VBZ
to  ||| S:4958 E:4961 ||| TO
increased  ||| S:4961 E:4971 ||| JJ
adherence  ||| S:4971 E:4991 ||| NN
of  ||| S:4991 E:4994 ||| IN
BPAEC  ||| S:4994 E:5000 ||| NNP
under  ||| S:5000 E:5006 ||| IN
simulated  ||| S:5006 E:5016 ||| JJ
arterial  ||| S:5016 E:5025 ||| JJ
flow  ||| S:5025 E:5030 ||| NN
conditions  ||| S:5030 E:5051 ||| NNS
To  ||| S:5051 E:5054 ||| TO
test  ||| S:5054 E:5059 ||| VB
whether  ||| S:5059 E:5067 ||| IN
functional  ||| S:5067 E:5078 ||| JJ
changes  ||| S:5078 E:5086 ||| NNS
may  ||| S:5086 E:5090 ||| MD
accompany  ||| S:5090 E:5100 ||| VB
the  ||| S:5100 E:5114 ||| DT
modified  ||| S:5114 E:5123 ||| JJ
morphology ||| S:5123 E:5133 ||| NN
,  ||| S:5133 E:5135 ||| ,
control  ||| S:5135 E:5143 ||| NN
and  ||| S:5143 E:5147 ||| CC
2  ||| S:5147 E:5149 ||| CD
day  ||| S:5149 E:5153 ||| NN
and  ||| S:5153 E:5157 ||| CC
100  ||| S:5157 E:5161 ||| CD
μM  ||| S:5161 E:5174 ||| JJ
resveratrol-treated  ||| S:5174 E:5194 ||| JJ
cells  ||| S:5194 E:5200 ||| NNS
were  ||| S:5200 E:5205 ||| VBD
exposed  ||| S:5205 E:5213 ||| VBN
to  ||| S:5213 E:5216 ||| TO
0  ||| S:5216 E:5218 ||| CD
min  ||| S:5218 E:5232 ||| NNS
( ||| S:5232 E:5233 ||| -LRB-
control ||| S:5233 E:5240 ||| NN
) ||| S:5240 E:5241 ||| -RRB-
,  ||| S:5241 E:5243 ||| ,
2  ||| S:5243 E:5245 ||| CD
min ||| S:5245 E:5248 ||| NN
,  ||| S:5248 E:5250 ||| ,
or  ||| S:5250 E:5253 ||| CC
5  ||| S:5253 E:5255 ||| CD
min  ||| S:5255 E:5259 ||| NN
of  ||| S:5259 E:5262 ||| IN
simulated  ||| S:5262 E:5272 ||| JJ
arterial  ||| S:5272 E:5281 ||| JJ
shear  ||| S:5281 E:5297 ||| NNS
stress  ||| S:5297 E:5304 ||| VBP
using  ||| S:5304 E:5310 ||| VBG
a  ||| S:5310 E:5312 ||| DT
parallel  ||| S:5312 E:5321 ||| JJ
plate  ||| S:5321 E:5327 ||| NN
perfusion  ||| S:5327 E:5337 ||| NN
chamber  ||| S:5337 E:5345 ||| NN
( ||| S:5345 E:5346 ||| -LRB-
see  ||| S:5346 E:5360 ||| VB
Materials  ||| S:5360 E:5370 ||| NNPS
and  ||| S:5370 E:5374 ||| CC
Methods ||| S:5374 E:5381 ||| NNP
) ||| S:5381 E:5382 ||| -RRB-
.  ||| S:5382 E:5384 ||| .
Following  ||| S:5384 E:5394 ||| VBG
the  ||| S:5394 E:5398 ||| DT
shear  ||| S:5398 E:5404 ||| JJ
challenge ||| S:5404 E:5413 ||| NN
,  ||| S:5413 E:5425 ||| ,
cells  ||| S:5425 E:5431 ||| NNS
remaining  ||| S:5431 E:5441 ||| VBG
attached  ||| S:5441 E:5450 ||| VBN
were  ||| S:5450 E:5455 ||| VBD
scored  ||| S:5455 E:5462 ||| VBN
by  ||| S:5462 E:5465 ||| IN
staining  ||| S:5465 E:5474 ||| NN
with  ||| S:5474 E:5489 ||| IN
rhodamine-phalloidin ||| S:5489 E:5509 ||| NNP
,  ||| S:5509 E:5511 ||| ,
as  ||| S:5511 E:5514 ||| RB
described ||| S:5514 E:5523 ||| VBN
.  ||| S:5523 E:5525 ||| .
Since  ||| S:5525 E:5531 ||| IN
the  ||| S:5531 E:5535 ||| DT
cells  ||| S:5535 E:5541 ||| NNS
were  ||| S:5541 E:5556 ||| VBD
evenly  ||| S:5556 E:5563 ||| RB
distributed  ||| S:5563 E:5575 ||| VBN
throughout  ||| S:5575 E:5586 ||| IN
the  ||| S:5586 E:5590 ||| DT
area  ||| S:5590 E:5595 ||| NN
of  ||| S:5595 E:5598 ||| IN
the  ||| S:5598 E:5602 ||| DT
coverslip  ||| S:5602 E:5622 ||| NN
exposed  ||| S:5622 E:5630 ||| VBN
to  ||| S:5630 E:5633 ||| TO
flow ||| S:5633 E:5637 ||| VB
,  ||| S:5637 E:5639 ||| ,
representative  ||| S:5639 E:5654 ||| JJ
pictures  ||| S:5654 E:5663 ||| NNS
were  ||| S:5663 E:5668 ||| VBD
taken  ||| S:5668 E:5674 ||| VBN
of  ||| S:5674 E:5687 ||| IN
the  ||| S:5687 E:5691 ||| DT
confocal  ||| S:5691 E:5700 ||| JJ
microscopy  ||| S:5700 E:5711 ||| JJ
fields  ||| S:5711 E:5718 ||| NNS
located  ||| S:5718 E:5726 ||| VBN
directly  ||| S:5726 E:5735 ||| RB
in  ||| S:5735 E:5738 ||| IN
the  ||| S:5738 E:5752 ||| DT
center  ||| S:5752 E:5759 ||| NN
of  ||| S:5759 E:5762 ||| IN
the  ||| S:5762 E:5766 ||| DT
coverslip ||| S:5766 E:5775 ||| NN
,  ||| S:5775 E:5777 ||| ,
and  ||| S:5777 E:5781 ||| CC
the  ||| S:5781 E:5785 ||| DT
number  ||| S:5785 E:5792 ||| NN
of  ||| S:5792 E:5795 ||| IN
cells  ||| S:5795 E:5801 ||| NNS
were  ||| S:5801 E:5816 ||| VBD
counted ||| S:5816 E:5823 ||| VBN
.  ||| S:5823 E:5825 ||| .
As  ||| S:5825 E:5828 ||| RB
can  ||| S:5828 E:5832 ||| MD
be  ||| S:5832 E:5835 ||| VB
seen  ||| S:5835 E:5840 ||| VBN
in  ||| S:5840 E:5843 ||| IN
Fig.  ||| S:5843 E:5848 ||| CD
4 ||| S:5848 E:5849 ||| CD
,  ||| S:5849 E:5851 ||| ,
compared  ||| S:5851 E:5860 ||| VBN
to  ||| S:5860 E:5863 ||| TO
the  ||| S:5863 E:5867 ||| DT
0  ||| S:5867 E:5869 ||| CD
min  ||| S:5869 E:5883 ||| JJ
sample ||| S:5883 E:5889 ||| NN
,  ||| S:5889 E:5891 ||| ,
a  ||| S:5891 E:5893 ||| DT
significant  ||| S:5893 E:5905 ||| JJ
percentage  ||| S:5905 E:5916 ||| NN
of  ||| S:5916 E:5919 ||| IN
resveratrol-treated  ||| S:5919 E:5949 ||| NNP
BPAEC  ||| S:5949 E:5955 ||| NNP
remained  ||| S:5955 E:5964 ||| VBD
attached  ||| S:5964 E:5973 ||| VBN
to  ||| S:5973 E:5976 ||| TO
the  ||| S:5976 E:5980 ||| DT
plastic  ||| S:5980 E:5988 ||| JJ
coverslips  ||| S:5988 E:5999 ||| NN
after  ||| S:5999 E:6005 ||| IN
2  ||| S:6005 E:6017 ||| CD
min  ||| S:6017 E:6021 ||| NNS
and  ||| S:6021 E:6025 ||| CC
5  ||| S:6025 E:6027 ||| CD
min  ||| S:6027 E:6031 ||| JJ
flow  ||| S:6031 E:6036 ||| NN
challenge ||| S:6036 E:6045 ||| NN
.  ||| S:6045 E:6047 ||| .
In  ||| S:6047 E:6050 ||| IN
comparison ||| S:6050 E:6060 ||| NN
,  ||| S:6060 E:6062 ||| ,
under  ||| S:6062 E:6078 ||| IN
identical  ||| S:6078 E:6088 ||| JJ
experimental  ||| S:6088 E:6101 ||| JJ
conditions ||| S:6101 E:6111 ||| NNS
,  ||| S:6111 E:6113 ||| ,
cells  ||| S:6113 E:6119 ||| NNS
adhering  ||| S:6119 E:6128 ||| VBP
to  ||| S:6128 E:6131 ||| TO
the  ||| S:6131 E:6145 ||| DT
coverslips  ||| S:6145 E:6156 ||| NN
decreased  ||| S:6156 E:6166 ||| VBD
dramatically  ||| S:6166 E:6179 ||| RB
in  ||| S:6179 E:6182 ||| IN
controls ||| S:6182 E:6190 ||| NNS
,  ||| S:6190 E:6192 ||| ,
with  ||| S:6192 E:6207 ||| IN
virtually  ||| S:6207 E:6217 ||| RB
no  ||| S:6217 E:6220 ||| DT
cells  ||| S:6220 E:6226 ||| NNS
remaining  ||| S:6226 E:6236 ||| VBG
after  ||| S:6236 E:6242 ||| IN
a  ||| S:6242 E:6244 ||| DT
5  ||| S:6244 E:6246 ||| CD
min  ||| S:6246 E:6250 ||| CD
simulated  ||| S:6250 E:6270 ||| JJ
flow ||| S:6270 E:6274 ||| NN
.  ||| S:6274 E:6276 ||| .
These  ||| S:6276 E:6282 ||| DT
results  ||| S:6282 E:6290 ||| NNS
suggest  ||| S:6290 E:6298 ||| VBP
that  ||| S:6298 E:6303 ||| IN
a  ||| S:6303 E:6305 ||| DT
functional  ||| S:6305 E:6316 ||| JJ
alteration ||| S:6316 E:6326 ||| NN
,  ||| S:6326 E:6338 ||| ,
measured  ||| S:6338 E:6347 ||| VBN
by  ||| S:6347 E:6350 ||| IN
greater  ||| S:6350 E:6358 ||| JJR
adherence  ||| S:6358 E:6368 ||| NN
of  ||| S:6368 E:6371 ||| IN
cells  ||| S:6371 E:6377 ||| NNS
under  ||| S:6377 E:6383 ||| IN
simulated  ||| S:6383 E:6403 ||| JJ
arterial  ||| S:6403 E:6412 ||| JJ
flow  ||| S:6412 E:6417 ||| NN
conditions ||| S:6417 E:6427 ||| NNS
,  ||| S:6427 E:6429 ||| ,
accompanied  ||| S:6429 E:6441 ||| VBN
the  ||| S:6441 E:6445 ||| DT
change  ||| S:6445 E:6452 ||| NN
in  ||| S:6452 E:6465 ||| IN
cellular  ||| S:6465 E:6474 ||| JJ
phenotype ||| S:6474 E:6483 ||| NN
,  ||| S:6483 E:6485 ||| ,
following  ||| S:6485 E:6495 ||| VBG
treatment  ||| S:6495 E:6505 ||| NN
with  ||| S:6505 E:6520 ||| IN
resveratrol ||| S:6520 E:6531 ||| NN
.  ||| S:6531 E:6561 ||| .
Effect  ||| S:6561 E:6568 ||| NN
of  ||| S:6568 E:6571 ||| IN
cell  ||| S:6571 E:6576 ||| NN
signaling  ||| S:6576 E:6586 ||| VBG
inhibitors  ||| S:6586 E:6597 ||| NN
on  ||| S:6597 E:6600 ||| IN
cell  ||| S:6600 E:6615 ||| NN
elongation  ||| S:6615 E:6626 ||| VBZ
induced  ||| S:6626 E:6634 ||| VBN
by  ||| S:6634 E:6637 ||| IN
resveratrol  ||| S:6637 E:6659 ||| JJ
Further  ||| S:6659 E:6667 ||| JJ
insights  ||| S:6667 E:6676 ||| NNS
into  ||| S:6676 E:6681 ||| IN
the  ||| S:6681 E:6685 ||| DT
nature  ||| S:6685 E:6692 ||| NN
of  ||| S:6692 E:6695 ||| IN
the  ||| S:6695 E:6709 ||| DT
resveratrol-induced  ||| S:6709 E:6729 ||| JJ
morphologcial  ||| S:6729 E:6743 ||| JJ
changes  ||| S:6743 E:6751 ||| NNS
came  ||| S:6751 E:6756 ||| VBD
from  ||| S:6756 E:6771 ||| IN
studies  ||| S:6771 E:6779 ||| NNS
using  ||| S:6779 E:6785 ||| VBG
selective  ||| S:6785 E:6795 ||| JJ
inhibitors  ||| S:6795 E:6806 ||| NN
for  ||| S:6806 E:6810 ||| IN
different  ||| S:6810 E:6830 ||| JJ
signaling  ||| S:6830 E:6840 ||| JJ
pathways ||| S:6840 E:6848 ||| NN
.  ||| S:6848 E:6850 ||| .
These  ||| S:6850 E:6856 ||| DT
include ||| S:6856 E:6863 ||| VBP
:  ||| S:6863 E:6865 ||| :
quin2-AM  ||| S:6865 E:6884 ||| CD
( ||| S:6884 E:6885 ||| -LRB-
intracellular  ||| S:6885 E:6899 ||| FW
[ ||| S:6899 E:6900 ||| -LRB-
Ca  ||| S:6900 E:6903 ||| NNP
2+ ||| S:6903 E:6905 ||| NNP
] ||| S:6905 E:6906 ||| -RRB-
) ||| S:6906 E:6907 ||| -RRB-
,  ||| S:6907 E:6909 ||| ,
herbimycin  ||| S:6909 E:6920 ||| VBG
A  ||| S:6920 E:6922 ||| DT
( ||| S:6922 E:6923 ||| -LRB-
tyrosine  ||| S:6923 E:6932 ||| FW
kinases ||| S:6932 E:6939 ||| FW
) ||| S:6939 E:6940 ||| -RRB-
,  ||| S:6940 E:6952 ||| ,
chelerythrine  ||| S:6952 E:6966 ||| NNS
( ||| S:6966 E:6967 ||| -LRB-
PKC ||| S:6967 E:6970 ||| NNP
) ||| S:6970 E:6971 ||| -RRB-
,  ||| S:6971 E:6973 ||| ,
cytochalasin  ||| S:6973 E:6986 ||| VBG
D  ||| S:6986 E:6988 ||| NNP
( ||| S:6988 E:6989 ||| -LRB-
actin  ||| S:6989 E:7005 ||| FW
microfilaments ||| S:7005 E:7019 ||| FW
) ||| S:7019 E:7020 ||| -RRB-
,  ||| S:7020 E:7022 ||| ,
and  ||| S:7022 E:7026 ||| CC
nocodazole  ||| S:7026 E:7037 ||| NNS
( ||| S:7037 E:7038 ||| -LRB-
disassembly  ||| S:7038 E:7050 ||| NN
of  ||| S:7050 E:7063 ||| IN
microtubules ||| S:7063 E:7075 ||| CD
) ||| S:7075 E:7076 ||| -RRB-
.  ||| S:7076 E:7078 ||| .
Cells  ||| S:7078 E:7084 ||| NNS
were  ||| S:7084 E:7089 ||| VBD
treated  ||| S:7089 E:7097 ||| VBN
with  ||| S:7097 E:7102 ||| IN
inhibitors ||| S:7102 E:7112 ||| NN
,  ||| S:7112 E:7114 ||| ,
at  ||| S:7114 E:7127 ||| IN
concentrations  ||| S:7127 E:7142 ||| NNS
indicated  ||| S:7142 E:7152 ||| VBD
in  ||| S:7152 E:7155 ||| IN
Materials  ||| S:7155 E:7165 ||| NNPS
and  ||| S:7165 E:7169 ||| CC
Methods ||| S:7169 E:7176 ||| NNP
,  ||| S:7176 E:7178 ||| ,
and  ||| S:7178 E:7192 ||| CC
then  ||| S:7192 E:7197 ||| RB
exposed  ||| S:7197 E:7205 ||| VBN
to  ||| S:7205 E:7208 ||| TO
resveratrol ||| S:7208 E:7219 ||| VB
.  ||| S:7219 E:7221 ||| .
Representative  ||| S:7221 E:7236 ||| NNP
confocal  ||| S:7236 E:7255 ||| VBD
microscopy  ||| S:7255 E:7266 ||| JJ
fields  ||| S:7266 E:7273 ||| NNS
for  ||| S:7273 E:7277 ||| IN
both  ||| S:7277 E:7282 ||| DT
control  ||| S:7282 E:7290 ||| NN
and  ||| S:7290 E:7304 ||| CC
resveratrol-treated  ||| S:7304 E:7324 ||| JJ
cells  ||| S:7324 E:7330 ||| NNS
were  ||| S:7330 E:7335 ||| VBD
counted  ||| S:7335 E:7343 ||| VBN
for  ||| S:7343 E:7347 ||| IN
elongated  ||| S:7347 E:7357 ||| NN
and  ||| S:7357 E:7371 ||| CC
non-elongated  ||| S:7371 E:7385 ||| JJ
cells ||| S:7385 E:7390 ||| NNS
.  ||| S:7390 E:7392 ||| .
The  ||| S:7392 E:7396 ||| DT
inhibitors  ||| S:7396 E:7407 ||| NN
used  ||| S:7407 E:7412 ||| VBD
noticeably  ||| S:7412 E:7433 ||| RB
suppressed  ||| S:7433 E:7444 ||| JJ
cell  ||| S:7444 E:7449 ||| NN
growth  ||| S:7449 E:7456 ||| NN
( ||| S:7456 E:7457 ||| -LRB-
particularly  ||| S:7457 E:7470 ||| RB
treatment  ||| S:7470 E:7480 ||| NN
with  ||| S:7480 E:7495 ||| IN
cytochalasin  ||| S:7495 E:7508 ||| JJ
D  ||| S:7508 E:7510 ||| NNP
and  ||| S:7510 E:7514 ||| CC
nocodazole ||| S:7514 E:7524 ||| CD
) ||| S:7524 E:7525 ||| -RRB-
,  ||| S:7525 E:7527 ||| ,
particularly  ||| S:7527 E:7540 ||| RB
controls  ||| S:7540 E:7549 ||| VBZ
not  ||| S:7549 E:7563 ||| RB
treated  ||| S:7563 E:7571 ||| VBN
with  ||| S:7571 E:7576 ||| IN
resveratrol ||| S:7576 E:7587 ||| NN
.  ||| S:7587 E:7589 ||| .
The  ||| S:7589 E:7593 ||| DT
degree  ||| S:7593 E:7600 ||| NN
of  ||| S:7600 E:7603 ||| IN
growth  ||| S:7603 E:7610 ||| NN
inhibition  ||| S:7610 E:7631 ||| VBZ
varied ||| S:7631 E:7637 ||| VBN
,  ||| S:7637 E:7639 ||| ,
depending  ||| S:7639 E:7649 ||| VBG
on  ||| S:7649 E:7652 ||| IN
preparations  ||| S:7652 E:7665 ||| NNS
of  ||| S:7665 E:7668 ||| IN
primary  ||| S:7668 E:7676 ||| JJ
BPAEC ||| S:7676 E:7681 ||| NNP
.  ||| S:7681 E:7693 ||| .
Interestingly ||| S:7693 E:7706 ||| RB
,  ||| S:7706 E:7708 ||| ,
cells  ||| S:7708 E:7714 ||| NNS
treated  ||| S:7714 E:7722 ||| VBN
with  ||| S:7722 E:7727 ||| IN
resveratrol ||| S:7727 E:7738 ||| NN
,  ||| S:7738 E:7740 ||| ,
which  ||| S:7740 E:7746 ||| WDT
had  ||| S:7746 E:7760 ||| VBD
to  ||| S:7760 E:7763 ||| TO
be  ||| S:7763 E:7766 ||| VB
reduced  ||| S:7766 E:7774 ||| VBN
to  ||| S:7774 E:7777 ||| TO
40  ||| S:7777 E:7780 ||| CD
h  ||| S:7780 E:7782 ||| NN
because  ||| S:7782 E:7790 ||| IN
of  ||| S:7790 E:7793 ||| IN
adverse  ||| S:7793 E:7801 ||| JJ
responses  ||| S:7801 E:7811 ||| NNS
of  ||| S:7811 E:7824 ||| IN
control  ||| S:7824 E:7832 ||| NN
cells  ||| S:7832 E:7838 ||| NNS
to  ||| S:7838 E:7841 ||| TO
inhibitors  ||| S:7841 E:7852 ||| VB
( ||| S:7852 E:7853 ||| -LRB-
see  ||| S:7853 E:7857 ||| VB
Materials  ||| S:7857 E:7867 ||| NNPS
and  ||| S:7867 E:7871 ||| CC
Methods ||| S:7871 E:7878 ||| NNP
) ||| S:7878 E:7879 ||| -RRB-
,  ||| S:7879 E:7891 ||| ,
afforded  ||| S:7891 E:7900 ||| VBN
better  ||| S:7900 E:7907 ||| JJR
growth  ||| S:7907 E:7914 ||| NN
in  ||| S:7914 E:7917 ||| IN
samples  ||| S:7917 E:7925 ||| NNS
containing  ||| S:7925 E:7936 ||| VBG
the  ||| S:7936 E:7950 ||| DT
inhibitors ||| S:7950 E:7960 ||| NN
.  ||| S:7960 E:7962 ||| .
Table  ||| S:7962 E:7968 ||| NN
1summarized  ||| S:7968 E:7980 ||| CD
results  ||| S:7980 E:7988 ||| NNS
averaged  ||| S:7988 E:7997 ||| VBD
from  ||| S:7997 E:8002 ||| IN
4  ||| S:8002 E:8014 ||| CD
separate  ||| S:8014 E:8023 ||| JJ
experiments ||| S:8023 E:8034 ||| NNS
,  ||| S:8034 E:8036 ||| ,
each  ||| S:8036 E:8041 ||| DT
performed  ||| S:8041 E:8051 ||| VBN
with  ||| S:8051 E:8056 ||| IN
a  ||| S:8056 E:8058 ||| DT
different  ||| S:8058 E:8078 ||| JJ
preparation  ||| S:8078 E:8090 ||| NN
of  ||| S:8090 E:8093 ||| IN
primary  ||| S:8093 E:8101 ||| JJ
BPAEC ||| S:8101 E:8106 ||| NNP
.  ||| S:8106 E:8108 ||| .
Since  ||| S:8108 E:8114 ||| IN
growth  ||| S:8114 E:8121 ||| NN
of  ||| S:8121 E:8124 ||| IN
control  ||| S:8124 E:8142 ||| NN
cells  ||| S:8142 E:8148 ||| NNS
as  ||| S:8148 E:8151 ||| IN
well  ||| S:8151 E:8156 ||| RB
as  ||| S:8156 E:8159 ||| IN
their  ||| S:8159 E:8165 ||| PRP$
response  ||| S:8165 E:8174 ||| NN
to  ||| S:8174 E:8177 ||| TO
resveratrol  ||| S:8177 E:8189 ||| VB
and  ||| S:8189 E:8203 ||| CC
addition  ||| S:8203 E:8212 ||| NN
of  ||| S:8212 E:8215 ||| IN
inhibitors  ||| S:8215 E:8226 ||| JJ
differed  ||| S:8226 E:8235 ||| NN
between  ||| S:8235 E:8243 ||| IN
BPAEC  ||| S:8243 E:8259 ||| NNP
preparations ||| S:8259 E:8271 ||| NNS
,  ||| S:8271 E:8273 ||| ,
cells  ||| S:8273 E:8279 ||| NNS
showing  ||| S:8279 E:8287 ||| VBG
the  ||| S:8287 E:8291 ||| DT
elongated  ||| S:8291 E:8301 ||| JJ
shape  ||| S:8301 E:8307 ||| NN
in  ||| S:8307 E:8310 ||| IN
each  ||| S:8310 E:8325 ||| DT
experiment  ||| S:8325 E:8336 ||| NN
were  ||| S:8336 E:8341 ||| VBD
calculated  ||| S:8341 E:8352 ||| VBN
as  ||| S:8352 E:8355 ||| IN
a  ||| S:8355 E:8357 ||| DT
percent  ||| S:8357 E:8365 ||| NN
of  ||| S:8365 E:8368 ||| IN
total  ||| S:8368 E:8374 ||| JJ
cells  ||| S:8374 E:8390 ||| NNS
counted  ||| S:8390 E:8398 ||| VBN
( ||| S:8398 E:8399 ||| -LRB-
ranging  ||| S:8399 E:8407 ||| VBG
from  ||| S:8407 E:8412 ||| IN
60-700 ||| S:8412 E:8418 ||| CD
) ||| S:8418 E:8419 ||| -RRB-
.  ||| S:8419 E:8421 ||| .
The  ||| S:8421 E:8425 ||| DT
numbers  ||| S:8425 E:8433 ||| NNS
obtained  ||| S:8433 E:8442 ||| VBN
in  ||| S:8442 E:8455 ||| IN
this  ||| S:8455 E:8460 ||| DT
manner  ||| S:8460 E:8467 ||| NN
were  ||| S:8467 E:8472 ||| VBD
used  ||| S:8472 E:8477 ||| VBN
to  ||| S:8477 E:8480 ||| TO
calculate  ||| S:8480 E:8490 ||| VB
the  ||| S:8490 E:8494 ||| DT
mean  ||| S:8494 E:8499 ||| NN
( ||| S:8499 E:8500 ||| -LRB-
% ||| S:8500 E:8501 ||| NN
) ||| S:8501 E:8502 ||| -RRB-
±  ||| S:8502 E:8504 ||| NNP
SD ||| S:8504 E:8506 ||| NNP
,  ||| S:8506 E:8508 ||| ,
as  ||| S:8508 E:8521 ||| RB
shown ||| S:8521 E:8526 ||| VBN
.  ||| S:8526 E:8528 ||| .
Addition  ||| S:8528 E:8537 ||| NN
of  ||| S:8537 E:8540 ||| IN
chelerythrine ||| S:8540 E:8553 ||| NN
,  ||| S:8553 E:8555 ||| ,
an  ||| S:8555 E:8558 ||| DT
inhibitor  ||| S:8558 E:8568 ||| NN
of  ||| S:8568 E:8571 ||| IN
protein  ||| S:8571 E:8589 ||| NN
kinase  ||| S:8589 E:8596 ||| VBD
C ||| S:8596 E:8597 ||| NNP
,  ||| S:8597 E:8599 ||| ,
caused  ||| S:8599 E:8606 ||| VBD
a  ||| S:8606 E:8608 ||| DT
significant  ||| S:8608 E:8620 ||| JJ
increase  ||| S:8620 E:8629 ||| NN
in  ||| S:8629 E:8632 ||| IN
percentage  ||| S:8632 E:8643 ||| NN
of  ||| S:8643 E:8656 ||| IN
elongated  ||| S:8656 E:8666 ||| JJ
cells  ||| S:8666 E:8672 ||| NNS
alone  ||| S:8672 E:8678 ||| RB
and  ||| S:8678 E:8682 ||| CC
did  ||| S:8682 E:8686 ||| VBD
not  ||| S:8686 E:8690 ||| RB
affect  ||| S:8690 E:8697 ||| VB
morphologic  ||| S:8697 E:8719 ||| JJ
response  ||| S:8719 E:8728 ||| NN
of  ||| S:8728 E:8731 ||| IN
cells  ||| S:8731 E:8737 ||| NNS
to  ||| S:8737 E:8740 ||| TO
resveratrol ||| S:8740 E:8751 ||| VB
.  ||| S:8751 E:8753 ||| .
Inhibitors  ||| S:8753 E:8764 ||| NNP
of  ||| S:8764 E:8777 ||| IN
intracellular  ||| S:8777 E:8791 ||| NNS
[ ||| S:8791 E:8792 ||| -LRB-
Ca  ||| S:8792 E:8795 ||| NNP
2+ ||| S:8795 E:8797 ||| NNP
]  ||| S:8797 E:8799 ||| -RRB-
and  ||| S:8799 E:8803 ||| CC
tyrosine  ||| S:8803 E:8812 ||| JJ
kinase  ||| S:8812 E:8819 ||| JJ
activity  ||| S:8819 E:8838 ||| NN
effectively  ||| S:8838 E:8850 ||| RB
reduced  ||| S:8850 E:8858 ||| VBN
the  ||| S:8858 E:8862 ||| DT
percentage  ||| S:8862 E:8873 ||| NN
of  ||| S:8873 E:8876 ||| IN
elongated  ||| S:8876 E:8886 ||| JJ
cells  ||| S:8886 E:8902 ||| NNS
elicited  ||| S:8902 E:8911 ||| VBN
by  ||| S:8911 E:8914 ||| IN
resveratrol ||| S:8914 E:8925 ||| NN
.  ||| S:8925 E:8927 ||| .
Results  ||| S:8927 E:8935 ||| NNS
in  ||| S:8935 E:8938 ||| IN
Table  ||| S:8938 E:8944 ||| NNP
1further  ||| S:8944 E:8953 ||| NNP
showed  ||| S:8953 E:8970 ||| VBD
that  ||| S:8970 E:8975 ||| DT
cytoskeletal  ||| S:8975 E:8988 ||| JJ
changes  ||| S:8988 E:8996 ||| NNS
elicited  ||| S:8996 E:9005 ||| VBN
by  ||| S:9005 E:9008 ||| IN
resveratrol  ||| S:9008 E:9020 ||| VBG
also  ||| S:9020 E:9035 ||| RB
appeared  ||| S:9035 E:9044 ||| VBD
to  ||| S:9044 E:9047 ||| TO
be  ||| S:9047 E:9050 ||| VB
linked  ||| S:9050 E:9057 ||| VBN
to  ||| S:9057 E:9060 ||| TO
integrity  ||| S:9060 E:9070 ||| NN
of  ||| S:9070 E:9073 ||| IN
actin  ||| S:9073 E:9089 ||| JJ
microfilaments  ||| S:9089 E:9104 ||| NN
and  ||| S:9104 E:9108 ||| CC
microtubule  ||| S:9108 E:9120 ||| JJ
network  ||| S:9120 E:9128 ||| NN
as  ||| S:9128 E:9131 ||| IN
the  ||| S:9131 E:9135 ||| DT
morphologic  ||| S:9135 E:9157 ||| JJ
changes  ||| S:9157 E:9165 ||| NNS
were  ||| S:9165 E:9170 ||| VBD
also  ||| S:9170 E:9175 ||| RB
substantially  ||| S:9175 E:9189 ||| RB
lowered  ||| S:9189 E:9197 ||| VBN
in  ||| S:9197 E:9200 ||| IN
cells  ||| S:9200 E:9206 ||| NNS
treated  ||| S:9206 E:9224 ||| VBN
with  ||| S:9224 E:9229 ||| IN
cytochalasin  ||| S:9229 E:9242 ||| JJ
D  ||| S:9242 E:9244 ||| NNP
and  ||| S:9244 E:9248 ||| CC
nocodazole ||| S:9248 E:9258 ||| NN
,  ||| S:9258 E:9260 ||| ,
which  ||| S:9260 E:9266 ||| WDT
inhibit  ||| S:9266 E:9284 ||| VBP
formation  ||| S:9284 E:9294 ||| NN
of  ||| S:9294 E:9297 ||| IN
actin  ||| S:9297 E:9303 ||| JJ
microfilaments  ||| S:9303 E:9318 ||| NN
and  ||| S:9318 E:9322 ||| CC
microtubule  ||| S:9322 E:9344 ||| JJ
network ||| S:9344 E:9351 ||| NN
,  ||| S:9351 E:9353 ||| ,
respectively ||| S:9353 E:9365 ||| RB
.  ||| S:9365 E:9395 ||| .
Effect  ||| S:9395 E:9402 ||| NN
of  ||| S:9402 E:9405 ||| IN
resveratrol  ||| S:9405 E:9417 ||| NN
on  ||| S:9417 E:9420 ||| IN
ERK1 ||| S:9420 E:9424 ||| CD
/ ||| S:9424 E:9425 ||| CD
2  ||| S:9425 E:9427 ||| CD
activation  ||| S:9427 E:9438 ||| NNS
and  ||| S:9438 E:9452 ||| CC
eIF4E ||| S:9452 E:9457 ||| NNP
,  ||| S:9457 E:9459 ||| ,
eNOS  ||| S:9459 E:9464 ||| JJ
expression  ||| S:9464 E:9485 ||| NN
Biochemical  ||| S:9485 E:9497 ||| NNP
changes  ||| S:9497 E:9505 ||| NNS
in  ||| S:9505 E:9508 ||| IN
resveratrol-treated  ||| S:9508 E:9528 ||| NNP
BPAEC  ||| S:9528 E:9534 ||| NNP
were  ||| S:9534 E:9549 ||| VBD
assessed  ||| S:9549 E:9558 ||| VBN
by  ||| S:9558 E:9561 ||| IN
western  ||| S:9561 E:9569 ||| JJ
blot  ||| S:9569 E:9574 ||| JJ
analyses ||| S:9574 E:9582 ||| NNS
.  ||| S:9582 E:9584 ||| .
Fig.  ||| S:9584 E:9589 ||| NNP
5shows  ||| S:9589 E:9596 ||| NNP
that  ||| S:9596 E:9601 ||| IN
in  ||| S:9601 E:9614 ||| IN
control  ||| S:9614 E:9622 ||| NN
cells ||| S:9622 E:9627 ||| NNS
,  ||| S:9627 E:9629 ||| ,
level  ||| S:9629 E:9635 ||| NN
of  ||| S:9635 E:9638 ||| IN
active  ||| S:9638 E:9645 ||| JJ
ERK1 ||| S:9645 E:9649 ||| NNP
/ ||| S:9649 E:9650 ||| NNP
2-P  ||| S:9650 E:9654 ||| NNP
remained  ||| S:9654 E:9673 ||| VBD
relatively  ||| S:9673 E:9684 ||| RB
constant  ||| S:9684 E:9693 ||| VB
up  ||| S:9693 E:9696 ||| RP
to  ||| S:9696 E:9699 ||| TO
48  ||| S:9699 E:9702 ||| CD
h  ||| S:9702 E:9704 ||| NNS
but  ||| S:9704 E:9708 ||| CC
showed  ||| S:9708 E:9715 ||| VBD
a  ||| S:9715 E:9717 ||| DT
precipitous  ||| S:9717 E:9739 ||| JJ
decline  ||| S:9739 E:9747 ||| NN
from  ||| S:9747 E:9752 ||| IN
48  ||| S:9752 E:9755 ||| CD
to  ||| S:9755 E:9758 ||| TO
96  ||| S:9758 E:9761 ||| CD
h  ||| S:9761 E:9763 ||| NNS
( ||| S:9763 E:9764 ||| -LRB-
panel  ||| S:9764 E:9770 ||| NN
A ||| S:9770 E:9771 ||| NNP
) ||| S:9771 E:9772 ||| -RRB-
.  ||| S:9772 E:9774 ||| .
Under  ||| S:9774 E:9780 ||| IN
the  ||| S:9780 E:9784 ||| DT
same  ||| S:9784 E:9799 ||| JJ
conditions ||| S:9799 E:9809 ||| NNS
,  ||| S:9809 E:9811 ||| ,
levels  ||| S:9811 E:9818 ||| NNS
of  ||| S:9818 E:9821 ||| IN
total  ||| S:9821 E:9827 ||| JJ
ERK1 ||| S:9827 E:9831 ||| CD
/ ||| S:9831 E:9832 ||| CD
2  ||| S:9832 E:9834 ||| CD
( ||| S:9834 E:9835 ||| -LRB-
panel  ||| S:9835 E:9841 ||| NN
B ||| S:9841 E:9842 ||| NNP
) ||| S:9842 E:9843 ||| -RRB-
,  ||| S:9843 E:9845 ||| ,
eIF4E  ||| S:9845 E:9861 ||| NNP
( ||| S:9861 E:9862 ||| -LRB-
panel  ||| S:9862 E:9868 ||| NN
C ||| S:9868 E:9869 ||| NNP
) ||| S:9869 E:9870 ||| -RRB-
,  ||| S:9870 E:9872 ||| ,
a  ||| S:9872 E:9874 ||| DT
downstream  ||| S:9874 E:9885 ||| JJ
effector  ||| S:9885 E:9894 ||| NN
of  ||| S:9894 E:9897 ||| IN
ERK1 ||| S:9897 E:9901 ||| CD
/ ||| S:9901 E:9902 ||| CD
ERK2 ||| S:9902 E:9906 ||| CD
,  ||| S:9906 E:9908 ||| ,
and  ||| S:9908 E:9912 ||| CC
actin  ||| S:9912 E:9928 ||| NNS
( ||| S:9928 E:9929 ||| -LRB-
panel  ||| S:9929 E:9935 ||| NN
E ||| S:9935 E:9936 ||| NN
)  ||| S:9936 E:9938 ||| -RRB-
showed  ||| S:9938 E:9945 ||| VBD
no  ||| S:9945 E:9948 ||| DT
substantial  ||| S:9948 E:9960 ||| JJ
change  ||| S:9960 E:9967 ||| NN
at  ||| S:9967 E:9970 ||| IN
all  ||| S:9970 E:9974 ||| DT
time  ||| S:9974 E:9979 ||| NN
points  ||| S:9979 E:9996 ||| NNS
assayed ||| S:9996 E:10003 ||| NN
,  ||| S:10003 E:10005 ||| ,
in  ||| S:10005 E:10008 ||| IN
control  ||| S:10008 E:10016 ||| NN
cells ||| S:10016 E:10021 ||| NNS
.  ||| S:10021 E:10023 ||| .
Treatment  ||| S:10023 E:10033 ||| NN
with  ||| S:10033 E:10038 ||| IN
25  ||| S:10038 E:10041 ||| CD
μM  ||| S:10041 E:10044 ||| JJ
and  ||| S:10044 E:10048 ||| CC
100  ||| S:10048 E:10062 ||| CD
μM  ||| S:10062 E:10065 ||| JJ
resveratrol  ||| S:10065 E:10077 ||| NN
prevented  ||| S:10077 E:10087 ||| VBD
the  ||| S:10087 E:10091 ||| DT
decrease  ||| S:10091 E:10100 ||| NN
in  ||| S:10100 E:10103 ||| IN
active  ||| S:10103 E:10110 ||| JJ
ERK1 ||| S:10110 E:10114 ||| CD
/ ||| S:10114 E:10115 ||| CD
2-P  ||| S:10115 E:10129 ||| CD
seen  ||| S:10129 E:10134 ||| VBN
at  ||| S:10134 E:10137 ||| IN
96  ||| S:10137 E:10140 ||| CD
h  ||| S:10140 E:10142 ||| NNS
( ||| S:10142 E:10143 ||| -LRB-
panel  ||| S:10143 E:10149 ||| NN
A ||| S:10149 E:10150 ||| NN
,  ||| S:10150 E:10152 ||| ,
last  ||| S:10152 E:10157 ||| JJ
3  ||| S:10157 E:10159 ||| CD
lanes ||| S:10159 E:10164 ||| NNS
) ||| S:10164 E:10165 ||| -RRB-
.  ||| S:10165 E:10167 ||| .
In  ||| S:10167 E:10170 ||| IN
addition ||| S:10170 E:10178 ||| NN
,  ||| S:10178 E:10180 ||| ,
these  ||| S:10180 E:10196 ||| DT
concentrations  ||| S:10196 E:10211 ||| NNS
of  ||| S:10211 E:10214 ||| IN
resveratrol  ||| S:10214 E:10226 ||| VBG
markedly  ||| S:10226 E:10235 ||| RB
increased  ||| S:10235 E:10245 ||| VBN
eNOS  ||| S:10245 E:10260 ||| JJ
expression  ||| S:10260 E:10271 ||| NN
as  ||| S:10271 E:10274 ||| IN
early  ||| S:10274 E:10280 ||| JJ
as  ||| S:10280 E:10283 ||| IN
6-h ||| S:10283 E:10286 ||| NNP
,  ||| S:10286 E:10288 ||| ,
which  ||| S:10288 E:10294 ||| WDT
reached  ||| S:10294 E:10302 ||| VBD
maximum  ||| S:10302 E:10320 ||| JJ
induction  ||| S:10320 E:10330 ||| NN
at  ||| S:10330 E:10333 ||| IN
48-h ||| S:10333 E:10337 ||| NNP
,  ||| S:10337 E:10339 ||| ,
and  ||| S:10339 E:10343 ||| CC
remained  ||| S:10343 E:10352 ||| VBD
substantially  ||| S:10352 E:10366 ||| RB
elevated  ||| S:10366 E:10375 ||| VBD
at  ||| S:10375 E:10388 ||| IN
96-h  ||| S:10388 E:10393 ||| NNP
( ||| S:10393 E:10394 ||| -LRB-
panel  ||| S:10394 E:10400 ||| NN
D ||| S:10400 E:10401 ||| NNP
) ||| S:10401 E:10402 ||| -RRB-
.  ||| S:10402 E:10404 ||| .
Quantification  ||| S:10404 E:10419 ||| NNP
of  ||| S:10419 E:10422 ||| IN
relative  ||| S:10422 E:10431 ||| JJ
changes  ||| S:10431 E:10439 ||| NNS
of  ||| S:10439 E:10452 ||| IN
total  ||| S:10452 E:10458 ||| JJ
ERK1 ||| S:10458 E:10462 ||| CD
/ ||| S:10462 E:10463 ||| CD
2 ||| S:10463 E:10464 ||| CD
,  ||| S:10464 E:10466 ||| ,
active  ||| S:10466 E:10473 ||| JJ
ERK1 ||| S:10473 E:10477 ||| CD
/ ||| S:10477 E:10478 ||| CD
2-P ||| S:10478 E:10481 ||| CD
,  ||| S:10481 E:10483 ||| ,
and  ||| S:10483 E:10487 ||| CC
eNOS  ||| S:10487 E:10492 ||| JJ
as  ||| S:10492 E:10495 ||| IN
a  ||| S:10495 E:10497 ||| DT
function  ||| S:10497 E:10506 ||| NN
of  ||| S:10506 E:10519 ||| IN
time  ||| S:10519 E:10524 ||| NN
of  ||| S:10524 E:10527 ||| IN
treatment  ||| S:10527 E:10537 ||| NN
with  ||| S:10537 E:10542 ||| IN
two  ||| S:10542 E:10546 ||| CD
concentrations  ||| S:10546 E:10561 ||| NNS
of  ||| S:10561 E:10564 ||| IN
resveratrol  ||| S:10564 E:10586 ||| NN
is  ||| S:10586 E:10589 ||| VBZ
depicted  ||| S:10589 E:10598 ||| VBN
in  ||| S:10598 E:10601 ||| IN
Figure  ||| S:10601 E:10608 ||| NNP
6 ||| S:10608 E:10609 ||| CD
.  ||| S:10609 E:10642 ||| .
Discussion  ||| S:10642 E:10672 ||| NNP
Modulation  ||| S:10672 E:10683 ||| NNP
of  ||| S:10683 E:10686 ||| IN
endothelial  ||| S:10686 E:10698 ||| JJ
cell  ||| S:10698 E:10703 ||| NN
shape  ||| S:10703 E:10709 ||| NN
by  ||| S:10709 E:10722 ||| IN
resveratrol  ||| S:10722 E:10744 ||| JJ
Size ||| S:10744 E:10748 ||| NN
,  ||| S:10748 E:10750 ||| ,
shape ||| S:10750 E:10755 ||| NN
,  ||| S:10755 E:10757 ||| ,
mutual  ||| S:10757 E:10764 ||| JJ
orientation ||| S:10764 E:10775 ||| NN
,  ||| S:10775 E:10777 ||| ,
and  ||| S:10777 E:10781 ||| CC
intercellular  ||| S:10781 E:10805 ||| JJ
contacts  ||| S:10805 E:10814 ||| NNS
in  ||| S:10814 E:10817 ||| IN
endothelium  ||| S:10817 E:10829 ||| NNS
are  ||| S:10829 E:10833 ||| VBP
not  ||| S:10833 E:10837 ||| RB
incidental  ||| S:10837 E:10848 ||| JJ
and  ||| S:10848 E:10852 ||| CC
statistic  ||| S:10852 E:10872 ||| JJ
events ||| S:10872 E:10878 ||| NNS
,  ||| S:10878 E:10880 ||| ,
but  ||| S:10880 E:10884 ||| CC
are  ||| S:10884 E:10888 ||| VBP
precisely  ||| S:10888 E:10898 ||| RB
and  ||| S:10898 E:10902 ||| CC
dynamically  ||| S:10902 E:10914 ||| VB
regulated ||| S:10914 E:10923 ||| VBN
.  ||| S:10923 E:10935 ||| .
Reversible  ||| S:10935 E:10946 ||| JJ
change  ||| S:10946 E:10953 ||| NN
of  ||| S:10953 E:10956 ||| IN
endothelial  ||| S:10956 E:10968 ||| JJ
cell  ||| S:10968 E:10973 ||| NN
shape ||| S:10973 E:10978 ||| NN
,  ||| S:10978 E:10980 ||| ,
mutual  ||| S:10980 E:10997 ||| JJ
orientation  ||| S:10997 E:11009 ||| NN
of  ||| S:11009 E:11012 ||| IN
cells  ||| S:11012 E:11018 ||| NNS
in  ||| S:11018 E:11021 ||| IN
certain  ||| S:11021 E:11029 ||| JJ
directions ||| S:11029 E:11039 ||| NNS
,  ||| S:11039 E:11041 ||| ,
changes  ||| S:11041 E:11049 ||| NNS
in  ||| S:11049 E:11062 ||| IN
intercellular  ||| S:11062 E:11076 ||| JJ
contacts ||| S:11076 E:11084 ||| NNS
,  ||| S:11084 E:11086 ||| ,
are  ||| S:11086 E:11090 ||| VBP
controlled  ||| S:11090 E:11101 ||| VBN
by  ||| S:11101 E:11104 ||| IN
a  ||| S:11104 E:11106 ||| DT
number  ||| S:11106 E:11113 ||| NN
of  ||| S:11113 E:11126 ||| IN
factors ||| S:11126 E:11133 ||| NNS
,  ||| S:11133 E:11135 ||| ,
such  ||| S:11135 E:11140 ||| JJ
as ||| S:11140 E:11142 ||| RB
,  ||| S:11142 E:11144 ||| ,
cooperative  ||| S:11144 E:11156 ||| JJ
stimulation  ||| S:11156 E:11168 ||| NN
of  ||| S:11168 E:11171 ||| IN
the  ||| S:11171 E:11185 ||| DT
receptors  ||| S:11185 E:11195 ||| NN
or  ||| S:11195 E:11198 ||| CC
the  ||| S:11198 E:11202 ||| DT
systems  ||| S:11202 E:11210 ||| NNS
of  ||| S:11210 E:11213 ||| IN
second  ||| S:11213 E:11220 ||| JJ
messengers  ||| S:11220 E:11231 ||| NNS
[  ||| S:11231 E:11233 ||| -LRB-
32 ||| S:11233 E:11235 ||| CD
,  ||| S:11235 E:11237 ||| ,
33 ||| S:11237 E:11239 ||| CD
] ||| S:11239 E:11240 ||| -RRB-
,  ||| S:11240 E:11252 ||| ,
dietary  ||| S:11252 E:11260 ||| JJ
ingredients ||| S:11260 E:11271 ||| NNS
,  ||| S:11271 E:11273 ||| ,
e.g. ||| S:11273 E:11277 ||| NNP
,  ||| S:11277 E:11279 ||| ,
retinoids  ||| S:11279 E:11289 ||| NNS
[  ||| S:11289 E:11291 ||| -LRB-
34 ||| S:11291 E:11293 ||| CD
] ||| S:11293 E:11294 ||| -RRB-
,  ||| S:11294 E:11296 ||| ,
exercise  ||| S:11296 E:11305 ||| NN
[  ||| S:11305 E:11317 ||| -LRB-
35 ||| S:11317 E:11319 ||| CD
,  ||| S:11319 E:11321 ||| ,
36 ||| S:11321 E:11323 ||| CD
] ||| S:11323 E:11324 ||| -RRB-
,  ||| S:11324 E:11326 ||| ,
and  ||| S:11326 E:11330 ||| CC
fluid-imposed  ||| S:11330 E:11344 ||| JJ
shear  ||| S:11344 E:11350 ||| JJ
stress  ||| S:11350 E:11357 ||| NN
[  ||| S:11357 E:11359 ||| -LRB-
37 ||| S:11359 E:11361 ||| CD
,  ||| S:11361 E:11363 ||| ,
38 ||| S:11363 E:11365 ||| CD
,  ||| S:11365 E:11367 ||| ,
39 ||| S:11367 E:11369 ||| CD
] ||| S:11369 E:11370 ||| -RRB-
.  ||| S:11370 E:11382 ||| .
For  ||| S:11382 E:11386 ||| IN
example ||| S:11386 E:11393 ||| NN
,  ||| S:11393 E:11395 ||| ,
endothelial  ||| S:11395 E:11407 ||| JJ
cells  ||| S:11407 E:11413 ||| NNS
are  ||| S:11413 E:11417 ||| VBP
known  ||| S:11417 E:11423 ||| VBN
to  ||| S:11423 E:11426 ||| TO
elongate  ||| S:11426 E:11435 ||| VB
and  ||| S:11435 E:11449 ||| CC
reorient  ||| S:11449 E:11458 ||| VB
their  ||| S:11458 E:11464 ||| PRP$
cytoskeletons  ||| S:11464 E:11478 ||| NN
in  ||| S:11478 E:11481 ||| IN
the  ||| S:11481 E:11485 ||| DT
direction  ||| S:11485 E:11495 ||| NN
of  ||| S:11495 E:11498 ||| IN
flow  ||| S:11498 E:11503 ||| NN
as  ||| S:11503 E:11516 ||| IN
a  ||| S:11516 E:11518 ||| DT
normal  ||| S:11518 E:11525 ||| JJ
physiological  ||| S:11525 E:11539 ||| JJ
response  ||| S:11539 E:11548 ||| NN
to  ||| S:11548 E:11551 ||| TO
prolonged  ||| S:11551 E:11561 ||| JJ
shear  ||| S:11561 E:11567 ||| JJ
stress  ||| S:11567 E:11584 ||| NN
[  ||| S:11584 E:11586 ||| -LRB-
29 ||| S:11586 E:11588 ||| CD
] ||| S:11588 E:11589 ||| -RRB-
.  ||| S:11589 E:11591 ||| .
Results  ||| S:11591 E:11599 ||| NNS
of  ||| S:11599 E:11602 ||| IN
the  ||| S:11602 E:11606 ||| DT
present  ||| S:11606 E:11614 ||| JJ
studies  ||| S:11614 E:11622 ||| NNS
show  ||| S:11622 E:11627 ||| VBP
that  ||| S:11627 E:11632 ||| DT
treatment  ||| S:11632 E:11652 ||| NN
with  ||| S:11652 E:11657 ||| IN
resveratrol  ||| S:11657 E:11669 ||| NN
induces  ||| S:11669 E:11677 ||| VBZ
a  ||| S:11677 E:11679 ||| DT
morphologic  ||| S:11679 E:11691 ||| JJ
change  ||| S:11691 E:11698 ||| NN
from  ||| S:11698 E:11703 ||| IN
a  ||| S:11703 E:11715 ||| DT
stellar  ||| S:11715 E:11723 ||| JJ
to  ||| S:11723 E:11726 ||| TO
an  ||| S:11726 E:11729 ||| DT
elongated  ||| S:11729 E:11739 ||| JJ
shape  ||| S:11739 E:11745 ||| NN
( ||| S:11745 E:11746 ||| -LRB-
Figure  ||| S:11746 E:11753 ||| NNP
1 ||| S:11753 E:11754 ||| CD
) ||| S:11754 E:11755 ||| -RRB-
.  ||| S:11755 E:11757 ||| .
It  ||| S:11757 E:11760 ||| PRP
is  ||| S:11760 E:11763 ||| VBZ
tempting  ||| S:11763 E:11782 ||| VBN
to  ||| S:11782 E:11785 ||| TO
speculate  ||| S:11785 E:11795 ||| VB
that  ||| S:11795 E:11800 ||| DT
appearance  ||| S:11800 E:11811 ||| NN
of  ||| S:11811 E:11814 ||| IN
such  ||| S:11814 E:11819 ||| JJ
cellular  ||| S:11819 E:11828 ||| JJ
phenotype  ||| S:11828 E:11848 ||| NN
involves  ||| S:11848 E:11857 ||| VBZ
formation  ||| S:11857 E:11867 ||| NN
of  ||| S:11867 E:11870 ||| IN
stress  ||| S:11870 E:11877 ||| NN
fibers ||| S:11877 E:11883 ||| NNS
,  ||| S:11883 E:11885 ||| ,
which  ||| S:11885 E:11891 ||| WDT
would  ||| S:11891 E:11907 ||| MD
rearrange  ||| S:11907 E:11917 ||| VB
the  ||| S:11917 E:11921 ||| DT
cytoskeleton  ||| S:11921 E:11934 ||| NN
in  ||| S:11934 E:11937 ||| IN
ways  ||| S:11937 E:11942 ||| NNS
that  ||| S:11942 E:11947 ||| WDT
facilitate  ||| S:11947 E:11958 ||| VBP
better  ||| S:11958 E:11975 ||| JJR
anchoring  ||| S:11975 E:11985 ||| NN
of  ||| S:11985 E:11988 ||| IN
the  ||| S:11988 E:11992 ||| DT
BPAEC  ||| S:11992 E:11998 ||| NNP
to  ||| S:11998 E:12001 ||| TO
the  ||| S:12001 E:12005 ||| DT
culture  ||| S:12005 E:12013 ||| NN
substratum  ||| S:12013 E:12024 ||| NNS
and  ||| S:12024 E:12038 ||| CC
contribute  ||| S:12038 E:12049 ||| VB
to  ||| S:12049 E:12052 ||| TO
the  ||| S:12052 E:12056 ||| DT
ability  ||| S:12056 E:12064 ||| NN
of  ||| S:12064 E:12067 ||| IN
BPAEC  ||| S:12067 E:12073 ||| NNP
to  ||| S:12073 E:12076 ||| TO
resist  ||| S:12076 E:12083 ||| VB
simulated  ||| S:12083 E:12103 ||| JJ
arterial  ||| S:12103 E:12112 ||| JJ
flow  ||| S:12112 E:12117 ||| NN
challenge ||| S:12117 E:12126 ||| NN
.  ||| S:12126 E:12128 ||| .
Only  ||| S:12128 E:12133 ||| JJ
studies  ||| S:12133 E:12141 ||| NNS
in  ||| S:12141 E:12144 ||| IN
the  ||| S:12144 E:12148 ||| DT
future  ||| S:12148 E:12155 ||| NN
would  ||| S:12155 E:12171 ||| MD
validate  ||| S:12171 E:12180 ||| VB
such  ||| S:12180 E:12185 ||| PDT
a  ||| S:12185 E:12187 ||| DT
possibility ||| S:12187 E:12198 ||| NN
.  ||| S:12198 E:12200 ||| .
It  ||| S:12200 E:12203 ||| PRP
is  ||| S:12203 E:12206 ||| VBZ
also  ||| S:12206 E:12211 ||| RB
interesting  ||| S:12211 E:12223 ||| JJ
to  ||| S:12223 E:12236 ||| TO
note  ||| S:12236 E:12241 ||| VB
that  ||| S:12241 E:12246 ||| IN
the  ||| S:12246 E:12250 ||| DT
observed  ||| S:12250 E:12259 ||| JJ
changes  ||| S:12259 E:12267 ||| NNS
in  ||| S:12267 E:12270 ||| IN
resveratrol-treated  ||| S:12270 E:12300 ||| JJ
BPAEC  ||| S:12300 E:12306 ||| NNS
are  ||| S:12306 E:12310 ||| VBP
similar  ||| S:12310 E:12318 ||| JJ
to  ||| S:12318 E:12321 ||| TO
that  ||| S:12321 E:12326 ||| WDT
described  ||| S:12326 E:12336 ||| VBD
for  ||| S:12336 E:12340 ||| IN
EC  ||| S:12340 E:12343 ||| NNP
subjected  ||| S:12343 E:12353 ||| VBN
to  ||| S:12353 E:12366 ||| TO
arterial  ||| S:12366 E:12375 ||| VB
shear ||| S:12375 E:12380 ||| NNS
.  ||| S:12380 E:12382 ||| .
We  ||| S:12382 E:12385 ||| PRP
propose  ||| S:12385 E:12393 ||| VBP
that  ||| S:12393 E:12398 ||| IN
this  ||| S:12398 E:12403 ||| DT
could  ||| S:12403 E:12409 ||| MD
represent  ||| S:12409 E:12419 ||| VB
a  ||| S:12419 E:12431 ||| DT
physiologically-relevant  ||| S:12431 E:12456 ||| JJ
mechanism  ||| S:12456 E:12466 ||| NN
by  ||| S:12466 E:12469 ||| IN
which  ||| S:12469 E:12475 ||| WDT
resveratrol ||| S:12475 E:12486 ||| VBZ
,  ||| S:12486 E:12498 ||| ,
as  ||| S:12498 E:12501 ||| IN
a  ||| S:12501 E:12503 ||| DT
polyphenolic  ||| S:12503 E:12516 ||| JJ
constituent  ||| S:12516 E:12528 ||| NN
of  ||| S:12528 E:12531 ||| IN
red  ||| S:12531 E:12535 ||| JJ
wine ||| S:12535 E:12539 ||| NN
,  ||| S:12539 E:12541 ||| ,
contributes  ||| S:12541 E:12553 ||| VBZ
to  ||| S:12553 E:12566 ||| TO
cardioprotection  ||| S:12566 E:12583 ||| VB
by  ||| S:12583 E:12586 ||| IN
inducing  ||| S:12586 E:12595 ||| JJ
resistance  ||| S:12595 E:12606 ||| NN
to  ||| S:12606 E:12609 ||| TO
potential  ||| S:12609 E:12629 ||| JJ
damage  ||| S:12629 E:12636 ||| NN
by  ||| S:12636 E:12639 ||| IN
shearing  ||| S:12639 E:12648 ||| JJ
forces ||| S:12648 E:12654 ||| NNS
.  ||| S:12654 E:12666 ||| .
The  ||| S:12666 E:12670 ||| DT
mechanism  ||| S:12670 E:12680 ||| NN
underlying  ||| S:12680 E:12691 ||| VBG
this  ||| S:12691 E:12696 ||| DT
cytoskeletal  ||| S:12696 E:12719 ||| JJ
rearrangement  ||| S:12719 E:12733 ||| JJ
due  ||| S:12733 E:12737 ||| JJ
to  ||| S:12737 E:12740 ||| TO
shear  ||| S:12740 E:12746 ||| VB
stress  ||| S:12746 E:12753 ||| NN
is  ||| S:12753 E:12756 ||| VBZ
ill-defined ||| S:12756 E:12767 ||| JJ
,  ||| S:12767 E:12769 ||| ,
but  ||| S:12769 E:12773 ||| CC
it  ||| S:12773 E:12786 ||| PRP
has  ||| S:12786 E:12790 ||| VBZ
been  ||| S:12790 E:12795 ||| VBN
found  ||| S:12795 E:12801 ||| VBN
to  ||| S:12801 E:12804 ||| TO
be  ||| S:12804 E:12807 ||| VB
linked  ||| S:12807 E:12814 ||| VBN
to  ||| S:12814 E:12817 ||| TO
tyrosine  ||| S:12817 E:12826 ||| VB
kinase  ||| S:12826 E:12833 ||| JJ
activity ||| S:12833 E:12841 ||| NN
,  ||| S:12841 E:12853 ||| ,
levels  ||| S:12853 E:12860 ||| NNS
of  ||| S:12860 E:12863 ||| IN
intracellular  ||| S:12863 E:12877 ||| JJ
calcium ||| S:12877 E:12884 ||| NN
,  ||| S:12884 E:12886 ||| ,
intact  ||| S:12886 E:12893 ||| JJ
actin  ||| S:12893 E:12909 ||| JJ
microfilaments ||| S:12909 E:12923 ||| NN
,  ||| S:12923 E:12925 ||| ,
and  ||| S:12925 E:12929 ||| CC
functional  ||| S:12929 E:12940 ||| JJ
microtubule  ||| S:12940 E:12952 ||| JJ
network ||| S:12952 E:12959 ||| NN
,  ||| S:12959 E:12961 ||| ,
but  ||| S:12961 E:12975 ||| CC
is  ||| S:12975 E:12978 ||| VBZ
independent  ||| S:12978 E:12990 ||| JJ
of  ||| S:12990 E:12993 ||| IN
protein  ||| S:12993 E:13001 ||| NN
kinase  ||| S:13001 E:13008 ||| VBD
C ||| S:13008 E:13009 ||| NNP
,  ||| S:13009 E:13011 ||| ,
intermediate  ||| S:13011 E:13034 ||| JJ
filaments ||| S:13034 E:13043 ||| NN
,  ||| S:13043 E:13045 ||| ,
and  ||| S:13045 E:13049 ||| CC
stretch-  ||| S:13049 E:13058 ||| JJ
and  ||| S:13058 E:13062 ||| CC
shear-activated  ||| S:13062 E:13088 ||| JJ
mechanosensitive  ||| S:13088 E:13105 ||| JJ
K  ||| S:13105 E:13107 ||| NNP
+channels  ||| S:13107 E:13117 ||| NNP
[  ||| S:13117 E:13119 ||| -LRB-
28 ||| S:13119 E:13121 ||| CD
] ||| S:13121 E:13122 ||| -RRB-
.  ||| S:13122 E:13124 ||| .
We  ||| S:13124 E:13127 ||| PRP
therefore  ||| S:13127 E:13137 ||| RB
sought  ||| S:13137 E:13154 ||| VBN
to  ||| S:13154 E:13157 ||| TO
determine  ||| S:13157 E:13167 ||| VB
whether  ||| S:13167 E:13175 ||| IN
a  ||| S:13175 E:13177 ||| DT
similar  ||| S:13177 E:13185 ||| JJ
mechanism  ||| S:13185 E:13195 ||| NN
could  ||| S:13195 E:13201 ||| MD
account  ||| S:13201 E:13219 ||| VB
for  ||| S:13219 E:13223 ||| IN
the  ||| S:13223 E:13227 ||| DT
resveratrol-mediated  ||| S:13227 E:13248 ||| JJ
endothelial  ||| S:13248 E:13260 ||| JJ
shape  ||| S:13260 E:13266 ||| NN
change ||| S:13266 E:13272 ||| NN
.  ||| S:13272 E:13284 ||| .
Our  ||| S:13284 E:13288 ||| PRP$
approach  ||| S:13288 E:13297 ||| NN
involved  ||| S:13297 E:13306 ||| VBN
using  ||| S:13306 E:13312 ||| VBG
a  ||| S:13312 E:13314 ||| DT
number  ||| S:13314 E:13321 ||| NN
of  ||| S:13321 E:13324 ||| IN
selective  ||| S:13324 E:13344 ||| JJ
inhibitors  ||| S:13344 E:13355 ||| NN
for  ||| S:13355 E:13359 ||| IN
various  ||| S:13359 E:13367 ||| JJ
signaling  ||| S:13367 E:13377 ||| JJ
pathway ||| S:13377 E:13384 ||| NN
.  ||| S:13384 E:13386 ||| .
These  ||| S:13386 E:13392 ||| DT
studies  ||| S:13392 E:13410 ||| NNS
showed  ||| S:13410 E:13417 ||| VBD
that  ||| S:13417 E:13422 ||| IN
quin2-AM  ||| S:13422 E:13431 ||| NNP
( ||| S:13431 E:13432 ||| -LRB-
[ ||| S:13432 E:13433 ||| -LRB-
Ca  ||| S:13433 E:13436 ||| NNP
2+ ||| S:13436 E:13438 ||| NNP
]  ||| S:13438 E:13440 ||| -RRB-
inhibitor ||| S:13440 E:13449 ||| NN
) ||| S:13449 E:13450 ||| -RRB-
,  ||| S:13450 E:13452 ||| ,
added  ||| S:13452 E:13458 ||| VBD
together  ||| S:13458 E:13477 ||| RB
with  ||| S:13477 E:13482 ||| IN
resveratrol ||| S:13482 E:13493 ||| NN
,  ||| S:13493 E:13495 ||| ,
clearly  ||| S:13495 E:13503 ||| RB
abolished  ||| S:13503 E:13513 ||| VBN
the  ||| S:13513 E:13517 ||| DT
endothelial  ||| S:13517 E:13529 ||| JJ
cell  ||| S:13529 E:13544 ||| NN
shape  ||| S:13544 E:13550 ||| NN
change  ||| S:13550 E:13557 ||| NN
induced  ||| S:13557 E:13565 ||| NN
by  ||| S:13565 E:13568 ||| IN
the  ||| S:13568 E:13572 ||| DT
polyphenol ||| S:13572 E:13582 ||| NN
.  ||| S:13582 E:13584 ||| .
In  ||| S:13584 E:13587 ||| IN
contrast ||| S:13587 E:13595 ||| NN
,  ||| S:13595 E:13607 ||| ,
chelerythrine ||| S:13607 E:13620 ||| NN
,  ||| S:13620 E:13622 ||| ,
a  ||| S:13622 E:13624 ||| DT
PKC  ||| S:13624 E:13628 ||| NNP
inhibitor ||| S:13628 E:13637 ||| NN
,  ||| S:13637 E:13639 ||| ,
which  ||| S:13639 E:13645 ||| WDT
added  ||| S:13645 E:13651 ||| VBD
alone  ||| S:13651 E:13667 ||| RB
triggered  ||| S:13667 E:13677 ||| VBD
a  ||| S:13677 E:13679 ||| DT
significant  ||| S:13679 E:13691 ||| JJ
shape  ||| S:13691 E:13697 ||| NN
change  ||| S:13697 E:13704 ||| NN
in  ||| S:13704 E:13707 ||| IN
BPAEC ||| S:13707 E:13712 ||| NNP
,  ||| S:13712 E:13714 ||| ,
had  ||| S:13714 E:13718 ||| VBD
no  ||| S:13718 E:13731 ||| DT
effect  ||| S:13731 E:13738 ||| NN
on  ||| S:13738 E:13741 ||| IN
resveratrol-elicited  ||| S:13741 E:13762 ||| JJ
morphological  ||| S:13762 E:13776 ||| JJ
change  ||| S:13776 E:13793 ||| NN
( ||| S:13793 E:13794 ||| -LRB-
Table  ||| S:13794 E:13800 ||| NNP
1 ||| S:13800 E:13801 ||| CD
) ||| S:13801 E:13802 ||| -RRB-
.  ||| S:13802 E:13804 ||| .
Analyzed  ||| S:13804 E:13813 ||| VBN
as  ||| S:13813 E:13816 ||| IN
a  ||| S:13816 E:13818 ||| DT
whole ||| S:13818 E:13823 ||| NN
,  ||| S:13823 E:13825 ||| ,
these  ||| S:13825 E:13831 ||| DT
experiments  ||| S:13831 E:13843 ||| NNS
suggest  ||| S:13843 E:13861 ||| VBP
that  ||| S:13861 E:13866 ||| IN
the  ||| S:13866 E:13870 ||| DT
change  ||| S:13870 E:13877 ||| NN
in  ||| S:13877 E:13880 ||| IN
cellular  ||| S:13880 E:13889 ||| JJ
phenotype ||| S:13889 E:13898 ||| NN
,  ||| S:13898 E:13900 ||| ,
as  ||| S:13900 E:13903 ||| IN
a  ||| S:13903 E:13905 ||| DT
consequence  ||| S:13905 E:13927 ||| NN
of  ||| S:13927 E:13930 ||| IN
resveratrol ||| S:13930 E:13941 ||| NNS
: ||| S:13941 E:13942 ||| :
EC  ||| S:13942 E:13945 ||| NNP
interaction ||| S:13945 E:13956 ||| NN
,  ||| S:13956 E:13958 ||| ,
is  ||| S:13958 E:13961 ||| VBZ
dependent  ||| S:13961 E:13971 ||| JJ
on  ||| S:13971 E:13974 ||| IN
Ca  ||| S:13974 E:13977 ||| NNP
2+ ||| S:13977 E:13979 ||| NNP
,  ||| S:13979 E:13991 ||| ,
tyrosine  ||| S:13991 E:14000 ||| JJ
kinases ||| S:14000 E:14007 ||| NN
,  ||| S:14007 E:14009 ||| ,
and  ||| S:14009 E:14013 ||| CC
intact  ||| S:14013 E:14020 ||| JJ
actin  ||| S:14020 E:14026 ||| JJ
microfilament  ||| S:14026 E:14040 ||| NN
and  ||| S:14040 E:14054 ||| CC
microtubules ||| S:14054 E:14066 ||| NN
.  ||| S:14066 E:14068 ||| .
These  ||| S:14068 E:14074 ||| DT
results  ||| S:14074 E:14082 ||| NNS
also  ||| S:14082 E:14087 ||| RB
raise  ||| S:14087 E:14093 ||| VB
the  ||| S:14093 E:14097 ||| DT
possibility  ||| S:14097 E:14119 ||| NN
that  ||| S:14119 E:14124 ||| IN
there  ||| S:14124 E:14130 ||| EX
is  ||| S:14130 E:14133 ||| VBZ
cellular  ||| S:14133 E:14142 ||| JJ
heterogeneity  ||| S:14142 E:14156 ||| NN
within  ||| S:14156 E:14163 ||| IN
endothelial  ||| S:14163 E:14185 ||| JJ
cells  ||| S:14185 E:14191 ||| NNS
used  ||| S:14191 E:14196 ||| VBN
in  ||| S:14196 E:14199 ||| IN
the  ||| S:14199 E:14203 ||| DT
studies ||| S:14203 E:14210 ||| NNS
,  ||| S:14210 E:14212 ||| ,
based  ||| S:14212 E:14218 ||| VBN
on  ||| S:14218 E:14221 ||| IN
the  ||| S:14221 E:14225 ||| DT
fact  ||| S:14225 E:14230 ||| NN
that  ||| S:14230 E:14235 ||| IN
a  ||| S:14235 E:14247 ||| DT
subset  ||| S:14247 E:14254 ||| NN
displayed  ||| S:14254 E:14264 ||| VBD
exquisite  ||| S:14264 E:14274 ||| JJ
sensitivity  ||| S:14274 E:14286 ||| NN
to  ||| S:14286 E:14289 ||| TO
chelerythrine ||| S:14289 E:14302 ||| VB
.  ||| S:14302 E:14314 ||| .
Overall ||| S:14314 E:14321 ||| RB
,  ||| S:14321 E:14323 ||| ,
these  ||| S:14323 E:14329 ||| DT
results  ||| S:14329 E:14337 ||| NNS
support  ||| S:14337 E:14345 ||| VBP
the  ||| S:14345 E:14349 ||| DT
notion  ||| S:14349 E:14356 ||| NN
that  ||| S:14356 E:14371 ||| IN
resveratrol  ||| S:14371 E:14383 ||| NN
and  ||| S:14383 E:14387 ||| CC
shear  ||| S:14387 E:14393 ||| JJ
stress  ||| S:14393 E:14400 ||| NN
induce  ||| S:14400 E:14407 ||| VB
elongation  ||| S:14407 E:14418 ||| VBN
of  ||| S:14418 E:14421 ||| IN
the  ||| S:14421 E:14425 ||| DT
EC  ||| S:14425 E:14438 ||| NNP
cytoskeleton  ||| S:14438 E:14451 ||| NN
via  ||| S:14451 E:14455 ||| IN
an  ||| S:14455 E:14458 ||| DT
overlapping  ||| S:14458 E:14470 ||| JJ
outside-in  ||| S:14470 E:14481 ||| JJ
signaling  ||| S:14481 E:14501 ||| JJ
mechanism ||| S:14501 E:14510 ||| NN
.  ||| S:14510 E:14522 ||| .
Prolonged  ||| S:14522 E:14532 ||| JJ
shear  ||| S:14532 E:14538 ||| NNS
stress  ||| S:14538 E:14545 ||| VBP
leading  ||| S:14545 E:14553 ||| VBG
to  ||| S:14553 E:14556 ||| TO
mechanotransduction  ||| S:14556 E:14586 ||| VB
signaling  ||| S:14586 E:14596 ||| NN
has  ||| S:14596 E:14600 ||| VBZ
been  ||| S:14600 E:14605 ||| VBN
shown  ||| S:14605 E:14611 ||| VBN
to  ||| S:14611 E:14614 ||| TO
activate  ||| S:14614 E:14623 ||| VB
the  ||| S:14623 E:14627 ||| DT
MAP  ||| S:14627 E:14631 ||| NNP
kinase  ||| S:14631 E:14648 ||| VBD
pathway  ||| S:14648 E:14656 ||| VBN
in  ||| S:14656 E:14659 ||| IN
EC ||| S:14659 E:14661 ||| NNP
.  ||| S:14661 E:14663 ||| .
Activation  ||| S:14663 E:14674 ||| NNP
of  ||| S:14674 E:14677 ||| IN
ERK1  ||| S:14677 E:14682 ||| NNP
and  ||| S:14682 E:14686 ||| CC
ERK2 ||| S:14686 E:14690 ||| NNP
,  ||| S:14690 E:14692 ||| ,
the  ||| S:14692 E:14696 ||| DT
major  ||| S:14696 E:14712 ||| JJ
components  ||| S:14712 E:14723 ||| NNS
of  ||| S:14723 E:14726 ||| IN
the  ||| S:14726 E:14730 ||| DT
MAPK  ||| S:14730 E:14735 ||| NNP
pathway ||| S:14735 E:14742 ||| NN
,  ||| S:14742 E:14744 ||| ,
presumably  ||| S:14744 E:14755 ||| RB
induces  ||| S:14755 E:14773 ||| VBZ
shear-specific  ||| S:14773 E:14788 ||| JJ
transcription  ||| S:14788 E:14802 ||| JJ
factors ||| S:14802 E:14809 ||| NNS
,  ||| S:14809 E:14811 ||| ,
such  ||| S:14811 E:14816 ||| JJ
as  ||| S:14816 E:14819 ||| IN
c-fos ||| S:14819 E:14824 ||| NNP
/ ||| S:14824 E:14825 ||| NNP
c-jun  ||| S:14825 E:14841 ||| NNP
and  ||| S:14841 E:14845 ||| CC
NFκB ||| S:14845 E:14849 ||| JJ
,  ||| S:14849 E:14851 ||| ,
ultimately  ||| S:14851 E:14862 ||| RB
leading  ||| S:14862 E:14870 ||| VBG
to  ||| S:14870 E:14873 ||| TO
changes  ||| S:14873 E:14881 ||| NNS
in  ||| S:14881 E:14884 ||| IN
gene  ||| S:14884 E:14899 ||| NN
expression  ||| S:14899 E:14910 ||| NN
[  ||| S:14910 E:14912 ||| -LRB-
30 ||| S:14912 E:14914 ||| CD
,  ||| S:14914 E:14916 ||| ,
31 ||| S:14916 E:14918 ||| CD
] ||| S:14918 E:14919 ||| -RRB-
.  ||| S:14919 E:14921 ||| .
Western  ||| S:14921 E:14929 ||| JJ
blot  ||| S:14929 E:14934 ||| JJ
analysis  ||| S:14934 E:14943 ||| NN
of  ||| S:14943 E:14946 ||| IN
control  ||| S:14946 E:14964 ||| NN
and  ||| S:14964 E:14968 ||| CC
25  ||| S:14968 E:14971 ||| CD
μM  ||| S:14971 E:14974 ||| JJ
and  ||| S:14974 E:14978 ||| CC
100  ||| S:14978 E:14982 ||| CD
μM  ||| S:14982 E:14985 ||| JJ
resveratrol-treated  ||| S:14985 E:15005 ||| JJ
BPAEC  ||| S:15005 E:15011 ||| NNP
showed  ||| S:15011 E:15028 ||| VBD
that  ||| S:15028 E:15033 ||| IN
there  ||| S:15033 E:15039 ||| EX
was  ||| S:15039 E:15043 ||| VBD
no  ||| S:15043 E:15046 ||| DT
increase  ||| S:15046 E:15055 ||| NN
in  ||| S:15055 E:15058 ||| IN
active  ||| S:15058 E:15065 ||| JJ
ERK  ||| S:15065 E:15069 ||| NNP
1 ||| S:15069 E:15070 ||| CD
/ ||| S:15070 E:15071 ||| CD
2  ||| S:15071 E:15073 ||| CD
at  ||| S:15073 E:15076 ||| IN
the  ||| S:15076 E:15080 ||| DT
6  ||| S:15080 E:15082 ||| CD
h  ||| S:15082 E:15094 ||| NNS
and  ||| S:15094 E:15098 ||| CC
2  ||| S:15098 E:15100 ||| CD
day  ||| S:15100 E:15104 ||| NN
time  ||| S:15104 E:15109 ||| NN
points ||| S:15109 E:15115 ||| NNS
.  ||| S:15115 E:15117 ||| .
Rather ||| S:15117 E:15123 ||| RB
,  ||| S:15123 E:15125 ||| ,
the  ||| S:15125 E:15129 ||| DT
decline  ||| S:15129 E:15137 ||| NN
in  ||| S:15137 E:15140 ||| IN
activated  ||| S:15140 E:15160 ||| JJ
ERK  ||| S:15160 E:15164 ||| NNP
1 ||| S:15164 E:15165 ||| CD
/ ||| S:15165 E:15166 ||| CD
2  ||| S:15166 E:15168 ||| CD
seen  ||| S:15168 E:15173 ||| VBN
from  ||| S:15173 E:15178 ||| IN
days  ||| S:15178 E:15183 ||| NNS
2  ||| S:15183 E:15185 ||| CD
to  ||| S:15185 E:15188 ||| TO
4  ||| S:15188 E:15190 ||| CD
of  ||| S:15190 E:15193 ||| IN
control  ||| S:15193 E:15201 ||| NN
cells ||| S:15201 E:15206 ||| NNS
,  ||| S:15206 E:15208 ||| ,
was  ||| S:15208 E:15222 ||| VBD
effectively  ||| S:15222 E:15234 ||| RB
suppressed  ||| S:15234 E:15245 ||| VBN
by  ||| S:15245 E:15248 ||| IN
resveratrol ||| S:15248 E:15259 ||| NN
,  ||| S:15259 E:15261 ||| ,
suggesting  ||| S:15261 E:15272 ||| VBG
that  ||| S:15272 E:15287 ||| IN
the  ||| S:15287 E:15291 ||| DT
polyphenol  ||| S:15291 E:15302 ||| NN
may  ||| S:15302 E:15306 ||| MD
act  ||| S:15306 E:15310 ||| VB
by  ||| S:15310 E:15313 ||| IN
affecting  ||| S:15313 E:15323 ||| VBG
the  ||| S:15323 E:15327 ||| DT
stability  ||| S:15327 E:15337 ||| NN
of  ||| S:15337 E:15350 ||| IN
active  ||| S:15350 E:15357 ||| JJ
ERK1 ||| S:15357 E:15361 ||| CD
/ ||| S:15361 E:15362 ||| CD
2  ||| S:15362 E:15364 ||| CD
( ||| S:15364 E:15365 ||| -LRB-
Figure  ||| S:15365 E:15372 ||| NNP
6 ||| S:15372 E:15373 ||| CD
) ||| S:15373 E:15374 ||| -RRB-
.  ||| S:15374 E:15376 ||| .
This  ||| S:15376 E:15381 ||| DT
may  ||| S:15381 E:15385 ||| MD
involve  ||| S:15385 E:15393 ||| VB
modulation  ||| S:15393 E:15404 ||| VBN
of  ||| S:15404 E:15417 ||| IN
MAPK  ||| S:15417 E:15422 ||| NNP
phosphatase-1  ||| S:15422 E:15436 ||| NNP
( ||| S:15436 E:15437 ||| -LRB-
MKP-1 ||| S:15437 E:15442 ||| NNP
) ||| S:15442 E:15443 ||| -RRB-
,  ||| S:15443 E:15445 ||| ,
a  ||| S:15445 E:15447 ||| DT
member  ||| S:15447 E:15454 ||| NN
of  ||| S:15454 E:15457 ||| IN
the  ||| S:15457 E:15471 ||| DT
immediate-early  ||| S:15471 E:15487 ||| JJ
response  ||| S:15487 E:15496 ||| NN
gene  ||| S:15496 E:15501 ||| NN
product  ||| S:15501 E:15509 ||| NN
functioning  ||| S:15509 E:15521 ||| VBG
as  ||| S:15521 E:15524 ||| IN
a  ||| S:15524 E:15536 ||| DT
dual  ||| S:15536 E:15541 ||| JJ
specificity  ||| S:15541 E:15553 ||| JJ
phosphase  ||| S:15553 E:15563 ||| NN
to  ||| S:15563 E:15566 ||| TO
reverse  ||| S:15566 E:15574 ||| VB
MAPK  ||| S:15574 E:15579 ||| NNP
[  ||| S:15579 E:15581 ||| -LRB-
40 ||| S:15581 E:15583 ||| CD
,  ||| S:15583 E:15585 ||| ,
41 ||| S:15585 E:15587 ||| CD
,  ||| S:15587 E:15589 ||| ,
42 ||| S:15589 E:15591 ||| CD
,  ||| S:15591 E:15603 ||| ,
43 ||| S:15603 E:15605 ||| CD
,  ||| S:15605 E:15607 ||| ,
44 ||| S:15607 E:15609 ||| CD
] ||| S:15609 E:15610 ||| -RRB-
,  ||| S:15610 E:15612 ||| ,
by  ||| S:15612 E:15615 ||| IN
resveratrol ||| S:15615 E:15626 ||| NN
.  ||| S:15626 E:15628 ||| .
Previously ||| S:15628 E:15638 ||| RB
,  ||| S:15638 E:15640 ||| ,
it  ||| S:15640 E:15643 ||| PRP
has  ||| S:15643 E:15647 ||| VBZ
been  ||| S:15647 E:15652 ||| VBN
reported  ||| S:15652 E:15671 ||| VBN
that  ||| S:15671 E:15676 ||| IN
MKP-1  ||| S:15676 E:15682 ||| NNP
is  ||| S:15682 E:15685 ||| VBZ
rapidly  ||| S:15685 E:15693 ||| RB
induced  ||| S:15693 E:15701 ||| VBN
in  ||| S:15701 E:15704 ||| IN
rat  ||| S:15704 E:15708 ||| FW
carotid  ||| S:15708 E:15716 ||| FW
arterial  ||| S:15716 E:15735 ||| FW
wall  ||| S:15735 E:15740 ||| FW
following  ||| S:15740 E:15750 ||| FW
balloon  ||| S:15750 E:15758 ||| FW
catheter  ||| S:15758 E:15767 ||| FW
injury  ||| S:15767 E:15774 ||| FW
[  ||| S:15774 E:15776 ||| -LRB-
45 ||| S:15776 E:15778 ||| CD
] ||| S:15778 E:15779 ||| -RRB-
.  ||| S:15779 E:15781 ||| .
Since  ||| S:15781 E:15787 ||| IN
no  ||| S:15787 E:15800 ||| DT
noticeable  ||| S:15800 E:15811 ||| JJ
change  ||| S:15811 E:15818 ||| NN
in  ||| S:15818 E:15821 ||| IN
active  ||| S:15821 E:15828 ||| JJ
ERK1 ||| S:15828 E:15832 ||| CD
/ ||| S:15832 E:15833 ||| CD
2  ||| S:15833 E:15835 ||| CD
occurred  ||| S:15835 E:15844 ||| VBD
at  ||| S:15844 E:15847 ||| IN
the  ||| S:15847 E:15851 ||| DT
6  ||| S:15851 E:15853 ||| CD
h  ||| S:15853 E:15855 ||| NNS
or  ||| S:15855 E:15868 ||| CC
2  ||| S:15868 E:15870 ||| CD
day  ||| S:15870 E:15874 ||| NN
time  ||| S:15874 E:15879 ||| NN
points ||| S:15879 E:15885 ||| NNS
,  ||| S:15885 E:15887 ||| ,
where  ||| S:15887 E:15893 ||| WRB
morphological  ||| S:15893 E:15907 ||| JJ
changes  ||| S:15907 E:15915 ||| NNS
clearly  ||| S:15915 E:15933 ||| RB
became  ||| S:15933 E:15940 ||| VBD
visible ||| S:15940 E:15947 ||| JJ
,  ||| S:15947 E:15949 ||| ,
following  ||| S:15949 E:15959 ||| VBG
treatment  ||| S:15959 E:15969 ||| NN
with  ||| S:15969 E:15974 ||| IN
resveratrol ||| S:15974 E:15985 ||| NN
,  ||| S:15985 E:15987 ||| ,
it  ||| S:15987 E:16000 ||| PRP
seems  ||| S:16000 E:16006 ||| VBZ
unlikely  ||| S:16006 E:16015 ||| JJ
that  ||| S:16015 E:16020 ||| IN
the  ||| S:16020 E:16024 ||| DT
activation  ||| S:16024 E:16035 ||| NN
of  ||| S:16035 E:16038 ||| IN
MAPK  ||| S:16038 E:16043 ||| NNP
is  ||| S:16043 E:16046 ||| VBZ
directly  ||| S:16046 E:16065 ||| RB
linked  ||| S:16065 E:16072 ||| VBN
to  ||| S:16072 E:16075 ||| TO
the  ||| S:16075 E:16079 ||| DT
observed  ||| S:16079 E:16088 ||| JJ
morphologic  ||| S:16088 E:16100 ||| JJ
changes ||| S:16100 E:16107 ||| NNS
.  ||| S:16107 E:16137 ||| .
Responses  ||| S:16137 E:16147 ||| NNS
of  ||| S:16147 E:16150 ||| IN
cultured  ||| S:16150 E:16159 ||| JJ
endothelial  ||| S:16159 E:16171 ||| JJ
cells  ||| S:16171 E:16177 ||| NNS
to  ||| S:16177 E:16180 ||| TO
arterial  ||| S:16180 E:16199 ||| VB
shear  ||| S:16199 E:16205 ||| NNS
stress  ||| S:16205 E:16222 ||| VBP
Another  ||| S:16222 E:16230 ||| DT
significant  ||| S:16230 E:16242 ||| JJ
contribution  ||| S:16242 E:16255 ||| NN
of  ||| S:16255 E:16258 ||| IN
the  ||| S:16258 E:16262 ||| DT
present  ||| S:16262 E:16280 ||| JJ
research  ||| S:16280 E:16289 ||| NN
is  ||| S:16289 E:16292 ||| VBZ
the  ||| S:16292 E:16296 ||| DT
demonstration  ||| S:16296 E:16310 ||| NN
that  ||| S:16310 E:16315 ||| WDT
resveratrol  ||| S:16315 E:16327 ||| VBZ
promoted  ||| S:16327 E:16336 ||| VBN
a  ||| S:16336 E:16348 ||| DT
greater  ||| S:16348 E:16356 ||| JJR
adherence  ||| S:16356 E:16366 ||| NN
of  ||| S:16366 E:16369 ||| IN
BPAEC  ||| S:16369 E:16375 ||| NNP
to  ||| S:16375 E:16378 ||| TO
the  ||| S:16378 E:16382 ||| DT
cultured  ||| S:16382 E:16391 ||| JJ
vehicle  ||| S:16391 E:16410 ||| NN
in  ||| S:16410 E:16413 ||| IN
vitro  ||| S:16413 E:16419 ||| NN
.  ||| S:16419 E:16432 ||| .
In  ||| S:16432 E:16435 ||| IN
vivo  ||| S:16435 E:16440 ||| NN
,  ||| S:16440 E:16442 ||| ,
such  ||| S:16442 E:16447 ||| PDT
a  ||| S:16447 E:16449 ||| DT
cellular  ||| S:16449 E:16458 ||| JJ
property  ||| S:16458 E:16477 ||| NN
could  ||| S:16477 E:16483 ||| MD
make  ||| S:16483 E:16488 ||| VB
endothelial  ||| S:16488 E:16500 ||| JJ
cells  ||| S:16500 E:16506 ||| NNS
less  ||| S:16506 E:16511 ||| RBR
likely  ||| S:16511 E:16518 ||| JJ
to  ||| S:16518 E:16521 ||| TO
dislodge  ||| S:16521 E:16530 ||| VB
to  ||| S:16530 E:16543 ||| TO
become  ||| S:16543 E:16550 ||| VB
part  ||| S:16550 E:16555 ||| NN
of  ||| S:16555 E:16558 ||| IN
a  ||| S:16558 E:16560 ||| DT
growing  ||| S:16560 E:16568 ||| VBG
thrombotic  ||| S:16568 E:16579 ||| JJ
plug ||| S:16579 E:16583 ||| NN
.  ||| S:16583 E:16585 ||| .
Restricted  ||| S:16585 E:16606 ||| JJ
detachment  ||| S:16606 E:16617 ||| NN
could  ||| S:16617 E:16623 ||| MD
also  ||| S:16623 E:16628 ||| RB
imply  ||| S:16628 E:16634 ||| VB
that  ||| S:16634 E:16639 ||| IN
there  ||| S:16639 E:16645 ||| EX
is  ||| S:16645 E:16648 ||| VBZ
less  ||| S:16648 E:16663 ||| JJR
degeneration  ||| S:16663 E:16676 ||| NN
of  ||| S:16676 E:16679 ||| IN
the  ||| S:16679 E:16683 ||| DT
endothelial  ||| S:16683 E:16695 ||| JJ
cell  ||| S:16695 E:16700 ||| NN
monolayer ||| S:16700 E:16709 ||| NN
,  ||| S:16709 E:16711 ||| ,
which ||| S:16711 E:16716 ||| WDT
,  ||| S:16716 E:16718 ||| ,
in  ||| S:16718 E:16731 ||| IN
turn ||| S:16731 E:16735 ||| NN
,  ||| S:16735 E:16737 ||| ,
would  ||| S:16737 E:16743 ||| MD
reduce  ||| S:16743 E:16750 ||| VB
the  ||| S:16750 E:16754 ||| DT
exposure  ||| S:16754 E:16763 ||| NN
of  ||| S:16763 E:16766 ||| IN
the  ||| S:16766 E:16770 ||| DT
underlying  ||| S:16770 E:16791 ||| JJ
subendothelial  ||| S:16791 E:16806 ||| JJ
matrix  ||| S:16806 E:16813 ||| JJ
components ||| S:16813 E:16823 ||| NNS
,  ||| S:16823 E:16825 ||| ,
thereby  ||| S:16825 E:16833 ||| RB
making  ||| S:16833 E:16840 ||| VBG
platelet  ||| S:16840 E:16859 ||| JJ
adhesion  ||| S:16859 E:16868 ||| NN
and  ||| S:16868 E:16872 ||| CC
aggregation  ||| S:16872 E:16884 ||| NN
less  ||| S:16884 E:16889 ||| RBR
likely ||| S:16889 E:16895 ||| JJ
.  ||| S:16895 E:16897 ||| .
The  ||| S:16897 E:16901 ||| DT
mechanism ||| S:16901 E:16910 ||| NN
( ||| S:16910 E:16911 ||| -LRB-
s ||| S:16911 E:16912 ||| LS
)  ||| S:16912 E:16924 ||| -RRB-
responsible  ||| S:16924 E:16936 ||| JJ
for  ||| S:16936 E:16940 ||| IN
the  ||| S:16940 E:16944 ||| DT
resveratrol-induced  ||| S:16944 E:16964 ||| JJ
cellular  ||| S:16964 E:16983 ||| JJ
properties  ||| S:16983 E:16994 ||| NNS
remain  ||| S:16994 E:17001 ||| VBP
to  ||| S:17001 E:17004 ||| TO
be  ||| S:17004 E:17007 ||| VB
further  ||| S:17007 E:17015 ||| RB
investigated ||| S:17015 E:17027 ||| VBN
.  ||| S:17027 E:17029 ||| .
One  ||| S:17029 E:17043 ||| CD
possibility  ||| S:17043 E:17055 ||| NN
centers  ||| S:17055 E:17063 ||| NNS
on  ||| S:17063 E:17066 ||| IN
modulation  ||| S:17066 E:17077 ||| NN
of  ||| S:17077 E:17080 ||| IN
the  ||| S:17080 E:17084 ||| DT
number  ||| S:17084 E:17091 ||| NN
of  ||| S:17091 E:17094 ||| IN
focal  ||| S:17094 E:17110 ||| JJ
contact  ||| S:17110 E:17118 ||| NN
adhesion  ||| S:17118 E:17127 ||| NN
sites ||| S:17127 E:17132 ||| NNS
,  ||| S:17132 E:17134 ||| ,
and ||| S:17134 E:17137 ||| CC
/ ||| S:17137 E:17138 ||| NNP
or  ||| S:17138 E:17141 ||| CC
the  ||| S:17141 E:17145 ||| DT
effective  ||| S:17145 E:17165 ||| JJ
redistribution  ||| S:17165 E:17180 ||| NN
of  ||| S:17180 E:17183 ||| IN
the  ||| S:17183 E:17187 ||| DT
focal  ||| S:17187 E:17193 ||| JJ
contacts ||| S:17193 E:17201 ||| NNS
,  ||| S:17201 E:17203 ||| ,
as  ||| S:17203 E:17206 ||| RB
well  ||| S:17206 E:17211 ||| RB
as  ||| S:17211 E:17214 ||| IN
the  ||| S:17214 E:17228 ||| DT
increased  ||| S:17228 E:17238 ||| JJ
production  ||| S:17238 E:17249 ||| NN
of  ||| S:17249 E:17252 ||| IN
the  ||| S:17252 E:17256 ||| DT
EC-specific  ||| S:17256 E:17268 ||| JJ
integrin  ||| S:17268 E:17277 ||| JJ
complex ||| S:17277 E:17284 ||| NN
,  ||| S:17284 E:17296 ||| ,
by  ||| S:17296 E:17299 ||| IN
resveratrol ||| S:17299 E:17310 ||| NN
,  ||| S:17310 E:17312 ||| ,
all  ||| S:17312 E:17316 ||| DT
of  ||| S:17316 E:17319 ||| IN
which  ||| S:17319 E:17325 ||| WDT
could  ||| S:17325 E:17331 ||| MD
contribute  ||| S:17331 E:17342 ||| VB
to  ||| S:17342 E:17345 ||| TO
the  ||| S:17345 E:17359 ||| DT
cardioprotective  ||| S:17359 E:17376 ||| JJ
mechanism  ||| S:17376 E:17386 ||| NN
of  ||| S:17386 E:17389 ||| IN
this  ||| S:17389 E:17394 ||| DT
polyphenol ||| S:17394 E:17404 ||| NN
.  ||| S:17404 E:17406 ||| .
However ||| S:17406 E:17413 ||| RB
,  ||| S:17413 E:17425 ||| ,
it  ||| S:17425 E:17428 ||| PRP
should  ||| S:17428 E:17435 ||| MD
be  ||| S:17435 E:17438 ||| VB
emphasized  ||| S:17438 E:17449 ||| VBN
that  ||| S:17449 E:17454 ||| IN
these  ||| S:17454 E:17460 ||| DT
experiments  ||| S:17460 E:17472 ||| NNS
involved  ||| S:17472 E:17491 ||| VBN
growing  ||| S:17491 E:17499 ||| VBG
EC  ||| S:17499 E:17502 ||| NNP
on  ||| S:17502 E:17505 ||| IN
plastic ||| S:17505 E:17512 ||| NN
,  ||| S:17512 E:17514 ||| ,
not  ||| S:17514 E:17518 ||| RB
on  ||| S:17518 E:17521 ||| IN
layers  ||| S:17521 E:17528 ||| NNS
of  ||| S:17528 E:17531 ||| IN
subendothelial  ||| S:17531 E:17556 ||| JJ
matrix  ||| S:17556 E:17563 ||| JJ
components  ||| S:17563 E:17574 ||| NNS
such  ||| S:17574 E:17579 ||| JJ
as  ||| S:17579 E:17582 ||| IN
collagen  ||| S:17582 E:17591 ||| NN
or  ||| S:17591 E:17594 ||| CC
fibrinogen ||| S:17594 E:17604 ||| NN
.  ||| S:17604 E:17606 ||| .
The  ||| S:17606 E:17620 ||| DT
latter  ||| S:17620 E:17627 ||| JJ
experimental  ||| S:17627 E:17640 ||| JJ
format  ||| S:17640 E:17647 ||| NN
simulating  ||| S:17647 E:17658 ||| VBD
a  ||| S:17658 E:17660 ||| DT
more  ||| S:17660 E:17675 ||| RBR
physiologically  ||| S:17675 E:17691 ||| JJ
relevant  ||| S:17691 E:17700 ||| JJ
subendothelial  ||| S:17700 E:17715 ||| JJ
matrices  ||| S:17715 E:17724 ||| NN
may  ||| S:17724 E:17738 ||| MD
yield  ||| S:17738 E:17744 ||| VB
vastly  ||| S:17744 E:17751 ||| RB
different  ||| S:17751 E:17761 ||| JJ
results ||| S:17761 E:17768 ||| NNS
.  ||| S:17768 E:17770 ||| .
These  ||| S:17770 E:17776 ||| DT
possibilities  ||| S:17776 E:17800 ||| NNS
warrant  ||| S:17800 E:17808 ||| VBP
further  ||| S:17808 E:17816 ||| JJ
investigation ||| S:17816 E:17829 ||| NN
.  ||| S:17829 E:17859 ||| .
Induction  ||| S:17859 E:17869 ||| NNP
of  ||| S:17869 E:17872 ||| IN
eNOS  ||| S:17872 E:17877 ||| JJ
and  ||| S:17877 E:17881 ||| CC
modulation  ||| S:17881 E:17892 ||| NN
of  ||| S:17892 E:17895 ||| IN
EC  ||| S:17895 E:17898 ||| NNP
growth  ||| S:17898 E:17905 ||| NN
by  ||| S:17905 E:17918 ||| IN
resveratrol  ||| S:17918 E:17940 ||| VBG
The  ||| S:17940 E:17944 ||| DT
endothelial  ||| S:17944 E:17956 ||| JJ
cell  ||| S:17956 E:17961 ||| NN
lining  ||| S:17961 E:17968 ||| NN
of  ||| S:17968 E:17971 ||| IN
the  ||| S:17971 E:17975 ||| DT
blood  ||| S:17975 E:17981 ||| NN
vessel  ||| S:17981 E:17988 ||| NN
is  ||| S:17988 E:18001 ||| VBZ
extremely  ||| S:18001 E:18011 ||| RB
sensitive  ||| S:18011 E:18021 ||| JJ
to  ||| S:18021 E:18024 ||| TO
damage  ||| S:18024 E:18031 ||| NN
from  ||| S:18031 E:18036 ||| IN
reactive  ||| S:18036 E:18045 ||| JJ
oxygen  ||| S:18045 E:18062 ||| NN
species  ||| S:18062 E:18070 ||| NNS
( ||| S:18070 E:18071 ||| -LRB-
ROS ||| S:18071 E:18074 ||| NNP
) ||| S:18074 E:18075 ||| -RRB-
,  ||| S:18075 E:18077 ||| ,
the  ||| S:18077 E:18081 ||| DT
results  ||| S:18081 E:18089 ||| NNS
of  ||| S:18089 E:18092 ||| IN
which  ||| S:18092 E:18098 ||| WDT
are  ||| S:18098 E:18102 ||| VBP
losses  ||| S:18102 E:18109 ||| NNS
of  ||| S:18109 E:18112 ||| IN
both  ||| S:18112 E:18127 ||| DT
microvascular  ||| S:18127 E:18141 ||| JJ
metabolic  ||| S:18141 E:18151 ||| JJ
function  ||| S:18151 E:18160 ||| NN
and  ||| S:18160 E:18164 ||| CC
barrier  ||| S:18164 E:18172 ||| NN
properties  ||| S:18172 E:18183 ||| NNS
[  ||| S:18183 E:18195 ||| -LRB-
46 ||| S:18195 E:18197 ||| CD
] ||| S:18197 E:18198 ||| -RRB-
.  ||| S:18198 E:18200 ||| .
To  ||| S:18200 E:18203 ||| TO
minimize  ||| S:18203 E:18212 ||| VB
such  ||| S:18212 E:18217 ||| JJ
oxidant  ||| S:18217 E:18225 ||| JJ
damage ||| S:18225 E:18231 ||| NN
,  ||| S:18231 E:18233 ||| ,
cells  ||| S:18233 E:18239 ||| NNS
rely  ||| S:18239 E:18244 ||| VBP
on  ||| S:18244 E:18247 ||| IN
the  ||| S:18247 E:18261 ||| DT
production  ||| S:18261 E:18272 ||| NN
of  ||| S:18272 E:18275 ||| IN
nitric  ||| S:18275 E:18282 ||| JJ
oxide  ||| S:18282 E:18288 ||| NN
( ||| S:18288 E:18289 ||| -LRB-
NO ||| S:18289 E:18291 ||| UH
)  ||| S:18291 E:18293 ||| -RRB-
by  ||| S:18293 E:18296 ||| IN
the  ||| S:18296 E:18300 ||| DT
enzyme  ||| S:18300 E:18307 ||| FW
nitric  ||| S:18307 E:18324 ||| FW
oxide  ||| S:18324 E:18330 ||| FW
synthase  ||| S:18330 E:18339 ||| FW
( ||| S:18339 E:18340 ||| -LRB-
eNOS ||| S:18340 E:18344 ||| NNP
) ||| S:18344 E:18345 ||| -RRB-
.  ||| S:18345 E:18347 ||| .
Biological  ||| S:18347 E:18358 ||| JJ
functions  ||| S:18358 E:18368 ||| NNS
attributed  ||| S:18368 E:18379 ||| VBD
to  ||| S:18379 E:18392 ||| TO
NO  ||| S:18392 E:18395 ||| RB
include  ||| S:18395 E:18403 ||| VB
vasodilation  ||| S:18403 E:18416 ||| NNS
[  ||| S:18416 E:18418 ||| -LRB-
47 ||| S:18418 E:18420 ||| CD
] ||| S:18420 E:18421 ||| -RRB-
,  ||| S:18421 E:18423 ||| ,
inhibition  ||| S:18423 E:18434 ||| VBG
of  ||| S:18434 E:18437 ||| IN
platelet  ||| S:18437 E:18456 ||| JJ
adhesion  ||| S:18456 E:18465 ||| NN
and  ||| S:18465 E:18469 ||| CC
aggregation  ||| S:18469 E:18481 ||| NNS
[  ||| S:18481 E:18483 ||| -LRB-
48 ||| S:18483 E:18485 ||| CD
] ||| S:18485 E:18486 ||| -RRB-
,  ||| S:18486 E:18488 ||| ,
reduction  ||| S:18488 E:18498 ||| NN
of  ||| S:18498 E:18501 ||| IN
expression  ||| S:18501 E:18522 ||| NN
of  ||| S:18522 E:18525 ||| IN
adhesion  ||| S:18525 E:18534 ||| JJ
molecules  ||| S:18534 E:18544 ||| NNS
and  ||| S:18544 E:18548 ||| CC
chemokines  ||| S:18548 E:18559 ||| NNS
[  ||| S:18559 E:18561 ||| -LRB-
49 ||| S:18561 E:18563 ||| CD
,  ||| S:18563 E:18565 ||| ,
50 ||| S:18565 E:18567 ||| CD
,  ||| S:18567 E:18569 ||| ,
51 ||| S:18569 E:18571 ||| CD
,  ||| S:18571 E:18573 ||| ,
52 ||| S:18573 E:18575 ||| CD
] ||| S:18575 E:18576 ||| -RRB-
,  ||| S:18576 E:18588 ||| ,
and  ||| S:18588 E:18592 ||| CC
suppression  ||| S:18592 E:18604 ||| NN
of  ||| S:18604 E:18607 ||| IN
cell  ||| S:18607 E:18612 ||| NN
growth  ||| S:18612 E:18619 ||| NN
and  ||| S:18619 E:18623 ||| CC
migration  ||| S:18623 E:18633 ||| NNS
[  ||| S:18633 E:18635 ||| -LRB-
53 ||| S:18635 E:18637 ||| CD
,  ||| S:18637 E:18639 ||| ,
54 ||| S:18639 E:18641 ||| CD
] ||| S:18641 E:18642 ||| -RRB-
.  ||| S:18642 E:18654 ||| .
Therefore ||| S:18654 E:18663 ||| RB
,  ||| S:18663 E:18665 ||| ,
we  ||| S:18665 E:18668 ||| PRP
investigated  ||| S:18668 E:18681 ||| VBD
whether  ||| S:18681 E:18689 ||| IN
resveratrol  ||| S:18689 E:18701 ||| JJ
treatment  ||| S:18701 E:18721 ||| NN
could  ||| S:18721 E:18727 ||| MD
lead  ||| S:18727 E:18732 ||| VB
to  ||| S:18732 E:18735 ||| TO
increased  ||| S:18735 E:18745 ||| VB
eNOS  ||| S:18745 E:18750 ||| JJ
expression  ||| S:18750 E:18761 ||| NN
in  ||| S:18761 E:18764 ||| IN
endothelial  ||| S:18764 E:18786 ||| JJ
cells ||| S:18786 E:18791 ||| NNS
.  ||| S:18791 E:18793 ||| .
We  ||| S:18793 E:18796 ||| PRP
determined  ||| S:18796 E:18807 ||| VBD
that  ||| S:18807 E:18812 ||| DT
resveratrol  ||| S:18812 E:18824 ||| JJ
treatment  ||| S:18824 E:18834 ||| NN
did  ||| S:18834 E:18848 ||| VBD
induce  ||| S:18848 E:18855 ||| VB
eNOS  ||| S:18855 E:18860 ||| JJ
expression  ||| S:18860 E:18871 ||| NN
at  ||| S:18871 E:18874 ||| IN
all  ||| S:18874 E:18878 ||| DT
time  ||| S:18878 E:18883 ||| NN
points  ||| S:18883 E:18890 ||| NNS
tested  ||| S:18890 E:18897 ||| VBD
( ||| S:18897 E:18898 ||| -LRB-
6  ||| S:18898 E:18900 ||| CD
h ||| S:18900 E:18901 ||| NN
,  ||| S:18901 E:18903 ||| ,
2  ||| S:18903 E:18915 ||| CD
days ||| S:18915 E:18919 ||| NNS
,  ||| S:18919 E:18921 ||| ,
and  ||| S:18921 E:18925 ||| CC
4  ||| S:18925 E:18927 ||| CD
days ||| S:18927 E:18931 ||| NNS
) ||| S:18931 E:18932 ||| -RRB-
.  ||| S:18932 E:18934 ||| .
These  ||| S:18934 E:18940 ||| DT
results  ||| S:18940 E:18948 ||| NNS
agreed  ||| S:18948 E:18955 ||| VBD
with  ||| S:18955 E:18960 ||| IN
a  ||| S:18960 E:18962 ||| DT
previous  ||| S:18962 E:18981 ||| JJ
report  ||| S:18981 E:18988 ||| NN
from  ||| S:18988 E:18993 ||| IN
this  ||| S:18993 E:18998 ||| DT
laboratory  ||| S:18998 E:19009 ||| NN
[  ||| S:19009 E:19011 ||| -LRB-
21 ||| S:19011 E:19013 ||| CD
] ||| S:19013 E:19014 ||| -RRB-
.  ||| S:19014 E:19016 ||| .
The  ||| S:19016 E:19020 ||| DT
peak  ||| S:19020 E:19025 ||| NN
expression  ||| S:19025 E:19036 ||| NN
of  ||| S:19036 E:19049 ||| IN
eNOS  ||| S:19049 E:19054 ||| NNP
occurred  ||| S:19054 E:19063 ||| VBD
at  ||| S:19063 E:19066 ||| IN
2  ||| S:19066 E:19068 ||| CD
days  ||| S:19068 E:19073 ||| NNS
in  ||| S:19073 E:19076 ||| IN
100  ||| S:19076 E:19080 ||| CD
μM  ||| S:19080 E:19083 ||| JJ
resveratrol-treated  ||| S:19083 E:19113 ||| JJ
cells ||| S:19113 E:19118 ||| NNS
.  ||| S:19118 E:19120 ||| .
These  ||| S:19120 E:19126 ||| DT
findings  ||| S:19126 E:19135 ||| NNS
could  ||| S:19135 E:19141 ||| MD
mean  ||| S:19141 E:19146 ||| VB
that  ||| S:19146 E:19151 ||| DT
dietary  ||| S:19151 E:19159 ||| JJ
resveratrol  ||| S:19159 E:19181 ||| NN
is  ||| S:19181 E:19184 ||| VBZ
capable  ||| S:19184 E:19192 ||| JJ
of  ||| S:19192 E:19195 ||| IN
providing  ||| S:19195 E:19205 ||| VBG
a  ||| S:19205 E:19207 ||| DT
gradual  ||| S:19207 E:19215 ||| JJ
yet  ||| S:19215 E:19219 ||| RB
sustained  ||| S:19219 E:19229 ||| VBN
increase  ||| S:19229 E:19248 ||| NN
in  ||| S:19248 E:19251 ||| IN
NO ||| S:19251 E:19253 ||| RB
.  ||| S:19253 E:19255 ||| .
The  ||| S:19255 E:19259 ||| DT
ability  ||| S:19259 E:19267 ||| NN
of  ||| S:19267 E:19270 ||| IN
resveratrol  ||| S:19270 E:19282 ||| VBG
to  ||| S:19282 E:19285 ||| TO
induce  ||| S:19285 E:19292 ||| VB
S ||| S:19292 E:19293 ||| NNP
/ ||| S:19293 E:19294 ||| NNP
G  ||| S:19294 E:19307 ||| NNP
2  ||| S:19307 E:19309 ||| CD
growth  ||| S:19309 E:19316 ||| NN
arrest  ||| S:19316 E:19323 ||| NN
[  ||| S:19323 E:19325 ||| -LRB-
20 ||| S:19325 E:19327 ||| CD
,  ||| S:19327 E:19329 ||| ,
21 ||| S:19329 E:19331 ||| CD
]  ||| S:19331 E:19333 ||| -RRB-
suggests  ||| S:19333 E:19342 ||| VBZ
an  ||| S:19342 E:19355 ||| DT
additional  ||| S:19355 E:19366 ||| JJ
mechanism  ||| S:19366 E:19376 ||| NN
for  ||| S:19376 E:19380 ||| IN
cells  ||| S:19380 E:19386 ||| NNS
to  ||| S:19386 E:19389 ||| TO
rapidly  ||| S:19389 E:19397 ||| RB
and  ||| S:19397 E:19401 ||| CC
efficiently  ||| S:19401 E:19423 ||| RB
repair  ||| S:19423 E:19430 ||| VB
any  ||| S:19430 E:19434 ||| DT
endothelial  ||| S:19434 E:19446 ||| JJ
cell  ||| S:19446 E:19451 ||| NN
damage ||| S:19451 E:19457 ||| NN
.  ||| S:19457 E:19459 ||| .
Overall ||| S:19459 E:19466 ||| RB
,  ||| S:19466 E:19468 ||| ,
the  ||| S:19468 E:19482 ||| DT
collective  ||| S:19482 E:19493 ||| JJ
effect  ||| S:19493 E:19500 ||| NN
of  ||| S:19500 E:19503 ||| IN
resveratrol  ||| S:19503 E:19515 ||| NNS
would  ||| S:19515 E:19521 ||| MD
be  ||| S:19521 E:19524 ||| VB
to  ||| S:19524 E:19527 ||| TO
decrease  ||| S:19527 E:19546 ||| VB
endothelial  ||| S:19546 E:19558 ||| JJ
injury  ||| S:19558 E:19565 ||| NN
and  ||| S:19565 E:19569 ||| CC
exposure  ||| S:19569 E:19578 ||| NN
of  ||| S:19578 E:19581 ||| IN
the  ||| S:19581 E:19585 ||| DT
subendothelial  ||| S:19585 E:19610 ||| JJ
matrix ||| S:19610 E:19616 ||| NN
,  ||| S:19616 E:19618 ||| ,
which  ||| S:19618 E:19624 ||| WDT
would  ||| S:19624 E:19630 ||| MD
lessen  ||| S:19630 E:19637 ||| VB
the  ||| S:19637 E:19641 ||| DT
probability  ||| S:19641 E:19653 ||| NN
of  ||| S:19653 E:19656 ||| IN
formation  ||| S:19656 E:19676 ||| NN
of  ||| S:19676 E:19679 ||| IN
atherosclerotic  ||| S:19679 E:19695 ||| JJ
plaques  ||| S:19695 E:19703 ||| NN
and  ||| S:19703 E:19707 ||| CC
the  ||| S:19707 E:19711 ||| DT
development  ||| S:19711 E:19723 ||| NN
of  ||| S:19723 E:19726 ||| IN
CHD  ||| S:19726 E:19730 ||| NNP
[  ||| S:19730 E:19742 ||| -LRB-
53 ||| S:19742 E:19744 ||| CD
,  ||| S:19744 E:19746 ||| ,
54 ||| S:19746 E:19748 ||| CD
,  ||| S:19748 E:19750 ||| ,
55 ||| S:19750 E:19752 ||| CD
] ||| S:19752 E:19753 ||| -RRB-
.  ||| S:19753 E:19786 ||| .
Conclusions  ||| S:19786 E:19806 ||| VBG
Our  ||| S:19806 E:19810 ||| PRP$
studies  ||| S:19810 E:19818 ||| NNS
suggest  ||| S:19818 E:19826 ||| VBP
that  ||| S:19826 E:19831 ||| IN
resveratrol  ||| S:19831 E:19843 ||| JJ
interacts  ||| S:19843 E:19853 ||| NN
with  ||| S:19853 E:19866 ||| IN
endothelial  ||| S:19866 E:19878 ||| JJ
cells  ||| S:19878 E:19893 ||| NNS
in  ||| S:19893 E:19896 ||| IN
vitro  ||| S:19896 E:19902 ||| VBG
to  ||| S:19902 E:19905 ||| TO
elicit  ||| S:19905 E:19912 ||| VB
morphological  ||| S:19912 E:19926 ||| NNS
and  ||| S:19926 E:19938 ||| CC
functional  ||| S:19938 E:19949 ||| JJ
changes ||| S:19949 E:19956 ||| NNS
.  ||| S:19956 E:19958 ||| .
Specifically ||| S:19958 E:19970 ||| RB
,  ||| S:19970 E:19972 ||| ,
resveratrol  ||| S:19972 E:19984 ||| VBD
induced  ||| S:19984 E:19992 ||| VBN
an  ||| S:19992 E:20003 ||| DT
elongated  ||| S:20003 E:20013 ||| JJ
shape ||| S:20013 E:20018 ||| NN
,  ||| S:20018 E:20020 ||| ,
interspersed  ||| S:20020 E:20033 ||| VBN
with  ||| S:20033 E:20038 ||| IN
long ||| S:20038 E:20042 ||| JJ
,  ||| S:20042 E:20044 ||| ,
tortuous  ||| S:20044 E:20061 ||| JJ
projections ||| S:20061 E:20072 ||| NNS
,  ||| S:20072 E:20074 ||| ,
in  ||| S:20074 E:20077 ||| IN
cultured  ||| S:20077 E:20086 ||| JJ
BPAEC ||| S:20086 E:20091 ||| NNP
.  ||| S:20091 E:20093 ||| .
Treated  ||| S:20093 E:20101 ||| JJ
cells  ||| S:20101 E:20107 ||| NNS
resisted  ||| S:20107 E:20124 ||| VBD
detachment  ||| S:20124 E:20135 ||| VBN
from  ||| S:20135 E:20140 ||| IN
the  ||| S:20140 E:20144 ||| DT
plastic  ||| S:20144 E:20152 ||| JJ
coverslips  ||| S:20152 E:20163 ||| NN
under  ||| S:20163 E:20169 ||| IN
simulated  ||| S:20169 E:20187 ||| JJ
arterial  ||| S:20187 E:20196 ||| JJ
shear  ||| S:20196 E:20202 ||| JJ
stress  ||| S:20202 E:20209 ||| NN
conditions ||| S:20209 E:20219 ||| NNS
.  ||| S:20219 E:20221 ||| .
These  ||| S:20221 E:20227 ||| DT
results ||| S:20227 E:20234 ||| NNS
,  ||| S:20234 E:20236 ||| ,
combined  ||| S:20236 E:20253 ||| VBN
with  ||| S:20253 E:20258 ||| IN
data  ||| S:20258 E:20263 ||| NNS
from  ||| S:20263 E:20268 ||| IN
our  ||| S:20268 E:20272 ||| PRP$
previous  ||| S:20272 E:20281 ||| JJ
studies ||| S:20281 E:20288 ||| NNS
,  ||| S:20288 E:20290 ||| ,
provide  ||| S:20290 E:20298 ||| VB
additional  ||| S:20298 E:20317 ||| JJ
support  ||| S:20317 E:20325 ||| NN
for  ||| S:20325 E:20329 ||| IN
the  ||| S:20329 E:20333 ||| DT
notion  ||| S:20333 E:20340 ||| NN
that  ||| S:20340 E:20345 ||| IN
resveratrol  ||| S:20345 E:20357 ||| JJ
acts  ||| S:20357 E:20362 ||| NNS
as  ||| S:20362 E:20365 ||| IN
an  ||| S:20365 E:20376 ||| DT
anti-atherosclerotic  ||| S:20376 E:20397 ||| JJ
agent ||| S:20397 E:20402 ||| NN
.  ||| S:20402 E:20404 ||| .
Whether  ||| S:20404 E:20412 ||| IN
these  ||| S:20412 E:20418 ||| DT
findings  ||| S:20418 E:20427 ||| NNS
can  ||| S:20427 E:20431 ||| MD
be  ||| S:20431 E:20442 ||| VB
extrapolated  ||| S:20442 E:20455 ||| VBN
to  ||| S:20455 E:20458 ||| TO
humans  ||| S:20458 E:20465 ||| NNS
require  ||| S:20465 E:20473 ||| VBP
further  ||| S:20473 E:20481 ||| JJ
study ||| S:20481 E:20486 ||| NN
.  ||| S:20486 E:20510 ||| .
Materials  ||| S:20510 E:20520 ||| NNS
and  ||| S:20520 E:20524 ||| CC
Methods  ||| S:20524 E:20551 ||| NNP
Cell  ||| S:20551 E:20556 ||| NNP
culture  ||| S:20556 E:20564 ||| NN
and  ||| S:20564 E:20568 ||| CC
treatment  ||| S:20568 E:20578 ||| NN
with  ||| S:20578 E:20583 ||| IN
resveratrol  ||| S:20583 E:20605 ||| VBG
The  ||| S:20605 E:20609 ||| DT
BPAEC  ||| S:20609 E:20615 ||| NNP
isolated  ||| S:20615 E:20624 ||| VBD
from  ||| S:20624 E:20629 ||| IN
the  ||| S:20629 E:20633 ||| DT
distal  ||| S:20633 E:20640 ||| JJ
main  ||| S:20640 E:20645 ||| JJ
intrapulmonary  ||| S:20645 E:20670 ||| JJ
artery  ||| S:20670 E:20677 ||| NN
of  ||| S:20677 E:20680 ||| IN
calf  ||| S:20680 E:20685 ||| JJ
lungs  ||| S:20685 E:20691 ||| NNS
were  ||| S:20691 E:20696 ||| VBD
cultured  ||| S:20696 E:20705 ||| VBN
in  ||| S:20705 E:20708 ||| IN
minimal  ||| S:20708 E:20716 ||| JJ
essential  ||| S:20716 E:20736 ||| JJ
medium  ||| S:20736 E:20743 ||| NN
( ||| S:20743 E:20744 ||| -LRB-
MEM ||| S:20744 E:20747 ||| NNP
)  ||| S:20747 E:20749 ||| -RRB-
supplemented  ||| S:20749 E:20762 ||| NN
with  ||| S:20762 E:20767 ||| IN
15 ||| S:20767 E:20769 ||| CD
%  ||| S:20769 E:20771 ||| NN
fetal  ||| S:20771 E:20777 ||| JJ
bovine  ||| S:20777 E:20784 ||| JJ
serum  ||| S:20784 E:20790 ||| NN
and  ||| S:20790 E:20804 ||| CC
containing  ||| S:20804 E:20815 ||| VBG
D-valine  ||| S:20815 E:20824 ||| JJ
as  ||| S:20824 E:20827 ||| IN
previously  ||| S:20827 E:20838 ||| RB
described  ||| S:20838 E:20848 ||| VBN
[  ||| S:20848 E:20850 ||| -LRB-
56 ||| S:20850 E:20852 ||| CD
] ||| S:20852 E:20853 ||| -RRB-
.  ||| S:20853 E:20865 ||| .
Plastic  ||| S:20865 E:20873 ||| JJ
coverslips  ||| S:20873 E:20884 ||| NN
on  ||| S:20884 E:20887 ||| IN
which  ||| S:20887 E:20893 ||| WDT
the  ||| S:20893 E:20897 ||| DT
cells  ||| S:20897 E:20903 ||| NNS
were  ||| S:20903 E:20908 ||| VBD
cultured  ||| S:20908 E:20917 ||| RB
were  ||| S:20917 E:20932 ||| VBD
sterilized  ||| S:20932 E:20943 ||| VBN
by  ||| S:20943 E:20946 ||| IN
washing  ||| S:20946 E:20954 ||| VBG
in  ||| S:20954 E:20957 ||| IN
ethanol ||| S:20957 E:20964 ||| NN
,  ||| S:20964 E:20966 ||| ,
followed  ||| S:20966 E:20975 ||| VBN
by  ||| S:20975 E:20978 ||| IN
rinsing  ||| S:20978 E:20996 ||| CD
three  ||| S:20996 E:21002 ||| CD
times  ||| S:21002 E:21008 ||| NNS
in  ||| S:21008 E:21011 ||| IN
MEM  ||| S:21011 E:21015 ||| NNP
and  ||| S:21015 E:21019 ||| CC
15  ||| S:21019 E:21022 ||| CD
min  ||| S:21022 E:21026 ||| JJ
exposure  ||| S:21026 E:21035 ||| NN
to  ||| S:21035 E:21038 ||| TO
UV  ||| S:21038 E:21041 ||| NNP
radiation ||| S:21041 E:21050 ||| NN
.  ||| S:21050 E:21062 ||| .
The  ||| S:21062 E:21066 ||| DT
coverslips  ||| S:21066 E:21077 ||| NN
were  ||| S:21077 E:21082 ||| VBD
placed  ||| S:21082 E:21089 ||| VBN
in  ||| S:21089 E:21092 ||| IN
6-well  ||| S:21092 E:21099 ||| CD
tissue  ||| S:21099 E:21106 ||| NN
culture  ||| S:21106 E:21124 ||| NN
plates ||| S:21124 E:21130 ||| NN
,  ||| S:21130 E:21132 ||| ,
and  ||| S:21132 E:21136 ||| CC
2  ||| S:21136 E:21138 ||| CD
ml  ||| S:21138 E:21141 ||| NN
of  ||| S:21141 E:21144 ||| IN
the  ||| S:21144 E:21148 ||| DT
cells ||| S:21148 E:21153 ||| NNS
,  ||| S:21153 E:21155 ||| ,
at  ||| S:21155 E:21158 ||| IN
an  ||| S:21158 E:21161 ||| DT
initial  ||| S:21161 E:21169 ||| JJ
density  ||| S:21169 E:21177 ||| NN
of  ||| S:21177 E:21180 ||| IN
1  ||| S:21180 E:21192 ||| CD
×  ||| S:21192 E:21194 ||| CD
10  ||| S:21194 E:21197 ||| CD
5cells ||| S:21197 E:21203 ||| CD
/ ||| S:21203 E:21204 ||| CD
ml ||| S:21204 E:21206 ||| NN
,  ||| S:21206 E:21208 ||| ,
were  ||| S:21208 E:21213 ||| VBD
added  ||| S:21213 E:21219 ||| VBN
to  ||| S:21219 E:21222 ||| TO
each  ||| S:21222 E:21227 ||| DT
of  ||| S:21227 E:21230 ||| IN
the  ||| S:21230 E:21234 ||| DT
wells ||| S:21234 E:21239 ||| NNS
.  ||| S:21239 E:21251 ||| .
Twenty-four  ||| S:21251 E:21263 ||| CD
h  ||| S:21263 E:21265 ||| NN
after  ||| S:21265 E:21271 ||| IN
seeding ||| S:21271 E:21278 ||| NN
,  ||| S:21278 E:21280 ||| ,
the  ||| S:21280 E:21284 ||| DT
coverslips  ||| S:21284 E:21295 ||| NN
were  ||| S:21295 E:21300 ||| VBD
treated  ||| S:21300 E:21318 ||| VBN
with  ||| S:21318 E:21323 ||| IN
0,10 ||| S:21323 E:21327 ||| NNP
,  ||| S:21327 E:21329 ||| ,
25 ||| S:21329 E:21331 ||| CD
,  ||| S:21331 E:21333 ||| ,
50 ||| S:21333 E:21335 ||| CD
,  ||| S:21335 E:21337 ||| ,
and  ||| S:21337 E:21341 ||| CC
100  ||| S:21341 E:21345 ||| CD
μM  ||| S:21345 E:21348 ||| JJ
resveratrol  ||| S:21348 E:21360 ||| NN
and  ||| S:21360 E:21364 ||| CC
maintained  ||| S:21364 E:21385 ||| VBN
for  ||| S:21385 E:21389 ||| IN
2  ||| S:21389 E:21391 ||| CD
days  ||| S:21391 E:21396 ||| NNS
at  ||| S:21396 E:21399 ||| IN
37°C  ||| S:21399 E:21404 ||| CD
until  ||| S:21404 E:21410 ||| IN
they  ||| S:21410 E:21415 ||| PRP
were  ||| S:21415 E:21420 ||| VBD
fixed  ||| S:21420 E:21426 ||| VBN
and  ||| S:21426 E:21430 ||| CC
stained  ||| S:21430 E:21438 ||| NN
for  ||| S:21438 E:21452 ||| IN
confocal  ||| S:21452 E:21461 ||| JJ
microscopy ||| S:21461 E:21471 ||| NN
.  ||| S:21471 E:21501 ||| .
Preparation  ||| S:21501 E:21513 ||| NN
and  ||| S:21513 E:21517 ||| CC
staining  ||| S:21517 E:21526 ||| NN
of  ||| S:21526 E:21529 ||| IN
slides  ||| S:21529 E:21546 ||| FW
Coverslips  ||| S:21546 E:21557 ||| FW
containing  ||| S:21557 E:21568 ||| FW
adhered  ||| S:21568 E:21576 ||| FW
BPAEC  ||| S:21576 E:21582 ||| NNP
were  ||| S:21582 E:21587 ||| VBD
washed  ||| S:21587 E:21594 ||| VBN
for  ||| S:21594 E:21598 ||| IN
5  ||| S:21598 E:21610 ||| CD
min  ||| S:21610 E:21614 ||| NN
in  ||| S:21614 E:21617 ||| IN
TBS ||| S:21617 E:21620 ||| NNP
,  ||| S:21620 E:21622 ||| ,
fixed  ||| S:21622 E:21628 ||| VBN
with  ||| S:21628 E:21633 ||| IN
5 ||| S:21633 E:21634 ||| CD
%  ||| S:21634 E:21636 ||| NN
glutaraldehyde  ||| S:21636 E:21651 ||| NN
in  ||| S:21651 E:21654 ||| IN
0.1  ||| S:21654 E:21658 ||| CD
M  ||| S:21658 E:21670 ||| NNP
cacodylate  ||| S:21670 E:21681 ||| NNS
( ||| S:21681 E:21682 ||| -LRB-
pH  ||| S:21682 E:21685 ||| NNP
7.4 ||| S:21685 E:21688 ||| CD
)  ||| S:21688 E:21690 ||| -RRB-
for  ||| S:21690 E:21694 ||| IN
15  ||| S:21694 E:21697 ||| CD
min ||| S:21697 E:21700 ||| NN
,  ||| S:21700 E:21702 ||| ,
washed  ||| S:21702 E:21709 ||| VBD
again  ||| S:21709 E:21715 ||| RB
for  ||| S:21715 E:21719 ||| IN
5  ||| S:21719 E:21721 ||| CD
min  ||| S:21721 E:21725 ||| NN
in  ||| S:21725 E:21738 ||| IN
TBS ||| S:21738 E:21741 ||| NNP
,  ||| S:21741 E:21743 ||| ,
then  ||| S:21743 E:21748 ||| RB
stored  ||| S:21748 E:21755 ||| VBN
in  ||| S:21755 E:21758 ||| IN
0.1  ||| S:21758 E:21762 ||| CD
M  ||| S:21762 E:21764 ||| NNP
cacodylate ||| S:21764 E:21774 ||| VBD
/ ||| S:21774 E:21775 ||| CD
7 ||| S:21775 E:21776 ||| CD
%  ||| S:21776 E:21778 ||| NN
sucrose  ||| S:21778 E:21786 ||| NN
at  ||| S:21786 E:21789 ||| IN
4°C  ||| S:21789 E:21803 ||| CD
until  ||| S:21803 E:21809 ||| IN
staining ||| S:21809 E:21817 ||| NN
.  ||| S:21817 E:21819 ||| .
Cells  ||| S:21819 E:21825 ||| NNS
were  ||| S:21825 E:21830 ||| VBD
permeabilized  ||| S:21830 E:21844 ||| VBN
with  ||| S:21844 E:21849 ||| IN
0.1 ||| S:21849 E:21852 ||| CD
%  ||| S:21852 E:21854 ||| NN
Triton  ||| S:21854 E:21871 ||| NNP
X-100 ||| S:21871 E:21876 ||| NNP
/ ||| S:21876 E:21877 ||| NNP
TBS  ||| S:21877 E:21881 ||| NNP
for  ||| S:21881 E:21885 ||| IN
3  ||| S:21885 E:21887 ||| CD
min ||| S:21887 E:21890 ||| NN
,  ||| S:21890 E:21892 ||| ,
washed  ||| S:21892 E:21899 ||| VBD
twice  ||| S:21899 E:21905 ||| RB
with  ||| S:21905 E:21910 ||| IN
TBS ||| S:21910 E:21913 ||| NNP
,  ||| S:21913 E:21915 ||| ,
blocked  ||| S:21915 E:21923 ||| VBD
twice  ||| S:21923 E:21939 ||| RB
for  ||| S:21939 E:21943 ||| IN
3  ||| S:21943 E:21945 ||| CD
min  ||| S:21945 E:21949 ||| NN
with  ||| S:21949 E:21954 ||| IN
0.1 ||| S:21954 E:21957 ||| CD
%  ||| S:21957 E:21959 ||| NN
bovine  ||| S:21959 E:21966 ||| NNS
serum  ||| S:21966 E:21972 ||| VBP
albumin  ||| S:21972 E:21980 ||| VBN
in  ||| S:21980 E:21983 ||| IN
TBS ||| S:21983 E:21986 ||| NNP
,  ||| S:21986 E:21988 ||| ,
and  ||| S:21988 E:22002 ||| CC
incubated  ||| S:22002 E:22012 ||| NN
with  ||| S:22012 E:22017 ||| IN
rhodamine-conjugated  ||| S:22017 E:22038 ||| JJ
phalloidin  ||| S:22038 E:22049 ||| NN
for  ||| S:22049 E:22053 ||| IN
20  ||| S:22053 E:22066 ||| CD
min ||| S:22066 E:22069 ||| NNS
.  ||| S:22069 E:22071 ||| .
Routinely ||| S:22071 E:22080 ||| RB
,  ||| S:22080 E:22082 ||| ,
5  ||| S:22082 E:22084 ||| CD
μl  ||| S:22084 E:22087 ||| NN
of  ||| S:22087 E:22090 ||| IN
rhodamine-phalloidin ||| S:22090 E:22110 ||| NNP
,  ||| S:22110 E:22112 ||| ,
dissolved  ||| S:22112 E:22132 ||| VBN
in  ||| S:22132 E:22135 ||| IN
200  ||| S:22135 E:22139 ||| CD
μl  ||| S:22139 E:22142 ||| JJ
TBS ||| S:22142 E:22145 ||| NNP
,  ||| S:22145 E:22147 ||| ,
was  ||| S:22147 E:22151 ||| VBD
used  ||| S:22151 E:22156 ||| VBN
for  ||| S:22156 E:22160 ||| IN
each  ||| S:22160 E:22165 ||| DT
coverslip  ||| S:22165 E:22175 ||| JJ
stained ||| S:22175 E:22182 ||| NN
.  ||| S:22182 E:22184 ||| .
The  ||| S:22184 E:22198 ||| DT
coverslips  ||| S:22198 E:22209 ||| NN
were  ||| S:22209 E:22214 ||| VBD
wash  ||| S:22214 E:22219 ||| VBN
with  ||| S:22219 E:22224 ||| IN
0.1 ||| S:22224 E:22227 ||| CD
%  ||| S:22227 E:22229 ||| NN
BSA ||| S:22229 E:22232 ||| NNP
/ ||| S:22232 E:22233 ||| NNP
TBS  ||| S:22233 E:22237 ||| NNP
for  ||| S:22237 E:22241 ||| IN
3  ||| S:22241 E:22243 ||| CD
min ||| S:22243 E:22246 ||| NN
,  ||| S:22246 E:22248 ||| ,
then  ||| S:22248 E:22263 ||| RB
mounted  ||| S:22263 E:22271 ||| VBN
in  ||| S:22271 E:22274 ||| IN
an  ||| S:22274 E:22277 ||| DT
inverted  ||| S:22277 E:22286 ||| JJ
position  ||| S:22286 E:22295 ||| NN
onto  ||| S:22295 E:22300 ||| IN
TBS-containing  ||| S:22300 E:22325 ||| JJ
beveled  ||| S:22325 E:22333 ||| JJ
glass  ||| S:22333 E:22339 ||| NN
slides  ||| S:22339 E:22346 ||| NNS
and  ||| S:22346 E:22350 ||| CC
sealed  ||| S:22350 E:22357 ||| VBN
with  ||| S:22357 E:22362 ||| IN
clear  ||| S:22362 E:22368 ||| JJ
nail  ||| S:22368 E:22383 ||| NN
polish ||| S:22383 E:22389 ||| NN
.  ||| S:22389 E:22419 ||| .
Perfusion  ||| S:22419 E:22439 ||| VBG
A  ||| S:22439 E:22441 ||| DT
parallel  ||| S:22441 E:22450 ||| JJ
plate  ||| S:22450 E:22456 ||| NN
perfusion  ||| S:22456 E:22466 ||| NN
chamber  ||| S:22466 E:22474 ||| NN
as  ||| S:22474 E:22477 ||| IN
described  ||| S:22477 E:22497 ||| VBN
previously  ||| S:22497 E:22508 ||| RB
[  ||| S:22508 E:22510 ||| -LRB-
57 ||| S:22510 E:22512 ||| CD
]  ||| S:22512 E:22514 ||| -RRB-
was  ||| S:22514 E:22518 ||| VBD
used  ||| S:22518 E:22523 ||| VBN
to  ||| S:22523 E:22526 ||| TO
generate  ||| S:22526 E:22535 ||| VB
simulated  ||| S:22535 E:22545 ||| JJ
arterial  ||| S:22545 E:22564 ||| JJ
flow  ||| S:22564 E:22569 ||| NN
conditions ||| S:22569 E:22579 ||| NNS
.  ||| S:22579 E:22581 ||| .
The  ||| S:22581 E:22585 ||| DT
chamber  ||| S:22585 E:22593 ||| NN
consisted  ||| S:22593 E:22603 ||| VBD
of  ||| S:22603 E:22606 ||| IN
three  ||| S:22606 E:22612 ||| CD
pieces ||| S:22612 E:22618 ||| NNS
:  ||| S:22618 E:22630 ||| :
two  ||| S:22630 E:22634 ||| CD
rectangular  ||| S:22634 E:22646 ||| CD
slabs  ||| S:22646 E:22652 ||| NNS
and  ||| S:22652 E:22656 ||| CC
a  ||| S:22656 E:22658 ||| DT
central  ||| S:22658 E:22666 ||| JJ
knob  ||| S:22666 E:22671 ||| NN
with  ||| S:22671 E:22676 ||| IN
a  ||| S:22676 E:22688 ||| DT
depression  ||| S:22688 E:22699 ||| NN
that  ||| S:22699 E:22704 ||| WDT
fits  ||| S:22704 E:22709 ||| VBZ
18  ||| S:22709 E:22712 ||| CD
by  ||| S:22712 E:22715 ||| IN
21  ||| S:22715 E:22718 ||| CD
mm  ||| S:22718 E:22721 ||| CD
coverslips ||| S:22721 E:22731 ||| NNS
.  ||| S:22731 E:22733 ||| .
The  ||| S:22733 E:22747 ||| DT
depression  ||| S:22747 E:22758 ||| NN
containing  ||| S:22758 E:22769 ||| VBG
the  ||| S:22769 E:22773 ||| DT
coverslip  ||| S:22773 E:22783 ||| NN
was  ||| S:22783 E:22787 ||| VBD
placed  ||| S:22787 E:22804 ||| VBN
perpendicularly  ||| S:22804 E:22820 ||| VBN
to  ||| S:22820 E:22823 ||| TO
the  ||| S:22823 E:22827 ||| DT
flow  ||| S:22827 E:22832 ||| NN
of  ||| S:22832 E:22835 ||| IN
perfusate ||| S:22835 E:22844 ||| NN
.  ||| S:22844 E:22846 ||| .
A  ||| S:22846 E:22848 ||| DT
laminar  ||| S:22848 E:22866 ||| JJ
arterial  ||| S:22866 E:22875 ||| JJ
shear  ||| S:22875 E:22881 ||| JJ
rate  ||| S:22881 E:22886 ||| NN
of  ||| S:22886 E:22889 ||| IN
650  ||| S:22889 E:22893 ||| CD
s  ||| S:22893 E:22895 ||| NNS
-1was  ||| S:22895 E:22901 ||| VBP
achieved  ||| S:22901 E:22910 ||| VBN
based  ||| S:22910 E:22916 ||| VBN
on  ||| S:22916 E:22919 ||| IN
the  ||| S:22919 E:22933 ||| DT
dimensions  ||| S:22933 E:22944 ||| NN
of  ||| S:22944 E:22947 ||| IN
the  ||| S:22947 E:22951 ||| DT
flow  ||| S:22951 E:22956 ||| NN
chamber  ||| S:22956 E:22964 ||| NN
slit  ||| S:22964 E:22969 ||| NNS
and  ||| S:22969 E:22973 ||| CC
a  ||| S:22973 E:22975 ||| DT
constant  ||| S:22975 E:22984 ||| JJ
flow  ||| S:22984 E:22999 ||| NN
rate  ||| S:22999 E:23004 ||| NN
of  ||| S:23004 E:23007 ||| IN
10  ||| S:23007 E:23010 ||| CD
ml ||| S:23010 E:23012 ||| CD
/ ||| S:23012 E:23013 ||| CD
min ||| S:23013 E:23016 ||| NNS
.  ||| S:23016 E:23018 ||| .
After  ||| S:23018 E:23024 ||| IN
preincubation  ||| S:23024 E:23038 ||| NN
at  ||| S:23038 E:23041 ||| IN
37°C ||| S:23041 E:23045 ||| NNP
,  ||| S:23045 E:23047 ||| ,
minimal  ||| S:23047 E:23065 ||| JJ
medium  ||| S:23065 E:23072 ||| NN
was  ||| S:23072 E:23076 ||| VBD
drawn  ||| S:23076 E:23082 ||| VBN
directly  ||| S:23082 E:23091 ||| RB
by  ||| S:23091 E:23094 ||| IN
an  ||| S:23094 E:23097 ||| DT
eight  ||| S:23097 E:23103 ||| CD
roller  ||| S:23103 E:23110 ||| NN
peristaltic  ||| S:23110 E:23132 ||| NNS
pump  ||| S:23132 E:23137 ||| VBP
through  ||| S:23137 E:23145 ||| IN
the  ||| S:23145 E:23149 ||| DT
perfusion  ||| S:23149 E:23159 ||| JJ
chamber  ||| S:23159 E:23167 ||| NN
containing  ||| S:23167 E:23178 ||| VBG
the  ||| S:23178 E:23192 ||| DT
BPAEC-covered  ||| S:23192 E:23206 ||| JJ
coverslip  ||| S:23206 E:23216 ||| NN
positioned  ||| S:23216 E:23227 ||| VBD
70  ||| S:23227 E:23230 ||| CD
mm  ||| S:23230 E:23233 ||| NN
from  ||| S:23233 E:23238 ||| IN
the  ||| S:23238 E:23242 ||| DT
inlet  ||| S:23242 E:23258 ||| JJ
valve  ||| S:23258 E:23264 ||| NN
at  ||| S:23264 E:23267 ||| IN
a  ||| S:23267 E:23269 ||| DT
rate  ||| S:23269 E:23274 ||| NN
of  ||| S:23274 E:23277 ||| IN
10  ||| S:23277 E:23280 ||| CD
ml ||| S:23280 E:23282 ||| CD
/ ||| S:23282 E:23283 ||| CD
min  ||| S:23283 E:23287 ||| NN
for  ||| S:23287 E:23291 ||| IN
either  ||| S:23291 E:23298 ||| DT
2  ||| S:23298 E:23300 ||| CD
min  ||| S:23300 E:23304 ||| NNS
or  ||| S:23304 E:23307 ||| CC
5  ||| S:23307 E:23309 ||| CD
min ||| S:23309 E:23312 ||| NNS
.  ||| S:23312 E:23314 ||| .
A  ||| S:23314 E:23326 ||| DT
recirculating  ||| S:23326 E:23340 ||| JJ
system  ||| S:23340 E:23347 ||| NN
was  ||| S:23347 E:23351 ||| VBD
employed  ||| S:23351 E:23360 ||| VBN
to  ||| S:23360 E:23363 ||| TO
recycle  ||| S:23363 E:23371 ||| VB
the  ||| S:23371 E:23375 ||| DT
medium  ||| S:23375 E:23392 ||| NN
after  ||| S:23392 E:23398 ||| IN
passing  ||| S:23398 E:23406 ||| VBG
through  ||| S:23406 E:23414 ||| IN
the  ||| S:23414 E:23418 ||| DT
chamber ||| S:23418 E:23425 ||| NN
.  ||| S:23425 E:23455 ||| .
Confocal  ||| S:23455 E:23464 ||| FW
microscopy  ||| S:23464 E:23485 ||| FW
Prepared  ||| S:23485 E:23494 ||| FW
slides  ||| S:23494 E:23501 ||| FW
containing  ||| S:23501 E:23512 ||| FW
adhered  ||| S:23512 E:23520 ||| FW
BPAEC  ||| S:23520 E:23526 ||| NNP
were  ||| S:23526 E:23531 ||| VBD
examined  ||| S:23531 E:23550 ||| VBN
using  ||| S:23550 E:23556 ||| VBG
a  ||| S:23556 E:23558 ||| DT
BioRad  ||| S:23558 E:23565 ||| JJ
confocal  ||| S:23565 E:23574 ||| JJ
microscope ||| S:23574 E:23584 ||| NN
.  ||| S:23584 E:23586 ||| .
The  ||| S:23586 E:23590 ||| DT
cells  ||| S:23590 E:23596 ||| NNS
were  ||| S:23596 E:23601 ||| VBD
imaged  ||| S:23601 E:23618 ||| VBN
following  ||| S:23618 E:23628 ||| VBG
excitation  ||| S:23628 E:23639 ||| NN
of  ||| S:23639 E:23642 ||| IN
rhodamine-phalloidin  ||| S:23642 E:23663 ||| JJ
with  ||| S:23663 E:23668 ||| IN
an  ||| S:23668 E:23681 ||| DT
argon  ||| S:23681 E:23687 ||| JJ
laser  ||| S:23687 E:23693 ||| NN
beam  ||| S:23693 E:23698 ||| NN
at  ||| S:23698 E:23701 ||| IN
a  ||| S:23701 E:23703 ||| DT
wavelength  ||| S:23703 E:23714 ||| NN
of  ||| S:23714 E:23717 ||| IN
554  ||| S:23717 E:23721 ||| CD
nm  ||| S:23721 E:23724 ||| NNS
using  ||| S:23724 E:23730 ||| VBG
either  ||| S:23730 E:23747 ||| RB
an  ||| S:23747 E:23750 ||| DT
inverted-  ||| S:23750 E:23760 ||| JJ
or  ||| S:23760 E:23763 ||| CC
an  ||| S:23763 E:23766 ||| DT
uprighted-staged  ||| S:23766 E:23783 ||| JJ
microscope  ||| S:23783 E:23794 ||| NN
equipped  ||| S:23794 E:23813 ||| VBN
with  ||| S:23813 E:23818 ||| IN
either  ||| S:23818 E:23825 ||| RB
a  ||| S:23825 E:23827 ||| DT
10X  ||| S:23827 E:23831 ||| NNP
or  ||| S:23831 E:23834 ||| CC
a  ||| S:23834 E:23836 ||| DT
20X  ||| S:23836 E:23840 ||| JJ
oil-free  ||| S:23840 E:23849 ||| JJ
objective  ||| S:23849 E:23859 ||| NN
and  ||| S:23859 E:23863 ||| CC
an  ||| S:23863 E:23876 ||| DT
epifluorescent  ||| S:23876 E:23891 ||| JJ
illumination  ||| S:23891 E:23904 ||| JJ
attachment ||| S:23904 E:23914 ||| NN
.  ||| S:23914 E:23916 ||| .
Cells  ||| S:23916 E:23922 ||| NNS
viewed  ||| S:23922 E:23929 ||| VBN
in  ||| S:23929 E:23942 ||| IN
representative  ||| S:23942 E:23957 ||| JJ
field  ||| S:23957 E:23963 ||| NN
screen  ||| S:23963 E:23970 ||| NN
captures  ||| S:23970 E:23979 ||| NNS
were  ||| S:23979 E:23984 ||| VBD
counted  ||| S:23984 E:24002 ||| VBN
manually  ||| S:24002 E:24011 ||| RB
for  ||| S:24011 E:24015 ||| IN
cell  ||| S:24015 E:24020 ||| NN
morphology  ||| S:24020 E:24031 ||| NNS
and  ||| S:24031 E:24035 ||| CC
classified  ||| S:24035 E:24046 ||| VBN
as  ||| S:24046 E:24049 ||| IN
either  ||| S:24049 E:24066 ||| DT
normal  ||| S:24066 E:24073 ||| JJ
or  ||| S:24073 E:24076 ||| CC
elongated ||| S:24076 E:24085 ||| NN
.  ||| S:24085 E:24115 ||| .
Inhibitor  ||| S:24115 E:24125 ||| JJ
study  ||| S:24125 E:24141 ||| NN
Passages  ||| S:24141 E:24150 ||| NNP
4-5  ||| S:24150 E:24154 ||| NNP
BPAEC  ||| S:24154 E:24160 ||| NNP
were  ||| S:24160 E:24165 ||| VBD
seeded  ||| S:24165 E:24172 ||| VBN
on  ||| S:24172 E:24175 ||| IN
plastic  ||| S:24175 E:24183 ||| JJ
coverslips  ||| S:24183 E:24204 ||| NN
as  ||| S:24204 E:24207 ||| IN
described  ||| S:24207 E:24217 ||| VBN
above ||| S:24217 E:24222 ||| IN
.  ||| S:24222 E:24224 ||| .
Inhibitor  ||| S:24224 E:24234 ||| JJ
concentrations  ||| S:24234 E:24249 ||| NNS
were  ||| S:24249 E:24254 ||| VBD
the  ||| S:24254 E:24268 ||| DT
same  ||| S:24268 E:24273 ||| JJ
as  ||| S:24273 E:24276 ||| IN
in  ||| S:24276 E:24279 ||| IN
[  ||| S:24279 E:24281 ||| -LRB-
28 ||| S:24281 E:24283 ||| CD
] ||| S:24283 E:24284 ||| -RRB-
.  ||| S:24284 E:24286 ||| .
Stock  ||| S:24286 E:24292 ||| NN
solutions  ||| S:24292 E:24302 ||| NNS
were  ||| S:24302 E:24307 ||| VBD
prepared  ||| S:24307 E:24316 ||| VBN
by  ||| S:24316 E:24329 ||| IN
dissolving  ||| S:24329 E:24340 ||| VBG
the  ||| S:24340 E:24344 ||| DT
inhibitors  ||| S:24344 E:24355 ||| NN
in  ||| S:24355 E:24358 ||| IN
DMSO ||| S:24358 E:24362 ||| NNP
.  ||| S:24362 E:24364 ||| .
The  ||| S:24364 E:24368 ||| DT
inhibitors  ||| S:24368 E:24379 ||| NN
used  ||| S:24379 E:24394 ||| VBN
and  ||| S:24394 E:24398 ||| CC
their  ||| S:24398 E:24404 ||| PRP$
stock  ||| S:24404 E:24410 ||| NN
solutions  ||| S:24410 E:24420 ||| NNS
were  ||| S:24420 E:24425 ||| VBD
as  ||| S:24425 E:24428 ||| RB
follows ||| S:24428 E:24435 ||| VBZ
:  ||| S:24435 E:24437 ||| :
quin2-AM  ||| S:24437 E:24456 ||| CD
( ||| S:24456 E:24457 ||| -LRB-
Sigma ||| S:24457 E:24462 ||| NNP
,  ||| S:24462 E:24464 ||| ,
2  ||| S:24464 E:24466 ||| CD
mM ||| S:24466 E:24468 ||| NN
) ||| S:24468 E:24469 ||| -RRB-
,  ||| S:24469 E:24471 ||| ,
herbimycin  ||| S:24471 E:24482 ||| VBG
A  ||| S:24482 E:24484 ||| DT
( ||| S:24484 E:24485 ||| -LRB-
GibcoBRL ||| S:24485 E:24493 ||| NNP
,  ||| S:24493 E:24495 ||| ,
0.175  ||| S:24495 E:24501 ||| NNP
mM ||| S:24501 E:24503 ||| NNP
) ||| S:24503 E:24504 ||| -RRB-
,  ||| S:24504 E:24516 ||| ,
chelerythrine  ||| S:24516 E:24530 ||| NNS
( ||| S:24530 E:24531 ||| -LRB-
Sigma ||| S:24531 E:24536 ||| NNP
,  ||| S:24536 E:24538 ||| ,
0.4  ||| S:24538 E:24542 ||| CD
mM ||| S:24542 E:24544 ||| NN
) ||| S:24544 E:24545 ||| -RRB-
,  ||| S:24545 E:24547 ||| ,
cytochalasin  ||| S:24547 E:24560 ||| VBG
D  ||| S:24560 E:24562 ||| NNP
( ||| S:24562 E:24563 ||| -LRB-
Sigma ||| S:24563 E:24568 ||| NNP
,  ||| S:24568 E:24570 ||| ,
8  ||| S:24570 E:24582 ||| CD
μM ||| S:24582 E:24584 ||| NN
) ||| S:24584 E:24585 ||| -RRB-
,  ||| S:24585 E:24587 ||| ,
nocodazole  ||| S:24587 E:24598 ||| NNS
( ||| S:24598 E:24599 ||| -LRB-
Sigma ||| S:24599 E:24604 ||| NNP
,  ||| S:24604 E:24606 ||| ,
0.66  ||| S:24606 E:24611 ||| NNP
mM ||| S:24611 E:24613 ||| NNP
) ||| S:24613 E:24614 ||| -RRB-
.  ||| S:24614 E:24616 ||| .
Quin2-AM ||| S:24616 E:24624 ||| NNP
,  ||| S:24624 E:24626 ||| ,
herbimycin  ||| S:24626 E:24637 ||| VBG
A ||| S:24637 E:24638 ||| DT
,  ||| S:24638 E:24650 ||| ,
chelerythrine ||| S:24650 E:24663 ||| NN
,  ||| S:24663 E:24665 ||| ,
and  ||| S:24665 E:24669 ||| CC
cytochalasin  ||| S:24669 E:24682 ||| JJ
D  ||| S:24682 E:24684 ||| NNP
were  ||| S:24684 E:24689 ||| VBD
stored  ||| S:24689 E:24696 ||| VBN
at  ||| S:24696 E:24699 ||| IN
-20°C ||| S:24699 E:24704 ||| NNP
,  ||| S:24704 E:24716 ||| ,
and  ||| S:24716 E:24720 ||| CC
nocodazole  ||| S:24720 E:24731 ||| NNS
was  ||| S:24731 E:24735 ||| VBD
stored  ||| S:24735 E:24742 ||| VBN
at  ||| S:24742 E:24745 ||| IN
4°C ||| S:24745 E:24748 ||| CD
.  ||| S:24748 E:24750 ||| .
The  ||| S:24750 E:24754 ||| DT
stock  ||| S:24754 E:24760 ||| NN
solutions  ||| S:24760 E:24780 ||| NNS
were  ||| S:24780 E:24785 ||| VBD
diluted  ||| S:24785 E:24793 ||| VBN
1 ||| S:24793 E:24794 ||| CD
: ||| S:24794 E:24795 ||| :
200  ||| S:24795 E:24799 ||| CD
in  ||| S:24799 E:24802 ||| IN
MEM  ||| S:24802 E:24806 ||| NNP
to  ||| S:24806 E:24809 ||| TO
give  ||| S:24809 E:24814 ||| VB
the  ||| S:24814 E:24818 ||| DT
following  ||| S:24818 E:24828 ||| JJ
final  ||| S:24828 E:24844 ||| JJ
concentrations ||| S:24844 E:24858 ||| NNS
:  ||| S:24858 E:24860 ||| :
quin2-AM  ||| S:24860 E:24869 ||| CD
( ||| S:24869 E:24870 ||| -LRB-
10  ||| S:24870 E:24873 ||| CD
μM ||| S:24873 E:24875 ||| NN
) ||| S:24875 E:24876 ||| -RRB-
,  ||| S:24876 E:24878 ||| ,
herbimycin  ||| S:24878 E:24889 ||| VBG
A  ||| S:24889 E:24891 ||| DT
( ||| S:24891 E:24892 ||| -LRB-
875  ||| S:24892 E:24896 ||| CD
nM ||| S:24896 E:24898 ||| NN
) ||| S:24898 E:24899 ||| -RRB-
,  ||| S:24899 E:24911 ||| ,
chelerythrine  ||| S:24911 E:24925 ||| NNS
( ||| S:24925 E:24926 ||| -LRB-
2  ||| S:24926 E:24928 ||| CD
μM ||| S:24928 E:24930 ||| NN
) ||| S:24930 E:24931 ||| -RRB-
,  ||| S:24931 E:24933 ||| ,
cytochalasin  ||| S:24933 E:24946 ||| VBG
D  ||| S:24946 E:24948 ||| NNP
( ||| S:24948 E:24949 ||| -LRB-
40  ||| S:24949 E:24952 ||| CD
nM ||| S:24952 E:24954 ||| NN
) ||| S:24954 E:24955 ||| -RRB-
,  ||| S:24955 E:24957 ||| ,
nocodazole  ||| S:24957 E:24978 ||| NNS
( ||| S:24978 E:24979 ||| -LRB-
3.3  ||| S:24979 E:24983 ||| CD
μM ||| S:24983 E:24985 ||| NN
) ||| S:24985 E:24986 ||| -RRB-
.  ||| S:24986 E:24988 ||| .
Inhibitors  ||| S:24988 E:24999 ||| NNP
were  ||| S:24999 E:25004 ||| VBD
applied  ||| S:25004 E:25012 ||| VBN
24  ||| S:25012 E:25015 ||| CD
h  ||| S:25015 E:25017 ||| NNS
prior  ||| S:25017 E:25023 ||| RB
to  ||| S:25023 E:25026 ||| TO
the  ||| S:25026 E:25040 ||| DT
addition  ||| S:25040 E:25049 ||| NN
of  ||| S:25049 E:25052 ||| IN
resveratrol ||| S:25052 E:25063 ||| NN
,  ||| S:25063 E:25065 ||| ,
except  ||| S:25065 E:25072 ||| IN
for  ||| S:25072 E:25076 ||| IN
quin2-AM ||| S:25076 E:25084 ||| NNP
,  ||| S:25084 E:25086 ||| ,
which  ||| S:25086 E:25092 ||| WDT
was  ||| S:25092 E:25106 ||| VBD
applied  ||| S:25106 E:25114 ||| VBN
1  ||| S:25114 E:25116 ||| CD
h  ||| S:25116 E:25118 ||| NNS
prior  ||| S:25118 E:25124 ||| RB
to  ||| S:25124 E:25127 ||| TO
resveratrol  ||| S:25127 E:25139 ||| VB
treatment ||| S:25139 E:25148 ||| NN
.  ||| S:25148 E:25150 ||| .
Since  ||| S:25150 E:25156 ||| IN
cells  ||| S:25156 E:25172 ||| NNS
treated  ||| S:25172 E:25180 ||| VBN
with  ||| S:25180 E:25185 ||| IN
various  ||| S:25185 E:25193 ||| JJ
inhibitors  ||| S:25193 E:25204 ||| NN
grew  ||| S:25204 E:25209 ||| VBD
less  ||| S:25209 E:25214 ||| RBR
well ||| S:25214 E:25218 ||| RB
,  ||| S:25218 E:25220 ||| ,
compared  ||| S:25220 E:25239 ||| VBN
to  ||| S:25239 E:25242 ||| TO
controls ||| S:25242 E:25250 ||| NNS
,  ||| S:25250 E:25252 ||| ,
treatment  ||| S:25252 E:25262 ||| NN
with  ||| S:25262 E:25267 ||| IN
100  ||| S:25267 E:25271 ||| CD
μM  ||| S:25271 E:25274 ||| JJ
resveratrol  ||| S:25274 E:25286 ||| NN
was  ||| S:25286 E:25300 ||| VBD
reduced  ||| S:25300 E:25308 ||| VBN
to  ||| S:25308 E:25311 ||| TO
approximately  ||| S:25311 E:25325 ||| RB
40  ||| S:25325 E:25328 ||| CD
h ||| S:25328 E:25329 ||| NNS
.  ||| S:25329 E:25331 ||| .
Fixing  ||| S:25331 E:25338 ||| NNP
and  ||| S:25338 E:25342 ||| CC
staining  ||| S:25342 E:25351 ||| NN
of  ||| S:25351 E:25364 ||| IN
cells  ||| S:25364 E:25370 ||| NNS
for  ||| S:25370 E:25374 ||| IN
confocal  ||| S:25374 E:25383 ||| JJ
microscopy  ||| S:25383 E:25394 ||| NN
was  ||| S:25394 E:25398 ||| VBD
as  ||| S:25398 E:25401 ||| RB
described  ||| S:25401 E:25411 ||| VBN
above ||| S:25411 E:25416 ||| IN
.  ||| S:25416 E:25446 ||| .
Western  ||| S:25446 E:25454 ||| JJ
blot  ||| S:25454 E:25459 ||| JJ
analysis  ||| S:25459 E:25478 ||| NN
Control  ||| S:25478 E:25486 ||| NNP
and  ||| S:25486 E:25490 ||| CC
treated  ||| S:25490 E:25498 ||| JJ
cells  ||| S:25498 E:25504 ||| NNS
were  ||| S:25504 E:25509 ||| VBD
lysed  ||| S:25509 E:25515 ||| VBN
by  ||| S:25515 E:25518 ||| IN
repeated  ||| S:25518 E:25537 ||| VBN
freeze-thaw  ||| S:25537 E:25549 ||| JJ
cycles  ||| S:25549 E:25556 ||| NNS
with  ||| S:25556 E:25561 ||| IN
buffer  ||| S:25561 E:25568 ||| NN
containing  ||| S:25568 E:25579 ||| VBG
10  ||| S:25579 E:25582 ||| CD
mM  ||| S:25582 E:25585 ||| JJ
HEPES  ||| S:25585 E:25591 ||| NNP
( ||| S:25591 E:25592 ||| -LRB-
pH  ||| S:25592 E:25605 ||| NNP
7.5 ||| S:25605 E:25608 ||| CD
) ||| S:25608 E:25609 ||| -RRB-
,  ||| S:25609 E:25611 ||| ,
1.5  ||| S:25611 E:25615 ||| CD
mM  ||| S:25615 E:25618 ||| JJ
Mg ||| S:25618 E:25620 ||| NNP
( ||| S:25620 E:25621 ||| -LRB-
OAc ||| S:25621 E:25624 ||| NNP
)  ||| S:25624 E:25637 ||| -RRB-
2  ||| S:25637 E:25639 ||| CD
,  ||| S:25639 E:25641 ||| ,
1  ||| S:25641 E:25643 ||| CD
mM  ||| S:25643 E:25646 ||| JJ
dithiothreitol  ||| S:25646 E:25661 ||| NNS
( ||| S:25661 E:25662 ||| -LRB-
DTT ||| S:25662 E:25665 ||| NNP
) ||| S:25665 E:25666 ||| -RRB-
,  ||| S:25666 E:25668 ||| ,
0.5 ||| S:25668 E:25671 ||| CD
%  ||| S:25671 E:25683 ||| NN
NP40 ||| S:25683 E:25687 ||| NN
,  ||| S:25687 E:25689 ||| ,
5 ||| S:25689 E:25690 ||| CD
%  ||| S:25690 E:25692 ||| NN
glycerol ||| S:25692 E:25700 ||| NN
,  ||| S:25700 E:25702 ||| ,
0.5  ||| S:25702 E:25706 ||| CD
mM  ||| S:25706 E:25709 ||| JJ
phenylmethylsulfonyl  ||| S:25709 E:25730 ||| JJ
fluoride ||| S:25730 E:25738 ||| NN
,  ||| S:25738 E:25750 ||| ,
and  ||| S:25750 E:25754 ||| CC
10  ||| S:25754 E:25757 ||| CD
μg ||| S:25757 E:25759 ||| CD
/ ||| S:25759 E:25760 ||| CD
ml  ||| S:25760 E:25763 ||| CD
each  ||| S:25763 E:25768 ||| DT
of  ||| S:25768 E:25771 ||| IN
the  ||| S:25771 E:25775 ||| DT
protease  ||| S:25775 E:25784 ||| JJ
inhibitors  ||| S:25784 E:25795 ||| JJ
aprotinin ||| S:25795 E:25804 ||| NN
,  ||| S:25804 E:25816 ||| ,
pepstatin ||| S:25816 E:25825 ||| NN
,  ||| S:25825 E:25827 ||| ,
and  ||| S:25827 E:25831 ||| CC
leupeptin ||| S:25831 E:25840 ||| NN
.  ||| S:25840 E:25842 ||| .
Cell-free  ||| S:25842 E:25852 ||| JJ
extracts  ||| S:25852 E:25861 ||| NN
were  ||| S:25861 E:25876 ||| VBD
obtained  ||| S:25876 E:25885 ||| VBN
by  ||| S:25885 E:25888 ||| IN
centrifugation  ||| S:25888 E:25903 ||| NN
in  ||| S:25903 E:25906 ||| IN
a  ||| S:25906 E:25908 ||| DT
microcentrifuge ||| S:25908 E:25923 ||| NN
.  ||| S:25923 E:25925 ||| .
Lysates  ||| S:25925 E:25943 ||| NNP
( ||| S:25943 E:25944 ||| -LRB-
7-10  ||| S:25944 E:25949 ||| FW
μg ||| S:25949 E:25951 ||| FW
)  ||| S:25951 E:25953 ||| -RRB-
from  ||| S:25953 E:25958 ||| IN
control  ||| S:25958 E:25966 ||| NN
and  ||| S:25966 E:25970 ||| CC
treated  ||| S:25970 E:25978 ||| JJ
cells  ||| S:25978 E:25984 ||| NNS
were  ||| S:25984 E:25989 ||| VBD
separated  ||| S:25989 E:26009 ||| VBN
on  ||| S:26009 E:26012 ||| IN
10 ||| S:26012 E:26014 ||| CD
%  ||| S:26014 E:26016 ||| NN
SDS-PAGE ||| S:26016 E:26024 ||| NN
.  ||| S:26024 E:26026 ||| .
The  ||| S:26026 E:26030 ||| DT
separated  ||| S:26030 E:26040 ||| JJ
proteins  ||| S:26040 E:26049 ||| NNS
were  ||| S:26049 E:26054 ||| VBD
transferred  ||| S:26054 E:26076 ||| VBN
to  ||| S:26076 E:26079 ||| TO
nitrocellulose  ||| S:26079 E:26094 ||| VB
membranes ||| S:26094 E:26103 ||| NNS
,  ||| S:26103 E:26105 ||| ,
and  ||| S:26105 E:26109 ||| CC
the  ||| S:26109 E:26113 ||| DT
membranes  ||| S:26113 E:26123 ||| NN
were  ||| S:26123 E:26138 ||| VBD
incubated  ||| S:26138 E:26148 ||| VBN
with  ||| S:26148 E:26153 ||| IN
the  ||| S:26153 E:26157 ||| DT
respective  ||| S:26157 E:26168 ||| JJ
primary  ||| S:26168 E:26176 ||| JJ
and  ||| S:26176 E:26180 ||| CC
secondary  ||| S:26180 E:26200 ||| JJ
antibodies ||| S:26200 E:26210 ||| NNS
.  ||| S:26210 E:26212 ||| .
The  ||| S:26212 E:26216 ||| DT
monoclonal  ||| S:26216 E:26227 ||| JJ
primary  ||| S:26227 E:26235 ||| JJ
antibodies  ||| S:26235 E:26246 ||| NNS
used  ||| S:26246 E:26251 ||| VBN
and  ||| S:26251 E:26265 ||| CC
their  ||| S:26265 E:26271 ||| PRP$
dilutions  ||| S:26271 E:26281 ||| NN
were  ||| S:26281 E:26286 ||| VBD
as  ||| S:26286 E:26289 ||| RB
follows ||| S:26289 E:26296 ||| VBZ
:  ||| S:26296 E:26298 ||| :
Phosphorylated ||| S:26298 E:26312 ||| NNP
,  ||| S:26312 E:26314 ||| ,
active  ||| S:26314 E:26331 ||| JJ
ERK1 ||| S:26331 E:26335 ||| CD
/ ||| S:26335 E:26336 ||| CD
2-P  ||| S:26336 E:26340 ||| CD
( ||| S:26340 E:26341 ||| -LRB-
RBI ||| S:26341 E:26344 ||| NNP
/ ||| S:26344 E:26345 ||| NNP
Sigma ||| S:26345 E:26350 ||| NNP
,  ||| S:26350 E:26352 ||| ,
1 ||| S:26352 E:26353 ||| CD
: ||| S:26353 E:26354 ||| :
1000 ||| S:26354 E:26358 ||| CD
) ||| S:26358 E:26359 ||| -RRB-
,  ||| S:26359 E:26361 ||| ,
total  ||| S:26361 E:26367 ||| JJ
ERK1 ||| S:26367 E:26371 ||| CD
/ ||| S:26371 E:26372 ||| CD
2  ||| S:26372 E:26374 ||| CD
( ||| S:26374 E:26375 ||| -LRB-
RBI ||| S:26375 E:26378 ||| NNP
/ ||| S:26378 E:26379 ||| NNP
Sigma ||| S:26379 E:26384 ||| NNP
,  ||| S:26384 E:26396 ||| ,
1 ||| S:26396 E:26397 ||| CD
: ||| S:26397 E:26398 ||| :
1000 ||| S:26398 E:26402 ||| CD
) ||| S:26402 E:26403 ||| -RRB-
,  ||| S:26403 E:26405 ||| ,
eIF4E  ||| S:26405 E:26411 ||| NNP
( ||| S:26411 E:26412 ||| -LRB-
Santa  ||| S:26412 E:26418 ||| NNP
Cruz ||| S:26418 E:26422 ||| NNP
,  ||| S:26422 E:26424 ||| ,
1 ||| S:26424 E:26425 ||| CD
: ||| S:26425 E:26426 ||| :
250 ||| S:26426 E:26429 ||| CD
) ||| S:26429 E:26430 ||| -RRB-
,  ||| S:26430 E:26432 ||| ,
eNOS  ||| S:26432 E:26437 ||| NNP
( ||| S:26437 E:26438 ||| -LRB-
Sigma  ||| S:26438 E:26444 ||| NNP
1 ||| S:26444 E:26445 ||| CD
: ||| S:26445 E:26446 ||| :
1000 ||| S:26446 E:26450 ||| CD
) ||| S:26450 E:26451 ||| -RRB-
.  ||| S:26451 E:26463 ||| .
Membranes  ||| S:26463 E:26473 ||| NNP
were  ||| S:26473 E:26478 ||| VBD
probed  ||| S:26478 E:26485 ||| VBN
with  ||| S:26485 E:26490 ||| IN
alkaline  ||| S:26490 E:26509 ||| JJ
phosphatase-conjugated  ||| S:26509 E:26532 ||| JJ
IgG  ||| S:26532 E:26536 ||| NN
( ||| S:26536 E:26537 ||| -LRB-
Santa  ||| S:26537 E:26543 ||| NNP
Cruz ||| S:26543 E:26547 ||| NNP
,  ||| S:26547 E:26549 ||| ,
1 ||| S:26549 E:26550 ||| CD
: ||| S:26550 E:26551 ||| :
1500 ||| S:26551 E:26555 ||| CD
)  ||| S:26555 E:26557 ||| -RRB-
or  ||| S:26557 E:26570 ||| CC
horseradish  ||| S:26570 E:26582 ||| JJ
peroxidase-conjugated  ||| S:26582 E:26604 ||| JJ
IgG  ||| S:26604 E:26608 ||| NN
( ||| S:26608 E:26609 ||| -LRB-
Santa  ||| S:26609 E:26615 ||| NNP
Cruz ||| S:26615 E:26619 ||| NNP
,  ||| S:26619 E:26631 ||| ,
1 ||| S:26631 E:26632 ||| CD
: ||| S:26632 E:26633 ||| :
2000 ||| S:26633 E:26637 ||| CD
) ||| S:26637 E:26638 ||| -RRB-
.  ||| S:26638 E:26640 ||| .
Specific  ||| S:26640 E:26649 ||| JJ
immunoreactive  ||| S:26649 E:26664 ||| JJ
bands  ||| S:26664 E:26670 ||| NNS
were  ||| S:26670 E:26675 ||| VBD
identified  ||| S:26675 E:26686 ||| VBN
by  ||| S:26686 E:26699 ||| IN
color  ||| S:26699 E:26705 ||| NN
reaction  ||| S:26705 E:26714 ||| NN
or  ||| S:26714 E:26717 ||| CC
enhanced  ||| S:26717 E:26726 ||| JJ
chemiluminescence ||| S:26726 E:26743 ||| NN
,  ||| S:26743 E:26755 ||| ,
respectively ||| S:26755 E:26767 ||| RB
.  ||| S:26767 E:26793 ||| .
